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Abstract 
 
Histone H3 lysine-27 trimethylation (H3K27me3) is an epigenetic mark that exerts a 
critical role in heritable gene repression. Levels of H3K27me3 at genomic target sites 
are tightly controlled by the opposing action of H3K27me3-specific methylases and 
demethylases, respectively. Modulation of H3K27me3 levels influence cell 
proliferation, survival and differentiation. In mammalian cells, Polycomb group protein 
Enhancer of Zeste Homologue 2 (Ezh2) catalyzes H3K27 trimethylation as 
component of the Polycomb Repressive Complex 2. Deposition of H3K27me3 at 
target genes is reversed by the action of H3K27me3 demethylases. The Jumonji-C 
containing proteins JMJD3/KDM6B and UTX/KDM6A are the only known enzymes 
involved in H3K27me3 demethylation. Jmjd3 has been previously shown to play an 
important role in mediating macrophage driven inflammatory responses and in in 
regulating somatic cell reprogramming and cellular senescence. In immune cells 
including B cells expression of Jmjd3 is tightly controlled. Whereas basal Jmjd3 levels 
are detected throughout B cell development, strong upregulation of demethylase 
expression is observed after stimulation through respectively the B cell antigen 
receptor, Toll-like receptors and members of the TNF receptor superfamily.  
To study the role of JMJD3 in B lymphocyte development and activation, I generated 
Jmjd3 conditional knock-out mice (JMJD3fl). Analysis of B cell-specific Jmjd3 KO mice 
revealed multiple defects linked to the lack of demethyalse activity. Jmjd3 regulated 
the size of the B cell progenitor pool acting primarily on the pre-B cell compartment 
that was reduced in mutant mice. Jmjd3 deficient animals showed also alterations in 
peripheral B cell development. An increase in the proportion and absolute number of 
splenic marginal zone B cells was associated to a reduction in peritoneal cavity B-1a 
B cells. In vivo BrdU labeling assays suggested a longer lifespan of Jmjd3 mutant 
mature B cells, which was not dependent on improved cell survival. Jmjd3 was 
dispensable for germinal center formation and T-cell dependent immune responses. 
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Moreover, measurement of basal serum immunoglobulin titers excluded a major role 
for Jmjd3 in plasma cell homeostasis. 
In vitro stimulation assays revealed a selective defect of Jmjd3 mutant B cells to 
proliferate in response to the TLR4 ligand LPS, which was alleviated by IL-4 co-
stimulation. Jmjd3 was critical to drive the first one-to-two cell divisions following LPS 
stimulation suggesting a critical role in the initial activation of the resting B cells. Upon 
stimulation with LPS, Jmjd3 mutant B cells showed neither specific defects in cell-
cycle progression nor increased apoptosis. Candidate gene expression analyses, 
supported by RNA sequencing data, revealed a comprehensive control exerted by 
Jmjd3 on the expression of a substantial number of cell-cycle regulated genes 
including those cyclins, CDK inhibitors and factors involved in DNA replication and 
mitosis. Regulation of gene expression mediated by Jmjd3 was not associated with 
measurable changes in global H3K27me3 levels.    
All together these results identify Jmjd3 as an important regulator of B cell 
lymphopoiesis and a selective effector of B cell innate immune responses.  
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1. Introduction 
 
1.1. Chromatin and epigenetics 
 
1.1.1. Chromatin structure 
In eukaryotic cells, genomic DNA is highly compacted by positively charged Histone 
(H) proteins that form a condensed structure known as chromatin. The nucleosome is 
the fundamental unit of chromatin. It consists of 147 bp of DNA wrapped around a 
histone core composed of two subunit each of respectively Histones H2A, H2B, H3 
and H4.  Sequential nucleosomes generate a fiber of 11 nm diameter that further 
compacts to a 30 nm structure termed chromatosome via incorporation of linker 
histone protein H1 (Luger 2003). The mechanisms involved in the establishment of 
the higher order structure of chromatin remain still poorly understood.  
Histone core subunits are structured proteins except for their N-terminal region that 
gets subjected to a number of post-translational modifications. Histone 
phosphorylation (serine and threonine residues) (Nowak et al., 2004), acetylation 
(lysine) (Grunstein et al., 1997), methylation (lysine and arginine) (Zhang et al., 2001), 
ubiquitination (lysine) (Davie et al., 1990), sumoylation (lysine) (Nathan et al., 2003), 
ADP ribosylation (Adameitz et al., 1984), glycosylation (Leibich et al., 1993), 
biotinylation (Hymes et al., 1995) and carbonylation (Wondrak et al., 2000) represent 
the most common modifications affecting N-terminus tails of core histones. Such 
covalent modifications exert a critical influence on gene expression by modulating the 
accessibility to DNA of the basic transcriptional machinery and sequence-specific 
transcription factors. 
The consequences of specific histone modifications on gene expression, DNA 
replication, DNA damage responses and other related chromatin biology processes 
have been extensively studied over the past decades. The combination of covalent 
modifications targeting histone core subunits constitute the so-called “Histone code” 
which is read by chromatin factors that ultimately influence complex processes such 
as defining the transcriptional status of a gene (Jenuwein and Allis, 2001). 
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1.1.2. Epigenetics 
Multicellular organisms consist of functionally distinct cell types that are determined 
by an invariant sequence of DNA. During development, the integration of extracellular 
signals with intrinsic transcriptional programs contributes to cell specialization and 
maintenance of cell identity. One central mechanism that contributes to the 
establishment of transcriptional programs that sustain lineage fate and, cellular 
identity is the epigenetic regulation of gene expression. The term epigenetics was first 
coined in 1942 by Conrad Waddington to describe casual developmental processes 
associated to a defined genotype (Waddington, 1942). Over the years, “epigenetics” 
has become a more specific term that defines those mechanisms leading to changes 
in gene expression that are inherited across generations, that are not caused by 
changes in the DNA sequence. Epigenetic modifications are commonly associated 
with defined states of the chromatin. Whereas euchromatin defines the portion of the 
genome   readily accessible to the transcriptional machinery,  heterochromatin 
defines a compacted state of chromatin that is commonly associated with gene 
repression. Heterochromatin can be further defined as constitutive (such as that of 
centrosomes), or facultative to define a reversible state of chromatin compaction. 
In mammals, epigenetic regulation of gene expression is mainly mediated by post-
translational  modifications of histones, DNA methylation, nucleosomal remodeling 
and small noncoding RNAs (Jaenisch and Bird, 2003). These mechanisms contribute 
in a critical manner to define the transcriptome of a specialized cell-type that is 
inherited through multiple cell divisions, propagating thereby cellular identity.  
 
1.1.2.1 Dynamics of Histone lysine methylation  
The N-terminus region of histone proteins undergoes a variety of post-translational 
modifications (PTMs), which influence a broad set of biological processes that include 
DNA replication, transcriptional regulation and DNA damage responses.  
Unlike Histone acetylation, which is generally associated with transcriptional 
activation, methylation of different lysine residues on core histone tails has different 
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transcriptional outcomes depending on the type of covalent modification. Moreover, 
lysine residues of Histone tails can be respectively unmethylated, monomethylated, 
dimethylated and thrimethylated contributing thereby to further diversify the biological 
outputs. 
In general, methylation of Histone H3 on lysine-4 (K4), -36 (K36) and -79 (K79) is 
associated with transcription-competent chromatin. Instead,  H3K9, H3K27 and 
H4K20 methylation is linked to regions of chromatin that are transcriptionally silent 
(Figure 1). In addition, whereas H3K4me3 is primarily found in close proximity to the 
transcriptional start site (TSS), H3K36me3 marks preferentially gene bodies (Barski et 
al., 2007). Silenced genes that are subjected to modulation are often associated with 
H3K27me3 deposition around the TSS, whereas H3K9me3 defines stably repressed 
genomic regions. Methylated CpG-islands located predominantly in promoter regions 
also contribute to stable gene repression (Lachner et al., 2003). The net result of 
histone marks associated respectively to active and inactive chromatin states define 
ultimately the transcriptional state of any given gene.  
 
Figure 1. Post-transcriptional modifications of histones. Histone tails undergo a variety of 
covalent modifications including acetylation (ac), methylation (me), phosphorylation (ph) and 
ubiquitination (ub), which influence the state of compaction of chromatin (Adapted from 
Bhaumik et al, 2010). 
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The degree of histone lysine methylation of any given genomic region is the result of 
a fine balance between the opposing functions of respectively histone lysine 
methyltransferases (KMTs) and demethylases (KDMs).  
 
1.1.2.1.1. Histone lysine methyltransferases 
SET domain-containing proteins represent a superfamily of histone lysine 
methyltransferases that catalyze the transfer of a methyl group from a donor 
substrate (represented by S-adenosyl L-methionine (AdoMat)) to the amino group of 
specific lysine residues. The SET domain is a highly conserved protein domain that 
was originally identified in three Drosophila Melanogaster Histone methyltransferases 
identified respectively as Suppressor of variegation 3-9 (Su(var)3-9) (responsible for 
H3K9 methylation) ; Trithorax (Trx) (that catalyzes H3K4 methylation)  and Enhancer 
of zeste (E(z)) (that promotes H3K27 methylation) (Tschiersch et al., 1994; Jones et 
al., 1993; Stassen et al., 1995). Among Histone methyltransferases, I will focus my 
attention in the last part of this section to discuss the contribution of the human 
orthologues of E(z) represented by Enhancer of Zeste Homologue-1  (EZH1) and- 2 
(EZH2).  
EZH1 and EZH2 belong to the superfamily of Polycomb group (PcG) proteins.    PcG 
proteins act as transcriptional repressors to regulate a variety of biological processes 
including cell cycle progression, senescence, apoptosis, tissue homeostasis, X-
chromosome inactivation, genomic imprinting and cell fate decision (Gieni and 
Hendzel, 2009; Bracken et al., 2007; Sparmann and van-Lohuzen, 2006). In 
mammals, PcG proteins exert their function within two main multi-subunit 
macromolecular complexes termed Polycomb repressive complex 1 (PRC1) and 
Polycomb repressive complex 2 (PRC2). The methyltransferase activity of PcG 
proteins resides within PRC2. It is primarily catalyzed by EZH2 through its SET 
domain. Other core components of PRC2 include Embryonic Ectoderm Development 
(EED), Suppressor of zeste 12 (Suz12) and Retinoblastoma suppressor associated 
protein 46/48 (RbAp46/48) (Kirmizis et al., 2004; Czermin et al., 2002). H3K27 
methylation can be also catalyzed by EZH1. However it has a weaker catalytic activity 
compared to EZH2 (Margueron et al., 2008). PRC2-dependent H3K27 methylation 
can trigger the recruitment to target sites of PRC1 (Cao et al., 2013). Recent studies 
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have revealed the existence of multiple independent forms of PRC1. The latter differ 
in subunit composition acting often in different cell types and/or stages of 
differentiation on selective sets of target genes. The catalytic subunits of PRC1 
consist of the E3 ubiquitin ligases Ring1a and Ring1b/RNF2, which catalyze 
monoubiquitylation of Histone H2A on lysine-119 (H2AK119Ub). Other components of 
PRC1 include Bmi1 and members respectively of CBX chromobox and Polyhomeotic 
homologue (PHC) protein families. 
PRC1 and PRC2 complexes are thought to act in concert to promote silenging of 
target genomic regions. According to a large body of evidences it has been proposed 
PRc2 is initially recruited to target sites. Here, it catalyzes H3K27 trimethylation, 
which in turns gets recognized by CBX proteins of PRC1 through their chromobox 
domain. Ultimately, PRC1 catalyzes H2AK119ub to prevent  transcriptional elongation 
by RNA polymerase II and hence mediate gene repression (Simon et al., 2009; 
Schuettengruber and Cavalli, 2009) (Figure 2a). Recent studies have, at least in part, 
put in question this model (Kalb et al., 2014; Cooper and Brockdorff, 2014; 
Blackledge et al., 2014). Indeed, it was shown that PRC1 could be recruited to target 
sites independent of PRC2. Once there, ubiquitination of H2AK119 recruited PRC2 in 
a complex with the H3K4 demethylase Jarid2 and the zinc finger protein Aebp2. 
Following this event, PRC2 catalyzed H3K27 trimethylation activating thereby a 
positive feedback loop that facilitated further recruitment of PRC1 (Figure 2b). 
 
 
 
 
 
 
 
 
	   23	  
 
 
Figure 2.Polycomb-mediated gene silencing. a) Model for PRC2-dependent model for 
recruitment of PRC1 to target sites, b) Alternative model of Polycomb recruitment. 
Monoubiquitilation of H2AK119 by PRC1 recruits PRC2, which, in turn, facilitates further 
recuitment of PRC1 to target sites via deposition of H3K27me3.  
 
1.1.2.1.2. Histone lysine demethylases 
Studies in the 1970s based on radioactive labeling of histone methyl groups indicated 
that this epigenenetic modification had approximately the same half-life as that of the 
histone itself (Byvoet et al., 1972; Borun et al., 1972). Hence,  histone methylation 
was considered as an irreversible modification, explaining thereby how epigenetic 
information was stored. Later studies revealed however a faster turnover of 
methylated histones which were constantly exchanged within nucleosomes during the 
cell-cycle (Annunziato et al., 1995).  To explain the turn over of methylated histones, 
two possible mechanisms were suggested, namely active exchange of methylated 
histones with their un-methylated counterparts or proteolytic removal of methylated 
histone tails. The isolation of the first lysine-specific demethylase LSD1/KDM1A 
confirmed the existence of an active process leading to the enzymatic removal of 
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methyl-groups from histones (Shi et al., 2004). The mechanism of action of LSD1 is 
conserved in most eukaryotes. LSD1 acts as an amine oxidase that catalyzes 
oxidative demethylation of mono- and dimethylated lysine residues using Flavin 
Adenine Dinucleotide (FAD) as a cofactor (Shi et al., 2004). Following the discovery 
of LSD1, Tsukada and colleagues described an iron- and α-ketoglutarate-dependent 
hydroxylation reaction able to promote histone demethylation (Tsukada et al., 2006). 
This study was confirmed by independent reports (Whetstine et al., 2006; Fodor et al., 
2006; Cloos et al., 2006). The idea of iron- and oxygen-dependent demethylation of 
histones came from the identification in Escherichia coli of AlkB, a DNA demethylase 
enzyme that catalyzes hydroxylation of the methyl group via decarboxylation of α-
ketoglutarate. Biochemical approaches using HeLa cells nuclear extracts led to 
identification of FBXL11/KDM2A that disposes an iron deoxygenase Jumonji-C 
(JmjC) domain similar to the AlkB catalytic site. The similarities between the catalytic 
domain of AlkB and the JmjC domain led to the finding of JmjC domain-containing 
proteins as an another class of histone lysine demethylases. JmjC domain-containing 
histone demethylases can act on all methylation states through an oxidative 
demethylation reaction, whereas LSD1 can only demethylate mono- and di-
methylated histones because it lacks a protonated nitrogen as hydrogen donor to 
demethylate the trimethyl mark (Figure 3).  
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Figure 3. Chemistry of Histone lysine demethylation a) FAD-dependent activity of Histone 
demethylases such as LSD1. Amine oxidation of protonated nitrogen creates an iminium ion 
that is spontaneously hydrolyzed and releases formaldehyde thus resulting in a mono-
methylated lysine. The mono-methylated residue can undergo the same reaction and be 
converted to its un-methylated form. b) Mechanism of demethylation by JmjC domain-
containing proteins. Fe2+, O2 and α-ketoglutarate coordinately act to hydroxylate the methyl 
group. JmjC domain-containing proteins are able to remove respectively one, two or three 
methyl groups form lysine residues. Carbon molecules in red are demethylated in each 
reaction (Adopted from Mosammaparast and Shi, 2010). 
 
In the past few years, additional JmjC domain-containing families with lysine specific 
demethylase activity have been identified (Table 1). Among them, only two display 
histone H3K27-specific demethylase activity, namely Ubiquitously transcribed 
Tetratricopeptide repeat X (UTX/KDM6A) and Jumonji domain-containing protein 3 
(JMJD3  /KDM6B).  
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Table 1. Nomenclature of histone demethylases and their substrate specificity 
Family 
name 
Family 
member 
Former name Substrate 
specificity 
References 
KDM1 KDM1 LSD1, AOF2,BHC110 H3K4me2/me1 
H3K9me2/me1 
p53 
(Shi et al., 2004) 
KDM2 KDM2A 
KDM2B 
JHDM1A,FBXL11 
JHDM1A,FBXL10 
H3K36me2/me1 Tsukada et al., 2006) 
KDM3 KDM3A 
KDM3B 
JHDM2A,JMJD1A 
JHDM2B,JMJD1B 
H3K9me2/me1 (Yamane et al., 2006) 
KDM4 KDM4A 
KDM4B 
KDM4C 
JMJD2A,JHDM3a 
JMJD2B 
JMJD2C, GASC1 
JMJD2D 
H3K9me3/me2 
H3K36me3/me2 
(Whetstine et al., 2006) 
KDM5 KDM5A 
KDM5B 
KDM5C 
KDM5D 
RBP2, JARID1A 
PLU-1, JARID1B 
SMCX, JARID1C 
SMCY, JARID1D 
H3K4me3/me2 (Christensen et al., 
2007; Iwase et al., 
2007; Klose et al., 
2007; Lee et al., 2007; 
Liang et al., 2007 
KDM6 KDM6A 
KDM6B 
UTX 
JMJD3   
H3K27me3/me2 (Agger et al., 2007; Lan 
et al., 2007) 
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1.2. Jmj-C domain-containing protein 3 (Jmjd3) 
 
1.2.1. Jmjd3 function in early mammalian development  
In mammals, oocyte fertilization gives rise to a totipotent cell called zygote.  During 
pre-implantation development, the parental genomes undergo extensive chromatin 
remodeling and epigenetic changes. One critical example is represented by 
extensive, genome-wide redistribution of H3K27me3 that is necessary to support 
later stages of development (Santenard et al, 2010). In bovine early development, 
gradual loss of H3K27me3 occurs independent of cell division suggesting an active 
mechanism for histone demethylation (Canovas et al., 2011). In support of this, 
inactivation of the H3K27 demethylase Jmjd3 impairs early bovine embryonic 
development prior to the blastocyst stage. Notably, the embryo inherits high levels of 
Jmjd3  maternal transcripts that are crucial before embryonic genome activation 
(EGA) that occurs after the first three to four cell divisions (Canovas et al., 2011). 
Interestingly, reports from gene-targeted mice, have revealed a dispensable role for 
jmjd3 in early embryonic development. Indeed, in the frame of a collaboration with 
Dr. G. Testa group (European Institute of Oncology, Milan, Italy) we could show that 
Jmjd3 mutant mice developed without major complications up to birth. Lack of Jmjd3 
was however incompatible with post-natal life, as no mutant pups survived the first 
hours following birth, due to respiratory defects (Burgold et al., 2012). Our results 
have been confirmed by other groups (Satoh et al, 2010;). These findings suggest 
that, depending on the species, Jmjd3 contributes at different stages of embryonic 
development. 
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1.2.2. Jmjd3 and lineage commitment 
Several studies in embryonic and adult stem cells have described the concomitant 
presence of respectively activating (H3K4me3) and repressive (H3K27me3) histone 
marks at the promoter of genes encoding for key developmental regulators. This 
epigenetic configuration has been called  bivalent domain (Bernstein et al., 2007; 
Mikkelsen et al., 2007). Bivalent domains contribute to the silencing of developmental 
genes in ES cells while keeping them poised for activation at later stages of 
differentiation. The observation that lineage-specific genes that are marked by 
H3K27me3 in ES cells, have lost H3K27 methylation  in their differentiated progeny 
pointed to the existence of H3K27me3 demethylases acting on these targets. In 
support of this hypothesis, it was shown that Jmjd3  is required for H3K27me3 
demethylation of neuronal genes to sustain their expression once ES cells are 
committed to the neuronal lineage (Burgold et al., 2008). Moreover, through H3K27 
demethylation Jmjd3 facilitates elongation of RNA polymerase II at poised genes 
(Estaras et al., 2013).  
The resolution of bivalent domains causes respectively stable gene activation (if 
H3K27me3 is erased) or repression (if H3K4me3 is erased). Hence the activity of 
opposing histone methyltransferases and demethylases targeting the same histone 
residue (e.g. H3K27) is tightly regulated. Moreover, H3K27me3 demethylases act in 
tight connection with H3K4me3 methylases to oppose the activity of PcG proteins and 
induce gene transcription (Cloos et al., 2008). Indeed, biochemical studies have 
revealed that Jmjd3 and UTX are commonly found in the same multiprotein complex 
containing the H3K4 methyltransferases Mixed-lineage leukemia (MLL) -2 and -3 that 
belong to the Trithorax protein family. It has been proposed that once recruited at 
bivalent genes, H3K27me3 demethylases erase the H3K27me3 repressive marks 
while the MLL proteins catalyze H3K4 trimethylation to ultimately facilitate elongation 
of paused RNA polymerase II (Agger et al., 2007). Through this mechanism, H3K27-
specific demethylases play an essential role to activate during development the Hox 
genes that are essential for axial patterning and antero-posterior embryonic 
development (Agger et al., 2007; Lan et al., 2007). In a similar fashion, the removal of 
H3K27me3 from the promoter of mesodermal genes, leads to the recruitment of β-
catenin which, in turn, triggers Wnt-induced mesoderm differentiation (Ohtani et al., 
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2013). Jmjd3 has been also shown to associate with the transcription factor Tbx3 to 
mediate expression of  Eomes  a critical inducer of endoderm differentiation 
(Kartikasari et al., 2013). Finally, a recent study has shown that Jmjd3 inhibits somatic 
cell reprogramming through the induction of cellular senescence by promoting active 
demethylation of the Cdkn2a locus (Zhao et al., 2013).  
 
1.2.3. Jmjd3 and cell cycle progression and cellular senescence 
A number of recent reports have revealed an essential contribution of the PcG/jmjd3 
axis in the regulation of the expression of the tumor suppressor locus Cdkn2a. 
Cdkn2a encodes for the cyclin-dependent kinase (CDK) inhibitor p16INK4a and the 
tumor suppressor p19ARF. In young and healthy cells Cdkn2a is repressed by PcG-
mediated H3K27 trimethylation : Upon aging or in response to oncogenic stimulation, 
Cdkn2a is strongly upregulated (Kotake et al., 2007; Agger et al., 2009; Barradas et 
al., 2009). p16INK4A, like other members of the INK4 family, prevents G1-to-S 
transition by inhibiting the binding of CDK4 and CDK6 (CDK4/6) to cyclin D1 and 
preventing phosphorylation of the Rb protein. In its un-phosphorylated state Rb is 
complexed to members of the E2F family of transcription activators, preventing their 
function. Since the induction of target genes is required for the entry into S phase 
(Serrano et al., 2003; Walkley and Orkin, 2006), the block of E2F activity by Cdkn2a 
blocks G1-to-S transition. Instead, p19ARF exerts its tumor suppressor role by 
facilitating p53-dependent apopotsis. Specifically, p19ARF binds to the E3 ligase 
MDM2 preventing thereby its interaction with the p53 tumor suppressor. The net 
result of this regulation is the elevation of p53 protein levels, which ultimately 
sensitize cells to undergo programmed cell death (Sherr, 2001). 
Cellular stress signals including hypoxia and oncogenic stimulation have been shown 
to induce Jmjd3 expression in both mouse and human fibroblasts. This condition, in 
turn, contributes to the induction of p16INK4A and p19ARF expression and consequently 
to p53-dependent cell-cycle arrest and/or cell death (Lee et al., 2014; Agger et al., 
2009; Barradas et al., 2009). These evidences implicate that Jmjd3 may act as a 
tumor suppressor gene.  
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In addition to its role in the regulation of p19ARF expression, Jmjd3 has been directly 
involved in the regulation of p53 protein levels. In mouse neural stem cells a direct 
interaction between p53 and Jmjd3 was described (Sola et al.,2011). It was reported 
that Jmjd3 regulated the methylation status of p53, facilitating thereby its nuclear 
localization. Similar results were obtained in glioblastoma stem cells, where Jmjd3 
promoted p53-dependent neuronal differentiation (Ene et al., 2012). Williams et al. 
have recently reported that Jmjd3 expression is upregulated upon DNA damage and 
together with p53 gets recruited to p53 target genes to trigger cell apoptosis (Williams 
et al, 2014).  Notably, Jmjd3 binding to p53 target genes did not affect local 
H3K27me3 levels, pointing to a demethylase-independent tumor suppressor activity 
exerted by Jmjd3. The modulation of p53 activity through the methylation of lysine 
residues at the C-terminus of the protein (K370, K372 and K382) has been previously 
reported for other histone demethylase including LSD1 and for the histone 
methyltransferases SET8 and SET9  (Huang et al., 2007; Chuikov et al., 2007; Shi et 
al., 2007). 
 
1.2.4. Jmjd3 gene regulation and target genes 
In macrophage and microglial cells Jmjd3 expression is induced by NF-kB and the 
JAK-STAT pathways in response to inflammatory stimuli (De Santa et al., 2007; 
Przanowski et al., 2014). In mammals, the NF-kB (Nuclear Factor kappa light-chain- 
enhancer of activated B cells) family of transcription factors consists of five related 
proteins, p50, p52, p65 (RelA), c-Rel and Rel B. NF-kB family members regulate 
many biological processes including proliferation, differentiation and 
survival/apoptosis. In unstimulated cells, NF-kB proteins are found in dimeric 
complexes in association with cytoplasmic IκB inhibitors that keep them in an inactive 
form. NF-κB activation, through either the classical or the non-canonical (alternative) 
pathway, is associated with the phosphorylation of IκB proteins that leads to their 
proteolytic degradation. Hence, NF-κB dimers are allowed to translocate to the 
nucleus and activate gene expression. A large set of stimuli can trigger the activation 
of the canonical NF-κB pathway including pro-inflammatory cytokines, pathogen-
associated molecular patterns and antigens binding to T-cell and B-cell antigen 
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receptors. NF-κB target genes include cell cycle regulators (cyclin D1, cyclin D2, c-
myc and c-myb), anti-apoptotic factors (caspase inhibitor of cIAP family of apoptotic 
proteins, BCl-2 family and Bcl-XL), pro-inflammatory cytokines (TNFα, IL-1, IL-6 and 
IL-12) and immunoregulatory factors (C3 complement, ICAM, VCAM, TCRα, β and 
MHC I) (Oeckinghaus and Ghosh, 2009; Jost and Ruland, 2006). 
The Janus Associated Kinase (JAK)-Signal Transducer and activator of transcription 
(STAT) pathway is involved in the transduction of extracellular signals including 
cytokines and growth factors . STAT transcription factors (from STAT1 to STAT6) are 
essential regulators of cell proliferation, survival and differentiation in different cell 
types including lymphocytes. Deregulation of JAK-STAT function is  commonly found 
in several B cell malignancies such as acute lymphocytic leukemia (ALL), chronic 
lymphocytic leukemia (CLL) and Hodgkin lymphomas (Mitchell and John, 2005; 
Furqan et al, 2013).  
Upon inflammation, monocytes differentiate into functionally distinct M1 (classical 
macrophages) and M2 (alternatively activated macrophages) macrophages. Several 
reports have shown that Jmjd3 expression contributes to macrophage polarization 
facilitating the development of M2 cells. This is achieved through H3K27 
demethylation at promoters of M2-specific genes (Ishii et al., 2009; Satoh et al, 2010; 
Tang et al., 2014). Stimulation of macrophages with IL-4 activates the JAK-STAT6 
signaling pathway, which results in translocation of STAT6 into the nucleus where it 
regulates the expression of specific target genes including Jmjd3 (Ishii et al., 2009).  
Microglia cells are central nervous system monocytes that display functional features 
of glial cells. Activation of microglia during chronic inflammation is associated with 
several neurological diseases. A recent work  has revealed cooperative activity of NF-
κB and STAT transcription factors in the induction of Jmjd3 gene expression 
(Przanowski et al. 2014). Specifically, LPS activation of microglia cells triggers NF-kB-
dependent Jmjd3 expression , which, in turn, contributes to the induction of several 
proinflammatory genes and cytokines including IL-6. The expression of cytokines by 
LPS-stimulated microglia cells activated in a autocrine/paracrine fashion the JAK-
STAT pathway which ultimately through the STAT1/STAT3 heterodimer potentiated 
Jmjd3 gene expression. Importantly, Jmjd3-dependent induction of imflammatory 
genes was independent of H3K27 demethyalse activity.  
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The genomic distribution of Jmjd3 and its relationship to H3K27me3, H3K4me3 and 
RNA polymerase II occupancy have been studied in different cell contexts. Genome-
wide analysis in macrophages (De Santa et al., 2009) and neural stem cells (Estaras 
et al., 2013) have shown that Jmjd3 binds to both promoters and gene bodies where 
it facilitates RNA polymerase II elongation. In a similar fashion, recruitment of UTX to 
target sites favors first demethylation of the promoter sequence and later RNA 
polymerase II elongation within the gene body (Seenundun et al., 2010). These 
results support a model whereby Jmjd3 and UTX facilitate gene transcription at least 
part in part by altering the chromatin context of targeted loci. In support of this, it was 
shown that Jmjd3 and UTX can facilitate the recruitment of the chromatin remodeler 
Brg1 andRNA polymerase II elongation factors SPT6 and SPT16 (Miller et al., 2010). 
Genomic distribution of Jmjd3 in activated murine macrophages has revealed a 
positive correlation between Jmjd3 binding and H3K4 trimethylation. Instead Jmjd3 is 
not commonly found at genes marked by H3K27me3 and bound by PRC2 (De Santa 
et al., 2009). This result suggests that H3K27me3 is not required for recruitment of 
Jmjd3 to its target genes.  
Gene expression analyses in Jmjd3 mutant macrophages after LPS activation, 
revealed a subset of genes deregulated in mutant cells. Importantly, however, 
H3K27me3 distribution was largely unaffected in Jmjd3 mutant macrophages.  (De 
Santa et al., 2007; Satoh et al., 2010). This results indicates that Jmjd3-dependent 
gene regulation is not strictly dependent on its demethylase activity. 
 
1.2.5. Jmjd3 and tumorigenesis 
UTX and Jmjd3 demethylase show a different expression pattern. Whereas UTX is 
ubiquitously and abundantly expressed in many cell types, Jmjd3 is expressed at low 
levels and peaks in response to a both cell extrinsic and intrinsic stimuli (De Santa et 
al, 2007; Burgold et al, 2007). 
Somatic inactivating mutations of the UTX gene are among the most common genetic 
alterations identified in several human cancer types including both epithelial and 
hematopoietic malignancies (van Haaften et al., 2009; Van der Meulen et al, 2014). 
	   33	  
Downregulation of Jmjd3 has been described in various cancers including breast, 
prostate, lung and liver carcinomas as well as hematopoietic malignancies such as 
DLBCL, Burkitt‘s lymphoma and multiple myelomas (Agger et al., 2009; Anderton et 
al., 2011; Pereira et al., 2011; Svotelis et al., 2011;Shen et al., 2012). Importantly, a 
combination of whole exome and genome sequencing has recently identified Jmjd3 
as a commonly mutated gene in Follicular B cell lymphoma (Pasqualucci et al., 2013). 
In such tumors mutations are predicted to cause inactivation of Jmjd3 function. 
Human JMJD3 maps to chromosome 17p in close proximity to TP53, which is 
commonly lost in variety of cancers. Hence it cannot be excluded that cancers 
showing loss of genomic regions encompassing TP53 may also lead to Jmjd3 
inactivation.   
Deregulated expression of the H3K27 methyltransferase Ezh2 is observed in a variety 
of solid cancers (such as breast, bladder, colon and prostate) and in hematopoietic 
tumors (Sparmann et al., 2006; Sauvageau and Sauvageau, 2010). Moreover, Ezh2 
gain-of-function mutations are observed in over 20% of germinal center derived 
Diffuse Large B cell Lymphoma (DLBCL) and Follicular B cell Lymphoma (Morin et 
al., 2010; McCabe et al., 2012; Sneeringer et al., 2010; Beguelin et al., 2013). 
Instead, inactivating mutations of Ezh2 are commonly found in myeloid malignancies 
and T cell lymphomas (Ernst et al., 2010).  
All together, these results indicate that cell-type and stage specific modulation of 
H3K27me3 is critical to control cell proliferation, differentiation and survival. 
Deregulation of such mechanism is commonly associated to malignant 
transformation. 
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1.3. B cell development 
 
B-lymphocytes as all other blood lineages are generated from pluripotent 
hematopoietic stem cells (HSCs) in the fetal liver during embyogenesis and in the 
bone marrow after birth. Differentiation of early B cell progenitors to mature B cells is 
a stepwise process that is tightly controlled by extrinsic and intrinsic factors to ensure 
B cell functionality while avoiding self-reactivity. Extensive research over the past two 
decades has greatly improved our knowledge on the basic mechanisms underlying B 
cell lymphopoiesis. This has been possible through the identification of surface 
markers and molecular events associated with specific stages of B cell development. 
Since processes that occur during B cell development are often shared with those 
occurring in other cell lineages, the understanding of the molecular mechanisms 
underlying regulation of B cell lymphopoiesis has important biological implications 
especially in the fields of developmental and cancer biology. 
 
1.3.1. Early B cell development  
In mammalian, B cell development starts in the fetal liver in prenatal life and 
continues in the bone marrow after birth as a lifelong process where pluripotent HSCs 
differentiate through a tightly regulated hierarchical process. The derivation from HSC 
of multipotent progenitors (MPP) is followed by the generation of the first lymphoid-
committed multipotent progenitors (LMPPs). The latter give rise to common lymphoid 
progenitors (CLPs), which represent a highly committed population of lymphoid 
precursors. The differentiation of early hematopoietic precursors enriched for 
pluripotent HSCs defined as lineage negative, stem-cell antigen 1 (Sca1) positive, c-
Kithi  cells (LSK subset) into  B lineage-committed cells involves the expression of 
FMS-related tyrosine kinase 3 (FLT3) which is associated with the earliest expression 
of lymphoid-specific genes (Hardy and Hayakawa, 2001; Welner et al., 2010). 
The protective function exerted by B and T cells relies on the ability to recognize a 
broad repertoire of foreign antigens through respectively the B- and T-cell antigen 
receptors (BCR and TCR). The BCR consists of two immunoglobulin heavy (H) and 
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light (L) chains which are linked via disulfide binds. Each Ig chain contains a variable 
region (V) that is responsible for the binding to the antigen and a constant region. The 
IgH chain constant region mediates the effector function of membrane-bound BCR, 
controlling ultimately B cell differentiation, proliferation and survival. 
Diversification of the Ig repertoire relies on a recombinatorial mechanism called VDJ 
recombination that assembles in a stochastic fashion one of multiple copies (in the 
order of hundreds for the V segments) of V, D and J segments to generate the 
variable (V) region genes of IgH and IgL chains. VDJ recombination is catalyzed by 
the Recombination Activating Gene 1 and 2 (RAG1 and RAG2) proteins (McBlane et 
al., 1995; van Gent et al., 1995; Hoim et al., 1998). RAG proteins cleave DNA in a 
sequence-specific fashion at so-called Recombination Signal sequences (RSSs) 
flanking each V, D (for the IgH V gene) and J segment. Once cleaved at RSS 
sequences, V, (D) and J gene segments are joined together by enzymes involved in 
the non-homologous end joining repair pathway (NHEJ) (Li and Johnson, 1995).  
To assemble the VH gene, DH and JH gene segments are first joined together, 
followed by a V to DJ recombination step. For the VL gene, V segments are directly 
joined to J segments. To further diversify the IgH repertoire non- templated n 
nucleotides are introduced respectively at the joining between V and D, and D and J 
segments by terminal deoxynucleotidyl transferase (Tdt).  
VDJ recombination proceeds in a highly ordered fashion. Specifically, rearrangement 
of VH genes precedes always that of VL genes. IgH V gene rearrangements occur in 
pro-B cells, which are defined on the basis of surface markers as B220+CD43+c-
Kit+IgM- cells. Once a functional/productive VH gene is assembled, expression of an 
IgH chain leads to the transition of the cells to the pre-B cell stage.  In pre-B cells 
(defined as B220+CD43-CD25+IgM-) the expression of a pre-B cell receptor composed 
of an IgH chain paired to the surrogate IgL chains V-preB and l5 triggers a 
proliferative burst that leads to clonal expansion of the cells. This process is driven by 
Interleukin-7 (IL7) and self-aggregation of the pre-BCR (Martensson and Ceredig, 
2000). Following this stage, pre-B cells exit the cell-cycle and reactivate expression of 
the Rag proteins to ultimately promote IgL chain V gene rearrangements. Once a 
functional IgL chain is produced, the correct pairing with the IgH chain will lead to the 
assembly on the surface of the cells of a BCR. The latter will stop further RAG-
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mediated recombination events and drive the cells to become IgMhiIgD-/loB220lo 
immature B cells. Immature B cells in the bone marrow undergo a stringent selection 
process that leads to the elimination of cells that express BCRs recognizing self 
antigens with high affinity. Alternatively, auto-reactive immature B cells may undergo 
IgL chain receptor editing, a process whereby secondary VL gene rearrangements are 
induced to replace the IgL chain as an attempt to eliminate auto/self reactivity of the 
BCR (Nemazee, 2006;  Edry and Melamed, 2004) In some instances, B cells 
expressing low-affinity self-reactive BCRs may evade clonal deletion and/or receptor 
editing and leave the bone marrow. As a result of chronic antigen stimulation such 
cells are usually in an anergic state (Cambier et al., 2007). Finally immature B cells 
that express functional, non-autoreactive BCRs leave the bone marrow and reach, 
through the blood stream, peripheral lymphoid organs such as spleen and lymph 
nodes to eventually complete their maturation (Rajewsky, 1996; Allman et al., 1993) 
(Figure 3).  
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Figure 4. Schematic view of B cell development. Postnatal B cell development starts in the 
bone marrow, where pro-B cells derived from hematopoietic stem cells undergo initial VDJ 
recombination at the IgH locus. Upon successful rearrangement of a productive IgH V-gene, 
the IgH chain pairs to surrogate IgL chains to form the pre-BCR receptor. After pre-BCR 
driven pre-B cell proliferation, cells undergo IgL chain V gene rearrangements. Once 
productive IgH and IgL chains are expressed and are able to pair, they form a BCR that is 
expressed on the B cell surface. The latter cells are defined immature/naïve B cells. The 
egress of immature B cells from the bone marrow is guaranteed only if cells do not express 
an autoreactive BCR (Adapted from Rajewsky, 1996). 
 
1.3.2. Peripheral B cell development 
 
1.3.2.1. Transitional B cells 
Around 20 million of short-lived B220+IgMhiIgD- immature B cells are generated every 
day in the bone marrow of wild-type adult mice.  Of those only 10% reaches 
secondary lymphoid organs and the majority of the immigrants die after few days. 
Therefore only a small fraction of immature B cells completes its development to 
become long-lived mature B cells (Rajewsky, 1996). Immature B cells,  also called 
transitional B cells, typically express high levels of IgM in combination with the early 
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differentiation marker AA4.1/CD93 the Heat Stable Antigen (HAS)/CD24 and low 
levels of B220. Based on the expression of CD23 and IgM, B220loAA4.1+ transitional 
B cells are divided into different subsets: Transitional T1 cells (IgMhiCD23-) represent 
the earliest immature B cells reaching the spleen. The latter B cells develop into 
transitional T2 cells (IgMhiCD23+) which are the direct precursors of long-lived mature 
B cells.  There exist also a population of so-called transitional T3 cells (IgMloCD23+), 
but their origin and function is yet to be fully understood (Allman et al., 2001). 
 
Figure 5. Peripheral B cell development. Newly generated immature B cells expressing 
functional, non-autoreactive, surface BCR migrate to secondary lymphoid organs where a 
fraction of them will complete differentiation to become respectively Follicular (Fo), Marginal 
Zone (MZ) or B-1 B cells. MZ and B-1 B cells are mainly recruited into T-cell independent 
immune response, giving rise ultimately to short-lived plasma cells. Fo B cells (and in part MZ 
B cells) are the major subset recruited into T-cell dependent immune responses, Upon 
antigen recognition and T-cell help, Fo B cells get recruited into germinal centers where they 
clonally expand and mutate their Ig V genes. Stringent antigen-driven selection leads only 
few B cells expressing high affinity BCRs to survive and exit the GC reaction as long-lived 
memory B cells or plasma cells. 
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1.3.2.2. Mature B cells 
Mature B cells in the mouse are divided into three major subsets represented 
respectively by Follicular, marginal zone (MZ) and B-1 B cells. 
1.3.2.2.1. Follicular B cells 
Follicular (Fo) B cells also called B-2 B cells, represent the major population of 
mature B cells. They are identified as IgMloIgD+CD21+CD23+ cells. Fo B cells are 
located in all secondary lymphoid organs including the spleen, lymph nodes and bone 
marrow.(Pillai et al., 2004). Fo B cells reside respectively within the white pulp of the 
spleen and the cortical area of lymph nodes where they home to defined regions 
called follicles. Fo/B-2 B cells recirculate through the blood stream. They are involved 
in both T-cell dependent and T-cell independent immune responses. In a T-cell 
dependent response, recognition of antigen by the BCR promotes the recruitment of 
Fo B cells into the germinal center (GC) reaction. This process is strictly dependent 
on CD4+ T cells, which recognize through their TCR the processed antigen presented 
by antigen-specific B cells via MHC-class II molecules. As a result of antibody affinity 
maturation occurring during the GC reaction, highly selected Fo B cells exit the GC to 
become long-lived memory B cells or antibody-secreting plasma cells. Fo B cells can 
also directly differentiate into short-lived low-affinity plasma cells after recognition of T 
cell-independent antigens (Casola, 2007).  
1.3.2.2.2. Marginal zone B cells 
MZ B cells (IgMhiIgDloCD21hiCD23lo) are self-replenishing mature B cells ( Martin and 
Kearney, 2002). MZ B cells reside in close proximity to the marginal sinus in the 
spleen, surrounding B cell follicles. MZ B cells are recruited into both T-cell 
dependent and –independent immune responses. Given their close vicinity to the 
bloodstream, MZ B cells represent the first barrier to blood-born pathogens. In this 
context, MZ B cells get rapidly activated through their BCR,  proliferate and ultimately 
differentiate into low-affinity antibody secreting plasma cells (Cinamon et al., 2008; 
Martin and Kearney, 2002). 
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1.3.2.2.3.  B-1 B cells 
B-1 B cells (IgMhiIgDloCD21loCD23lo) represent a subset of mature B cells which 
resides primarily in body cavity serosa including pleural and peritoneal cavities 
(Casola, 2007). According to CD5 expression, B-1 B cells are divided respectively 
into B-1a (CD5+) and B-1b (CD5-) B cells (Stall et al., 1992). 
B-1a B cells originate from the para-aortic splanchnopleura in early mouse embryos. 
At later stages of embryonic development, the fetal liver represents the major source 
of B-1a B cells. Fetal liver-derived B-1a B cells represent the major subset of B-1a B 
cells found in post-natal mice (Dorshkind and Montecino-Rodriguez, 2007). Indeed, 
de novo B-1a B cell generation is highly inefficient in the bone marrow of adult life 
(Herzenberg, 2000).  
B-1b B cells are mainly originated from HSCs residing in the fetal liver. However, 
differently from their B-1a counterparts, B-1b B cells get also efficiently generated 
from HSC residing in the bone marrow of adult mice (Dorshkind and Montecino-
Rodriguez, 2007). In contrast to continuous de novo generation of B-2 B cells from 
bone marrow precursors, B-1 B cells have self-renewal capacity and undergo limited 
proliferation to sustain the population size throughout life. B-1 B cells express BCRs 
that recognize with low affinity self-antigens that cross-react with microbial 
components. As a result of this, B-1 B cells are the main producers of low-affinity so-
called natural IgM antibodies that represent a first barrier against bacterial infections 
(Hardy, 2006). Upon recognition of T cell independent antigens B-1 B cells are 
recruited together with MZ B cells into an immune response that leads ultimately to 
the generation of short-lived antigen-specific IgM- and IgG3-secreting plasma cells 
(Baumgarth, 2010). 
 
1.3.2.3. Determinants of peripheral B cell development 
Differentiation of immature transitional B cells into functionally distinct mature B cell 
subsets is an essential step in development of B cells and has been intensely 
investigated for a decade. Maturation of transitional B cells to become respectively 
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Fo, MZ and B-1 B cells is mediated by a limited number of receptors, signaling 
pathways and transcription factors that are outlined below. 
 
1.3.2.3.1. The BCR 
BCR signaling is an important component controlling the maturation of  transitional B 
cells.  Using a number of independent experimental approaches based primarily on 
the analysis of BCR transgenic and gene targeted mice, it has been proposed that 
strength of the BCR signal controls the fate of developing immature B cells.  
Summarizing a large body of evidences it has been proposed that immature B cells 
require a stronger signal to develop into B-1 B cells as compared to MZ B and Fo B 
cells (Casola et al., 2010; Pillai et al., 2004, Casola, 2007) Fo B cells have been 
suggested to require the lowest BCR signal among all B cell subset, for their 
development.  Whether differences in signal strength reflect quantitative rather than 
qualitative differences remains to date a highly debated matter. Moreover, it remains 
to be demonstrated whether antigen plays a role in the selection of immature B cells 
(Pillai et al., 2004, Casola, 2007). In this regard, recent high throughput antibody 
repertoire analysis in mouse mature B cell subsets exclude a major contribution of 
antigen in the selection of short lived  immature B cells (Kaplinsky et al 2014). 
 
1.3.2.3.2. BAFF 
B-cell activating factor (BAFF) is a member of the tumor necrosis factor family (TNF) 
that is produced by myeloid lineage cells and plays an important role in the 
generation and maintenance of mature B cells  (Schiemann et al., 2001, Schneider 
and Tschopp, 2003; Mackay and Browning; 2002; Khan, 2009). BAFF binds to three 
different receptors: transmembrane activator, calcium modulator, and cyclophilin 
ligand interactor (TACI); B cell maturation Ag (BCMA); and BAFF-R. BAFF-R is the 
main receptor that controls maturation and survival of mature B cells. Indeed, BAFF-R 
mutant mice display a significant reduction in the number of transitional and Fo B 
cells. An even more dramatic effect was observed for the MZ B cell compartment 
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which was almost lacking in BAFF-R mutant mice. In sharp contrast, development 
and persistence of B1-B cells was shown to be independent of BAFF (Crowley et al., 
2008: Scholz et al., 2008). BAFF simulation leads to the rapid activation in B cells of 
the serine/threonine kinase AKT that promotes cell growth, glycolysis and protein 
synthesis through activation of mammalian target of rapamycin (mTOR) pathway 
(Matsuzawa et al., 2008; Patke et al., 2006; ). Moreover, signaling through BAFF-R 
induces the expression of anti-apoptotic factors such as B-cell chronic lymphocytic 
leukemia/lymphoma-2 (Bcl-2) and Bcl-extra long (Bcl-xl) (Woodland et al., 2006). 
Importantly, recent work has shown a critical intersection between BAFF-R and BCR 
signaling with the tyrosine kinase Syk being the key signaling molecule connecting 
the two pathways (Schweighoffer et al., 2013). These studies support a model 
whereby BAFF-R coopts the BCR to sustain the survival of mature B cells. 
 
1.3.2.3.3. NFAT 
Nuclear factor of activated B cells (NFAT) is a family of five transcription factors that 
regulate the transcription of pro-survival genes in lymphocytes (Rao et al, 1997; 
Crabtree and Olson, 2002; Muller and Rao, 2010). NFAT family members NFATc1, 
NFATc2 and NFATc3 are expressed in mature B cells where they  get activated in 
response to BCR cross-linking or CD40 signaling (Verweij et al., 1990; Choi et al., 
1994). The latter stimuli induce a transient rise in intracellular Ca+ levels, which in turn 
through the Calmodulin-calcineurin axis promote nuclear relocalization and hence 
activation of NFAT transcriptional function. NFATc1 is essential for B-1a B cell 
development and survival(Berland and Wortis, 2003). 
 
1.3.2.3.4. Pax5 
The transcription factor Pax5 is a master regulator of B cell development. Pax5 is 
expressed starting from pro-B cells and remains active throughout B cell development  
(Fuxa and Busslinger, 2007). Pax-5 gets silenced when B cells differentiate ultimately 
in antibody-secreting plasma cells. In early B cell precursors Pax-5 is essential to 
enforce B cell identity by sustaining the activity of other B-lineage transcription factors 
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(such as Ebf1 and E2A), preventing at the same time expression of determinants 
(such as Notch-1) driving alternative lineage fates (e.g. T cells) (Nutt et al, 1999; 
Cobaleda et al., 2007a; Revilla et al., 2012; Souabni et al., 2002). In pro-B cells, Pax5 
is critical for VDJ recombination. In particular, it was shown that Pax5 is essential for 
IgH locus contraction. The latter process is critical to allow RAG proteins to employ 
distal VH genes in the recombination process (Fuxa et al., 2004). Elegant experiment 
in the Busslinger lab have also shown that PAX5 is required to sustain B cell identity 
in mature B cells. Indeed conditional inactivation of Pax5 in mature B cells caused a 
major transcriptional reprogramming of mutant cells that could commit to other cell 
types including T cells and macrophages (Cobaleda et al., 2007b). Pax5 acts both as 
a transcriptional activator and repressor. Among the genes induced by Pax5 there are 
critical effectors of the BCR signaling pathway through which it likely controls B cell 
survival. Conversely, Pax5 represses genes that are expressed in terminally 
differentiated plasma cells and in other cell lineages to enforce B cell identity (Nera et 
a;l., 2006).  
 
1.3.2.3.5. Notch2 
In mammals, the family of Notch receptors includes 4 members (Notch-1 to -4), which 
recognize 5 ligands of the Jagged and Delta-like (Dll) families respectively. Notch 
proteins are membrane-bound receptors that get cleaved in response to ligand 
interaction. Intracellular cleaved Notch translocates to the nucleus where it regulates 
gene expression through the transcription factor RBPjk (Kopan and Ilagan, 2009). 
Notch signaling regulates multiple cell fate decisions in hematopoiesis  (Radtke et al., 
2004a,b).  
Notch2 is the main Notch member involved in the regulation of B cell development. 
Work performed on Notch2 deficient mice has revealed an essential function for the 
transcription factor (and its ligand Dll-1) in the development of MZ B cells (Saito et al., 
2003). This conclusion was further confirmed analyzing gene-targeted mice lacking 
critical regulators of the Notch pathway such as RBP-JK and MINT (Tanigaki et al., 
2002; Kurado et al., 2003). Recent work has established a critical role for notch2 in 
MZ B cell maintenance. Indeed, acute inactivation of Notch2 in established MZ B cells 
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led to the rapid disappearance of B cells residing in the MZ. Interesting such B cells 
did not undergo apoptosis but rather migrated away from the MZ, indicating that 
Notch2 is essential for the retention of B cells in the MZ area (Simonetti et al., 2013).  
 
1.3.3. B cell immunity 
B cell immune responses are classified respectively as T-cell dependent (TD) and T-
cell independent (TI) depending on the nature of the antigens encountered through 
their BCRs. The end result of a B cell immune response is the production of soluble, 
antigen-specific, antibodies, which contribute to the establishment of humoral 
immunity. Soluble antigens are essential for a fully functional immune system as they 
contribute to the clearance of pathogens in multiple ways including complement 
fixation, phagocytosis, and prevention of entry into target cells.  
 
1.3.3.1. T-cell independent immune responses 
In T-cell independent (TI) immune responses, B cells get activated and differentiate 
into short-lived plasma cells, without the help of T cells. All major B cell subsets can 
potentially get recruited into TI immune responses. Given their close proximity to the 
blood stream, MZ B cells represent the elective subset that is activated in response to 
blood borne pathogens. During T-cell independent immune responses B cells get 
activated as a result of the triggering of different types of receptors, depending on the 
type of antigens they interact with. There are two main types of TI antigens:  
Type-1 antigens (TI-1): Trigger a polyclonal B cell response that results from the 
stimulation of receptors other than the BCR. An example of TI-type 1 antigen is 
lipopolysaccharide (LPS) a constituent of the cell wall of Gram-negative bacteria. In 
the presence of high levels of LPS, activation of B cells through Toll-like receptor-4 
(TLR) is sufficient to trigger a polyclonal unspecific antibody response. In case LPS 
levels are in the low range (and hence not sufficient to activate cells only through the 
TLR4 receptor) only B cells recognizing the antigen through the BCR will get 
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activated. In this case the antibody response with be antigen (LPS)-specific. Both 
immature and mature B cells can get recruited in TI-type 1 immune responses. 
Type-2 antigens (TI-2): share in common highly repetitive structures. Polysaccharides 
of encapsulated bacteria including S. pneumonia, N.meningitidis and H. influenza 
represent typical examples of TI-2 antigens. Recognition of highly repetitive antigens 
in a BCR-dependent fashion leads to potent cross-linking of the BCRs, which 
ultimately triggers terminal differentiation.   B-1 B cells and MZ B cells represent the 
major B cell subsets recruited into TI type-2 immune responses.  
1.3.3.2. T-cell dependent immune responses 
T-cell dependent immune responses are predominantly triggered by protein antigens 
that are recognized by the BCR through one of its epitopes. Within the B cells, protein 
antigens get cleaved in smaller peptides, which are in turn loaded onto MHC-class II 
molecules and presented to CD4+ T cells.  Interaction between antigen-specific B and 
T cells at the border between T cell and B cell zones leads to full activation of B cells 
which in turn migrate back to the follicle to nucleate a germinal center (GC). In the 
GC, clonal expansion of antigen specific B cells is accompanied by substantial 
genetic rearrangements occurring at the Ig loci. Specifically, Ig somatic hypermutation 
(SHM) leads to the introduction of non-templated mutations within the V region of Ig 
genes. At the same time double strand breaks accumulating at IgH constant region 
genomic loci allow the substitution of Cµ with that of another isotype through a 
process called Ig class switch recombination (CSR). Both Ig SHM and CSR are 
catalyzed by Activation induced cytidine Deaminase (AID) (Muramatsu et al., 2000). 
As a result of Ig SHM, the progeny of the founder antigen-specific B cells that got 
recruited into the GC undergoes a stringent selection process that allows only very 
few B cells, namely those expressing high affinity BCRs, to exit the GC after 
differentiating into long-lived memory B cells of plasma cells (Basso and Dalla-
Favera, 2010; Klein and Dalla-Favera, 2008; Rajewsky, 1996). 
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Figure 6. Schematic view of the GC reaction. During a T cell dependent immune response, 
antigen-specific B cells receive T cell help and initiate a germinal center reaction. In GCs,  B 
cells initially proliferate vigorously within the “dark zone” while they undergo Ig V gene 
somatic hypermutation (SHM). In the light zone, GC B cells exit cell-cycle and undergo 
stringent selection based on the recognition through the BCR of antigen presented by 
Follicular Dendritic Cells (FDC). Capture of antigen and presentation to Follicular helper T 
cells represents a critical step in positive selection of GC B cells. Iterative cycles of 
proliferation, Ig SHM and selection allows the generation of B cells expressing high affinity 
BCrs. Ultimately, the latter cells exit the GC reaction after differentiating respectively into 
long-lived memory B cells or terminally differentiated plasma cells. The output of the GC 
reaction includes B cells that have undergone Ig class switch recombination that allows the 
exchange of the effector function of the immunoglobulins expressed/secreted by post-GC B 
cells. 
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1.3.4. Terminal B cell differentiation 
Plasma cells represent an essential component of humoral immunity. Depending on 
their lifespan, antibody-secreting cells can be either short-lived or long-lived. The 
former are mainly generated during T-cell independent immune response. Short-lived 
plasma cells accumulate predominantly in extrafollicular regions of secondary 
lymphoid organs. Instead, long-lived plasma cells are generated as a result of a T-cell 
dependent immune response. Long-lived plasma cells reside often for a life-long time 
in the bone marrow where they keep secreting high affinity antibodies. Within the 
bone marrow, plasma cells occupy specific niches where they receive extrinsic 
signals that are required to sustain their survival. The Bcma/Mcl1 axis has been 
recently shown to play a crucial role in the regulation of bone marrow plasma cell 
survival (Peperzak et al., 2013). The differentiation of B cells into plasma cells is 
controlled by a complex transcriptional regulatory network which has been heavily 
investigated in the past decade. Three major transcription factors, namely 
Blimp1/Prdm1, IRF4 and Xbp1, are required for plasma cell differentiation and 
maintenance. Terminal differentiation requires also stable repression of the master 
regulator of B cell identity, Pax5 (Nera et a;l., 2006). 
 
1.3.4.1. Master regulators of PC differentiation 
1.3.4.1.1. B lymphocyte-induced maturation protein-1 (Blimp-1) 
Blimp1 is a transcription factor that is encoded by the Prdm1 (Positive regulatory 
domain-containing 1) gene (Sciammas and Davis, 2004). Blimp-1 represses the 
expression of Bcl6 (Calame et al., 2003), the master regulator of the GC response 
(Cattoretti et al., 2005) and of Pax5 (Lin et al., 2002). Through this mechanism, Blimp-
1 enables the exit of B cells from the GC reaction (BCL6) and the silencing of the B-
cell specific program (Pax5). Blimp1 is also critical to induce the expression of Xbp-1, 
which is strictly required to sustain the unfolded protein response in cells secreting 
large amounts of antibodies (Calfon et al., 2002). Although Blimp-1 is critical for 
terminal B cell differentiation (Shapiro-Shelef et al., 2003), its expression is not strictly 
required to trigger the earliest steps of this process (Kallies et al., 2007).  
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1.3.4.1.2. X-box binding protein-1 (Xbp-1) 
Xbp-1 is a basic-leucine zipper transcription factor that is expressed in many cell 
types. Expression of Xbp-1 is induced upon terminal B cell differentiation (Reimold et 
al., 2001). Activation of Xbp1 transcriptional activity requires post-transcriptional 
modification of its mRNA through an unconventional splicing step mediated by the 
IRE1 endoribonuclease (Calfon et al., 2002). The Xbp1 transcription factor induces 
the expression of a large set of genes that counteracts proteotoxic stress linked to the 
high rate of Ig synthesis  (Cenci and Sitia, 2007; Cenci, 2012; Shaffer et al., 2004) 
 
1.3.4.1.3. Interferon regulatory factor 4 (Irf4) 
Interferon Regulatory factor 4 (IRF) is a member of the IRF family, which plays crucial 
functions at different stages of B cell development (Shaffer et al., 2009). In pre-B 
cells, Irf4 downregulates pre-BCR signaling through induction of Ikaros and Aiolos 
transcription factors (Ma et al., 2008). In peripheral B cells, IRF4 plays a critical role in 
the regulation of the Fo vs MZ B cell fate. Recent work has demonstrated that IRF4 
regulates Notch2 protein expression and thereby controls MZ B cell differentiation 
(Simonetti et al., 2013). Irf4 is required for GC nucleation (Ochiai et al., 2013) and 
function (Klein et al., 2006; sciammas et al., 2006). Irf-4 deficient mice do not produce 
antigen-specific antibodies in response to immunization with T-cell dependent 
antigens. This impairment is in part due to the failure to form GCs and in part to the 
essential role played by IRF4 in plasma cell differentiation (Sciammas et al., 2006; 
Klein et al., 2006; Ochiai et al., 2013). IRF4 controls the proliferation and survival of B 
cells upon BCR cross-linking or LPS treatment in vitro, whereas proliferative 
responses to anti-CD40 stimulation were unaffected by Irf4 inactivation (Mittrucker et 
al., 1997). IRF4, in cooperation with STAT3, upregulates the expression of 
Prdm1/Blimp-1 in an IL-21-dependent mechanism (Kwon et al., 2009), linking in this 
way two central  transcription factor required for terminal B cell differentiation. IRF4 
plays also a critical role in Ig CSR through regulation of AID expression (Sciammas et 
al, 2006; Klein et al, 2006). Unlike other IRF family members, IRF4 expression is 
upregulatd by mitogenic stimuli including BCR engagement, LPS, CD40 ligand and 
IL-4,  through both the  NF-κB and JAK-STAT pathways (Mittrucker et al.,1997; Gupta 
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et al., 1999). In mature B cells (including GC B cells) IRF4 expression levels are 
tightly controlled (Ochiai et al., 2013) by different mechanism that possibly 
microRNAs (Gururajan et al., 2010). 
 
1.3.5. Memory B cells 
Memory B cells are long-lived, antigen-specific B lymphocytes that are preferentially, 
but not exclusively (Takemori et al., 2014) generated as a result of the transition of B 
cells through the GC reaction (Rajewsky, 1996 ). The molecular mechanisms 
underlying memory B cell differentiation are yet poorly understood. Scheeren and co-
workers have suggested that activation of the STAT5 transcription factor in late GC B 
cells can drive memory B cell differentiation (Scheeren et al., 2005). Recent work by 
the McHeyzer-Williams group has revealed the existence of different transcriptional 
programs sustaining the identity of different types of memory B cells differing for the 
IgH chain isotype expressed by the cells (Wang et al., 2012). Finally, whether 
cognate antigen recognition is required for the maintenance of the memory B cell pool 
remains still highly controversial (Yoshida et al., 2010). 
 
1.4. Role of histone demethylases in hematopoiesis 
 
Functional in vivo studies on histone demethylases have started to unravel the role 
exerted by these proteins in the control of fundamental biological processes such as 
stem cell self-renewal, proliferation, differentiation as well as malignant transformation 
(Kooistra and Helin, 2012). Conditional inactivation of the H3K4/K9me3 demethylase 
Lsd1 resulted in severe pancytopenia due to the combined defects on early and late 
hematopoietic differentiation. Deletion of Lsd1 in HSCs caused a severe defects in 
HSC self-renewal and the loss of myeloid progenitor cells. Bu acting at the level of 
megakaryocyte-erythroid progenitors, Lsd1 inactivation also interfered with their 
differentiation into  granulocytes and erythrocytes. Finally, Lsd1 inactivation prevented 
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differentiation of HSC cells by preventing the repression of hematopoietic 
stem/progenitor-specific genes (Kerenyi et al., 2013).  
The  H3K27 demethylase UTX has also been implicated in erythroid, megakaryocyte 
and granulocyte differentiation (Thieme et al., 2013). Utx is expressed in 
hematopoietic stem and progenitor cells as well as in differentiated blood lineage 
cells. Utx deficient mice display severe anemia leading to compensatory 
extramedullary erythropoiesis (Liu et al., 2012; Thieme et al., 2013).  
Although several studies have suggested a critical role for Jmjd3 in M2 macrophage 
polarization (De Santa et al., 2007; Satoh et al., 2010; Ivashkiv, 2013), Jmjd3 function 
in hematopoietic cells has been yet poorly studied. Using fetal liver transplantation 
studies, Satoh and colleagues have shown that Jmjd3-/- HSCs gavre rise to relatively 
normal proportions of B- and T-lymphocytes, dendritic cells, natural killer cells, 
neutrophils and macrophages in the spleen. Moreover, activation of Jmjd3-deficient B 
with mitogens displayed apparently a normal proliferative response (Satoh et al., 
2012). In the present study we have extended this initial findings using a conditional 
knock-out approach to study the intrinsic role of JMJd3 in B cell development. 
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2. Materials and Methods 
2.1. Mice 
 
Mice strains were housed and bred at IFOM-IEO Campus Animal facility. Animal 
handling was performed following recommendations of European Community.  
 
2.1.1. Mice strains 
JMJD3fl conditional KO mice were bred to Mb1-Cre (Hobeika et al., 2006) and PGK-
Cre (Lallemand et al., 1998) strains. These two Cre lines have C57BL/6 genetic 
background. 
 
2.1.1. Mice immunization 
 
8-10 week old mice were immunized with Alum (Imject ® Alum, aqueous solution of 
aluminium hydroxide (40 mg/ml) and magnesium hydroxide (40 mg/ml), Pierce) 
precipitated NP27CGG (100 µg per mouse, 4-Hydroxy-3-nitrophenylacetyl hapten 
conjugated to chicken gamma globulin, Biosearch Tech.) intraperitoneally. 
 
2.2. DNA methods 
 
2.2.1 Isolation of genomic DNA from mouse-tail biopsies 
 
Tail tips collected by animal facility were incubated in 400 µl of tail lysis buffer 
containing Proteinase K (100 µg/ml) at 56˚C overnight, shaking at 700 rpm.  Tissue 
lysate was transferred into a new tube and 1 ml of isopropanol was added and mixed 
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by inverting the tubes several times. After centrifugation at full speed for 10 minutes, 
DNA pellet was air-dried and resuspended in 200 µl of miliQ water.  
Tail lysis buffer 
              100 mM Tris-HCl 
              5 mM EDTA 
              200 mM NaCl 
              0.2 % SDS 
 
2.2.2. Polymerase chain reaction (PCR) 
 
PCR reactions were performed in three steps: denaturation of DNA template, primer 
annealing and polymerization (Table 2). Reactions were prepared usually in a total 
volume of 25 µl with 0.2 mM dNTPs, 0.5 mM primers, DNA template, 0.5 U of   
GOTaq® DNA polymerase, 25 mM MgCl2 and 1X GoTaq® Felexi buffer.  
 
Table 2. Thermal cycling of PCR amplification 
                 Step                            Temperature     Time        Number of cycles 
Initial Denaturation 95 ˚C 2 minutes 1 cycle 
    
Deanturation 95˚C 0.5 minute  
Annealing variable* 0.5 miute 30 cycles 
Extension 72˚C  1minute/ kb  
    
Final extension 72˚C 5 minutes 1cycle 
Hold 4˚C   
             
              * The annealing temperature for each pair of primers was optimized 
                 based on the sequence of primers. 
 
PCR reactions were run on an agarose gel in presence of 1X Tris-acetate-EDTA 
buffer (TAE), the percentage of agarose was defined by the size of the DNA 
fragments: 
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 DNA fragment size         % agarose             
< 100 bp                                     3 % 
0.1 to 2.5 kb                              2 % 
2.5 to 15 kb                               1 % 
15 to 30 kb                               0.4 %            
 
2.2.3. Genotyping sterategy 
 
PCR was performed on genomic DNA extracted from tail biopsies of the mice from 
different strains using primers listed in Table 3. Reactions were run in automatic 
thermocycler GeneAmp PCR System9700 (Applied Biosystems). 
 
 
Table 3. Genotyping primers, annealing temperatures and amplicons 
Primers (5’-3’) Annealing Amplicon 
JMJD3 Frt-βgeo vs. WT   
JBaygd2              AGGATACAGGAGCCACGCG   
GT3 Rev             TCCGGAGCGGATCTCAAAC 60 282 bp 
   
JMJD3 Frt-βgeo vs.  Frt-βgeo Cre deleted   
PolyA Fw                 TCTTATCATGTCTGGATCCGG   
LoxP R1                  GGAAGAGCAGATGAGACTGG 60 132 bp 
   
JMJD3 Frt-βgeo vs. FLP deleted   
JBaygd2                    AGGATACAGGAGCCACGCG   
JBaygr2                     TGACTCTCCACTCGATCACCC 60 259 bp 
   
JMJD3 fl vs. WT   
Jmjd3 Flox Fw2      GTCTTCTCTGTCCATTGCTGTC   
Jmjd3 Flox Rv        GGCTCTGTTAGGTACTGCCAG 58 169 bp 
   
JMJD3 Cre deleted allele   
JBaygd2                  AGGATACAGGAGCCACGCG   
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LoxP R1                  GGAAGAGCAGATGAGACTGG 60 322 bp 
   
Mb1-Cre    
Mb1-Cre Fw            CCCTGTGGATGCCACCTC   
Mb1-Cre Rv             GTCCTGGCATCTGTCAGAG 58 430 bp 
   
PGK-Cre*   
PGK-CreFw    GCCTGCATTACCGGTCGATGCAACGA   
PGK-Cre Rv    GTGGCAGATGGCGCGGCAACACCAT 58 700 bp 
 
* Mb1-Cre primers can also be used for PGK-Cre genotyping. 
 
 
2.2.4. Plasmid preparation 
 
Bacteria were grown overnight at 37˚C incubator and plasmids were isolated and 
purified with the Qiagen Plasmid Mini or Maxi kits (Qiagen). The alkaline lysis based 
purification procedure was performed according to the manufacturer’s protocol. 
 
 
2.3. RNA methods 
 
2.3.1. RNA extraction and cDNA synthesis 
 
Total RNA was isolated from the cells with the Qiagen RNeasy Micro and Mini kits 
(Qiagen) according to the instructions of the manufacturer. Finally RNA was 
resuspended in RNAse-free water and quantified with the NanoDrop ND-1000 
spectrophotometer (Thermo Fisher Scientific). 
CDNA synthesis was carried out using SuperScript® VILO™ kit (Invitrogen) following 
the instructions of the supplier. In general, 200 ng of total RNA was reverse 
transcribed using SuperScript® III Reverse transcriptase and SuperScript® VILO™ 
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Master Mix in 20 µl of reaction volume. Samples were incubated at 25˚C for 10 
minutes, 42˚C for 1 hour and 85˚C for 5 minutes. 
 
2.3.2. Quantitative real-time PCR (qRT-PCR) 
 
qRT-PCR was performed on LightCycler® 480 II real-time PCR system (Roche) using   
SYBR Green I  Master Mix. Reaction conditions were 95˚C for 10 minutes, 45 cylces 
of 95˚C for 1 second, 60˚C for 10 seconds, 72˚C for 1 second. Correct PCR products 
were confirmed by melting curve analysis. Each sample was analyzed in triplicates 
and normalized to Ribosomal Protein Large, P0 (RPLP0) housekeeping gene 
(Laborda 1991; Akamine et al., 2007). Normalization was used to correct sample-to-
sample variation in RNA concentration. Relative mRNA amounts were calculated by 
comparative cycle threshold (Ct) method using formula 2-ΔCt. Primers are listed in 
Table 4. 
To measure the deletion efficiency of JMJD3, qPCR analysis was performed on 
genomic DNA. Primers were used to detect the remaining JMJD3 exon 4 that is 
flanked by LoxP sites. Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) gene 
was used as a loading control for genomic DNA qPCRs (Table 4).  
 
Table 4. Primers sequences for quantitative PCR analysis 
 
Rplp0 Fw TTCATTGTGGGAGCAGAC RNA 
Rplp0 Rv CAGCAGTTTCTCCAGAGC RNA 
p16/Ink4A Fw GAACTCTTTCGGTCGTACC RNA 
p16/Ink4A Rv CCAGCGTGTCCAGGAAG RNA 
p19/Arf Fw GCTCTGGCTTTCGTGAACATG RNA 
p19/Arf Rv TCGAATCTGCACCGTAGTTGAG RNA 
Irf4 Fw CAATGTCCTGTGACGTTTGG RNA 
Irf4 Rv GGCTTCAGCAGACCTTATGCT RNA 
Tp53 Fw CAAAAGAAAAACCACTTGAT RNA 
Tp53 Rv CGGAACATCTCGAAGCGTTTA RNA 
Jmjd3 5F CAGCTCCTTTACCCCCATCT  
 
RNA 
Jmjd3 6R TTCCTCACTGTCGTGCTCTG RNA 
	   56	  
 
Jmjd3 7F CCCAGCTCTGGAACTTTCAT  
 
RNA 
Jmjd3 8R CTAAGGCCCTCCTCTCCTGA 
 
RNA 
Jmjd3 9F GTCTGCCACTCCCTCCAC  
 
RNA 
Jmjd3 10R CCATGGCTCTCTGCTCCT 
 
RNA 
Jmjd3 10F CGTTTCACCAGCAGCATCTA  
 
RNA 
Jmjd3 11R AAAATGGTTTCCGACTGCTG 
 
RNA 
Jmjd3 11F ATG GCAGACCTCACCATCA  
 
RNA 
Jmjd3 13R CCCCTGATGACGGTGATG 
 
RNA 
Jmjd3 14F AGACGAGAACTGGGACCTGA  
 
RNA 
Jmjd3 16R TGCCAAACTTGATGATGTGA 
 
RNA 
Jmjd3 ex.16 Fw AGAGGTGGTTGCCACAGCTA RNA 
Jmjd3 ex.17 Rv GTTGCCTGTGGATGTTACCC RNA 
Ccnd2 Fw GGACATCCAACCCTACATGC RNA 
Ccnd2 Rv CGCACTTCTGTTCCTCACAG RNA 
Cclnd3 Fw GCTTACTGGATGCTGGAGGTA RNA 
Cclnd3 Rv AAGACAGGTAGCGATCCAGGT RNA 
c-Myc Fw TCAAGAGGCGAACACACAAC RNA 
c-Myc Rv GGCCTTTTCATTGTTTTCCA RNA 
Prdm1 Fw ACGTGTGGGTACGACCTTG RNA 
Prdm1 Rv CTGCCAATCCCTGAAACCT RNA 
Jmjd3 Δ Fw TGCTGACCTGGTAAGGGAAA DNA 
Jmjd3 Δ Rv CGATGCATCCAGCCTAAATC DNA 
Gapdh4d Fw AGCGCTGACCTTGAGGTCTCCTTG DNA 
Gapdh4d Rv GTTGCCTACGCAGGTCTTGCTGAC DNA 
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2.4. Protein methods 
 
2.4.1. Immunoblot analysis 
 
Cells were collected by centrifugation at 1200 rpm for 5 minutes and washed with ice-
cold PBS. To extract protein, cell pellet was resuspended in 8M Urea lysis buffer (8 M 
Urea, 0.1 M NaH2PO4, 0.01 M Tris pH 8.0) and incubated 30 minutes rotating at 4˚C. 
Sonication was performed in 3 cylces of 10 seconds each. Cell lyate was then 
centrifuged at maximum speed for 10 minutes to remove cell debris. Lysates were 
quantified with a protein assay reagent (BioRad Laboratoris). 20-50 µg of proteins, in 
Laemmli loading buffer (62.5 mM Tris-Hcl pH 6.8, 2% (w/v) SDS, 5% (v/v) 2-
mercaptoethanol and 10% (v/v) glycerol) and 10 µl of NOVEX® Sharp Pre Stained 
protein standard (Invitrogen) were loaded onto SDS-polyacrilamide gels prepared at 
different percentage of polyacrilamide based on the size of the protein of interest. In 
general, to prepare a 6% resolving gel(lower) 30% acrylamide/ bisacrylamide 
(EuroClone) , 1.5 M Tris pH 8.8, 10% SDS, 10% ammonium persulfate and 1x 
tetramethylethylenediamine (TEMED, Termo Scientific) were used. For a 5% stacking 
gel (upper) 30% acrylamide/ bisacrylamide (EuroClone), 1.0 M Tris ph 6.8, 10% SDS, 
10% ammunium persulfate and 1X TEMED was made. SDS-polyacrylamide gel was 
run for 3 hours at 30 v and transferred by iBlot® Dry Blotting Device (invitrogen) onto 
nitrocellulose membrane (iBlot® Transfer Stack, Invitrogen) in 7 minutes. After 
blotting, the membranes were stained with Ponceau S staining solution (0.1% 
ponceau S (w/v) and 5% acetic acid (w/v)) to verify equal loding and transfer. 
Membranes were rinsed with water and blocked in blocking solution 5% BSA in TBS-
T (20 mM Tris-HCl pH 7.4, 500 mM NaCl, 0.1% Tween-20) for 1 hour at room 
temperature shaking. Filters were then rinsed with water and incubated with primary 
antibodies (Table 5), diluted in blocking solution for 1-2 hours at room temperature or 
overnight at 4˚C. After three rounds of 10-minute washes in TBS-T, membranes were 
incubated with the appropriate horseradish peroxidase conjugated secondary 
antibody diluted in the proper solution for 1 hour at room temperature rotaiting. After 
three washes with TBS-T, each for 10 minutes, the bound secondary antibody was 
revealed using ECL Western Blotting Substrate (Pierce) and detected using 
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Chemidoc™ XRS+ imaging system (BioRad). Images were then analyzed with Image 
Lab™ software (BioRad) 
 
Table 5. List of antibodies used for immunoblotting 
Primary antibodies Clone Company Dilution 
Rabbit anti-Jmjd3 polyclonal SI0871 Home made 1/300 
Rabbit anti-H3K27me3 polyclonal 07-449 Upstate 1/2500 
Rabbit anti-H3 total 07-690 Millipore 1/25000 
    
Secondary antibody    
Polyclonal goat anti-mouse 170-6516 BioRad 1/20000 
Polyclonal goat anti-rabbit 170-6515 BioRad 1/20000 
 
 
2.5. Cell culture methods 
 
2.5.1. ES cell techniques 
 
2.5.1.1.  Culturing mouse Embryonic Stem (ES) cells  
E14-Tg2α ES cells were cultured on 0.1% gelatin in antibiotic-free ES medium 
containing leukemia Inhibitory Facotr (LIF). ES cells were grown at 37˚C, 5% CO2 
with maximal humidity. Cells were daily fed with fresh medium and passaged every 2-
3 days at 70-80% confluency: cells were washed twice with Phosphate Buffered 
Saline (PBS, without Ca2+ and Mg2+) and incubated with trypsin-EDTA at 37˚C for 5 
minutes, trypsine-EDTA were neutralized by adding ES medium and cells were 
dissociated by vigorous pipetting. After 5 minutes centrifugation at 1200 rpm 
Supernatant was aspirated and cell pellet was resuspended in fresh medium and 
plated at the proper density (for ES cell maintenance 1-2 × 106 cells per 10-cm tissue-
culture dish). 
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To facilitate the ES cell colony pick up, ES cells were plated on Mouse Embryonic 
Fibroblast cells (MEFs) exposed to Mitomycin C as feeders. 
ES cell medium 
             15% Fetal Calf Serum (FCS) 
             1 mM sodium pyrovate  
             200mM 1x L-Glutamine 
             10 mM 1x non-essential amino acids 
            100 µM 2-β-mercaptoethanol 
            1000 U/ml Leukemia Inhibitory Factor (LIF, prepared by Transgenic 
             facility) 
             Dulbecco’s Modified Eagle’s Medium (DMEM with high Glucose) 
 
2.5.1.2. Preparing Mouse Embryonic Fibroblast cells as feeder layer 
Mouse Embryonic Fibroblasts (MEFs) have been used as feeder cell layers for the 
culture and maintenance of mouse and human ES cells. MEFs provide an unknown 
mixture of nutrients and substrates, which allow long-term growth and proliferation of 
ES cells. To this end MEFs at early passeges (maximum passage three) are 
mitotically inactivated using mytomicin C which inhibits DNA synthesis and nuclear 
division. 
MEFs at passage zero were provided by the IFOM transgenic facility, cells were 
expanded and frozen in 90% FBS with 10% dimethylsulfoxide (DMSO) up to passage 
3 before MEFs become senesced. When feeder cells were required, MEFs were 
thawed on 0.1% gelatin coated tissue-culture dishes and incubated at 37˚C, 5% CO2. 
Confluent MEFs were then mitotically inactivated in MEF medium containing 10 µg/ml 
mitomycin C (Sigma) for 3 hours in the incubator. Cells were then washed twice with 
PBS, trypsinized and seeded at a density of 6 ×104 cells/cm2 onto the tissue-culture 
dishes. After inactivation cells can be frozen for later use. 
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MEF medium 
                 10% fetal calf serum (FCS) 
                  1X sodium pyrovate 
                   200 mM 1X L-glutamine 
                   Dulbecco’s modified Eagle’s medium (DMEM, high glucose) 
 
2.5.1.3 ES cell transfection 
ES cells in low passage number were thawed and cultured for a week in ES cell 
media. Confluent ES cells were fed with fresh medium a few hours before 
transfection, then trypsinized and collected to 107 cells in 15 ml falcon tube and 
centrifuged at 1200 rpm for 5 minutes. Cells were then washed with PBS to eliminate 
the salts and resuspended in 700 µl of PBS. Transfection was done in 4mm Gene 
Pulser cuvettes using a Bio-Rad electroporator. 25 µg of linearized targeting vector 
were used for transfection of 107 cells. High DNA concentration during transfection 
results in higher numbers of stable transformants but may also be toxic to ES cells 
when exceeding 50-100 µg DNA/ml transfection buffer.  
100 µl of linearized DNA in water were added to the ES cell suspension in the cuvette 
and electroporation was performed with the following parameters: exponential 
waveform, 230 v, 500 µF, ∞ Ω.  After electroporation, cells were incubated 5-10 
minutes at room temperature, then transferred to 30 ml ES media for each 107 cells 
and plated 3-5 ×106 cells per 10-cm dish. To assign the cell viability after 
electroporation,  103 transfected and 103 nontransfected cells were plated onto 6 well-
plate, cells were grown without selection and colonies were counted after 1 week. 
Moreover to control the stringency of selection, 5 × 106  nontransfected cells were 
cultured onto a 10-cm dish and fed everyday with fresh medium containing G418 
(Geneticin®; Gibco). The concentration of G418 should be chosen such that no viable 
cells should remain at day 8-10 of selection when the first transfected colonies may 
be picked. Selection of targeted ES cells was started 36 hours after transfection.  
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2.5.1.4. ES cell colony picking 
ES colonies were picked starting day 10 post transfection and plated in 96-well 
plates. ES plates were fed 2 hours before picking with fresh media. Meanwhile, a 96-
well plate (U-bottom) was pepared with 20 µl of 2x trypsin-EDTA solution (plus 1% 
chicken serum). ES 9cm plates were washed twice with 10 ml PBS. After second 
wash, 10 ml of PBS were added to the plate and colonies were picked under a tissue 
culture hood equipped with a stereomicroscope using 20 µl micro-pipettor with sterile 
disposable tips. Each picked colony then transferred into one well of the U-bottom 96-
well plate containing 20 µl of 2X trypsin-EDTA. Colony pick up was performed for 30 
minutes and picked clones were controlled under the microscope to see whether the 
cells were dissociated, if not plate was incubated for 5 minutes at 37˚C incubator. 110 
µl of ES media were added to each well using multichannel pipettor and cells were 
pipetted vigorously. Cell suspensions were then transferred to a 96-well plate (flat 
bottom) containing MEF feeder cells. 
To increase the chance of indentifying homologous recombinants, the 9-cm plate with 
ES colonies was washed twice with PBS and fed with ES media and G418 and 
placed again at incubator. Colony pick up was repeated every two days. 
When cells reached the confluency, each well was washed twice with PBS and 50 µl 
of 1x trypsine-EDTA were added, plate was incubated 5 minutes at 37˚C and cells 
were dissociated by pipetting, then trypsin-EDTA were neutralized adding 100 µl of 
ES medium and cells of each well were divided into three 96-well plates (50 µl of cells 
per plate) containing MEF feeders in 150 µl of ES media plus G418. 
 
2.5.1.5. Freezing ES cells in 96-well plates 
Subconfluent ES cells were washed twice with 100 µl of PBS and trypsinized with 50 
µl of 1x trypsine-EDTA, after 5 miniutes incubation at 37˚C, trypsin-EDTA were 
neutralized with 50 µl of 2x freezing medium (20% dimethylsulfoxide (DMSO) in ES- 
tested fetal calf serum (FCS)) to each well, cells were dissociated by vigorous 
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pipetting. 100 µl of sterile mineral oil were added to each well and 96-well plate was 
sealed with parafilm and store at -80˚C until the end of screening. 
 
2.5.1.6 Isolation of genomic DNA from ES cells in 96-well plate 
Confluent ES cells were washed twice with 1X PBS and incubated in ES cell lysis 
buffer (50µl/ well) overnight at 56˚ C. To precipitate the DNA, 100 µl of 75 mM NaCl in 
absolute ethanol was added to each well and plate was incubated for 3 hours at room 
temperature, shaking at 350 rpm. After centrifugation at 1300 rpm for < 2 minutes, the 
DNA pellet was washed three times with 100 µl of ice-cold 70% ethanol. Finally, the 
dried DNA was resuspended in 25µl of water overnight. 
ES cell lysis buffer         
                10 mM NaCl  
                10 mM Tris-HCl pH 7.5 
                10 mM EDTA 
                0.5 % sarcosyl  
                1mg/ml Proteinase K (freshly added) 
                miliQ H2O up to the volume 
 
2.5.1.7. ES cell restriction digest in 96-well plate 
To digest the ES genomic DNA, 10 µl of restriction enzyme mixture were added to 
each well. The plate was wrapped with parafilm and incubated overnight at proper 
temperature. 
Restriction enzyme mixture: 
                    1 mM  Dithiotheritol  (DTT) 
                    1 mM  Spermidine 
                    100 µg/ml  Bovine serum albumine (BSA) 
                    50 µg/ml RNase A 
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                    1X restriction buffer 
                    20 U restriction enzyme per sample 
                    miliQ H2O up to the volume 
 
2.5.1.8. Southern analysis  
2.5.1.8.1. Blotting and prehybridization 
Genomic DNA was digested by the relevant restriction enzyme overnight and then the 
entire digestion reaction was run on 0.9% agarose gel at 40 v overnight. The day after 
agarose gel was stained with 1 µg/ml ethidium bromide for 20 minutes and  DNA 
digestion checked by exposure to short wavelength UV. To transfer the digested DNA 
to the nylon membrane, DNA was depurinated in the gel by soaking in 0.25 N HCl for 
10 minutes at room temperature, gently shaking. After rinsing the gel with water, gel 
was equilibrated in alkaline transfer buffer  (0.4 N NaOH and 0.6 N NaCl) for one 
hour. Blot apparatus for upward capillary transfer was assembled and digested DNA 
was transferred onto an Amersham Hybond™-XL membrane (GE Healthcare) in 
transfer buffer overnight.   
After transfer, the membrane was neutralized by 1 minute incubation with  0.2 M Tris-
HCl pH 7.5 in 1X  saline sodium citrate (SSC) and baked for 2 hours at 80˚C to 
crosslink the DNA to the membrane. 
Membrane was rinsed with 2x SSC and pre-hybridized in modified Church & Gilbert’s 
buffer at 65˚C in a rotor oven for an overnight. 
Modified Church & Gilbert’s buffer 
                     32.9 g    Sodium phosphate- monobasic (Na2HPO4, MW 137.99) 
                     70.1 g    Sodium phosphate- dibasic  (NaH2PO4, MW 268.07)                        
                     7% (w/v)  SDS 
                     1.0 g Sodium pyrophosphate 
                     2mM EDTA 
                     miliQ H2O up to 1 liter 
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2.5.1.8.2. Preparation of radioactive DNA probe 
DNA probe was labeled with ladderman™ labling kit (TaKaRa) using  [ α- 32P]dCTP 
(3000 Ci/mmol) ; in a safe-lock tube 130 ng (10ng-1µg) of DNA probe were combined 
with 2µl of random primer and distilled sterilized water up to 14 µl. DNA was 
denatured at 95˚C for 3 minutes and cooled on ice for 5 minutes. After brief 
centrifugation, 2.5 µl of 10X buffer , 2.5 µl of dNTP mixture, 5 µl of labeled [α- 
32P]dCTP (1.85 MBq, 50 µ Ci) and 1µl of Bca DNA polymerase were added to the 
reaction and incubated at 55˚C for one hour. To purify the labeled probes from 
unincorporated dNTPS, labeling reaction was loaded on illustra ™ ProbeQuant™ G-
50 Micro columns (GE Healthcare) and centrifuged at 2800 rpm for 2 minutes. Then 
labeled probes were denatured by 5 minutes incubation at 95˚C and placed on ice for 
2 minutes. After brief spin the labeled probes were added to the modified Church & 
Gilbert’s buffer. The membrane was hybridized overnight in the rotating oven at 65˚C. 
After hybridization, membrane was washed with 2X SSC-0.1% SDS for 10 minutes at 
room temperature to eliminate the probe, then two more washes in 2X SSC- 0.1% 
SDS at 65˚C for 20 minutes were performed. In case of requirement to stringent 
washes, the following buffers have been used (indicated according to increased 
stringency):  
                  1X SSC- 0.1% SDS 
                   1X SSC- 0.5% SDS  
                   0.5X SSC- 1% SDS  
Autoradiography was performed by exposing the membrane to BioMax MR film 
(KODAK) for 7 days at -80˚C. 
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2.5.1.9. Karyotyping ES cells 
ES cells were cultured on 0.1% gelatine to 70% confluency and treated with 0.1 µg/ml 
KaryoMAX® colcemid (Gibco) in medium for one hour at 37˚C to block the cells in 
metaphase. Cells were then trypsinized and centrifuged at 1200 rpm for 5 minutes. 10 
ml of warm hypotonic solution (0.075 M KCl in water) were added drop by drop to the 
cell pellet gently shaking and cells were incubated at 37˚C for 25 minutes. For pre-
fixation, 10 drops of cold fixative (three parts of methanol and one part of glacial 
acetic acid) were added to the cell suspension, tube was gently inverted few times 
and centrifuged at 1200 rpm for 5 minutes. Afterwards, 3ml of cold fixative were 
added dropwise while gently vortexing to resuspend the cells. after centrifigation at 
1200 rpm for 5 minutes, the pellet was resuspended in 1ml cold fixative and 60 µl of 
the cell suspension were dropped onto the glass slide pre-warmed at 57˚C from about 
40 cm height. Drops were then spread all over the slide and air-dried for 15 minutes. 
Metaphases were stained in 1µg/ml DAPI in saline sodium citrate for 5 minutes in the 
dark and dried overnight at room temperature light protected. For each slide, 10 
metaphases were counted to score the number of chromosomes. 
 
2.5.1.10. Cre-recombination of targeted ES cells 
To induce Cre-mediated recombination in targeted ES cells, the cells were treated 
with TAT-Cre fusion protein (Peitz et al., 2002). the cells were trypsinized and 2 ×105 
cells were plated on a 6-well tissue culture plate. After 6 hours cells attached and 
washed three times with PBS. For transduction ES cells were incubated with 5µM of 
TAT-Cre protein diluted in 1:1 mixture of PBS and DMEM (high glucose with L-
glutamine) and incubated 16-18 hours at 37˚C, 5% Co2. Cells were washed with PBS 
, trypsinized and cultured for further 1-2 days. Genomic DNA was extracted from 
treated cells and Cre recombination was confirmed by PCR.   
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2.5.2. B-cell techniques 
 
2.5.2.1. B cell harvest and purification from different lymphoid 
organs 
 
For B cell analysis, mice of 8-12 weeks of age were used. BM cell suspension was 
collected by flushing tibia with 5 ml of B cell medium. Cells of peritoneal cavity lavage 
ware obtained by injection of 8 ml of B cell medium into the peritoneal cavity followed 
by collection of 6 ml of medium. SPL, LN and PP were collected and smashed to get 
single-cell suspension. Erythrocyte lysis was carried out on SPL and BM cell 
suspensions with incubation of cell pellet in 1 ml of erythrocyte lysis buffer for 3 
minutes on ice. Reaction was stopped by adding 10 ml of B cell medium and cells 
were washed with Fluorescence-activated cell sorting (FACS) buffer. Cells were 
counted using Erythrosin B dye (sigma) to distinguish live and dead cells. All 
centrifugation steps were performed at 1200 rpm, 4˚C for 5 minutes. 
 
Erythrocyte lysis buffer 
           Solution A                0.17 M Tris, pH 7.65 
           Solution B                0.83 % NH4Cl 
           Working solution       9 parts B + 1 part A 
 
B cell medium 
                10% FBS 
                 200 µM 1X L-glutamine 
                 1mM sodium pyrovate  
                 10 mM non-essential amino acids 
                 50 µM 2-β-mercaptoethanol 
                 DMEM (high glucose) 
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FACS buffer 
                1X PBS 
                1% BSA 
               0.05 % NaN3 
Spelnic B cells were purified using MACS® Column Technology (Milteny Biotec) 
following manufacturer’s B cell isolation Kit depletion protocol (Milteny Biotec). In 
general, CD43-expressing B cells (activated B cells, PCs and B-1a B cells), T cells, 
NK cells, dendritic cells, machrophages, granulocytes and erythrocytes were 
indirectly magnetically labeled with a cocktail of biotin-conjugated antibodies against 
CD43(Ly-48), CD4 (L3T4) and Ter-119, followed by Anti-Biotin MicroBeads 
incubation. This procedure allows the isolation of untouched resting B cells from 
single-cell suspension of lymphoid tissues. 
2.5.2.2. B cell harvest and purification 
 
Purified B cells were cultured in B cell medium and stimulated with 20 µg/ml LPS 
(Lipopolysachharide, Sigma) with or without 25 ng/ml IL-4 (Recombinant Murine 
Interleukine 4, GRF-10600, Immunological Science); or 1µg/ml anti-RP105 
(Monoclonal rat-anti mouse CD180, functional grade purified RP/14, eBioscience), 
CpG at final concentration of 10mM, anti-CD40 2µg/ml (eBioscience) with 25 ng/ml 
IL-4, anti-IgM (Jakson Research, Goat anti-mouse IgM) at concentration of 20 µg/ml. 
B cells were cultured at a density of 0.5-1 x 106 cells/ml at 37˚C, 5% CO2. 
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2.6. Imaging methods 
 
2.6.1. Immunoastaining for flow cytometry and cell sorting  
  
Cells were washed with PBS and stained in 10 µl per 1 ×106 cells in FACS buffer 
containing the specific antibodies listed in Table 6. After 20 minutes incubation at 4˚C 
in dark, cells were washed twice with 200 µl of FACS buffer. Samples were acquired 
and analyzed using FACSCalibur (Becton Dickinson) and FlowJo software. Cell 
sorting was performed using FACSAria Cell sorter (Becton Dickinson). 
 
 
Table 6. List of antibodies used for surface staining 
Antibodies and antigen Company Dilution 
Monoclonal Rat-anti mouse CD5 (PE) eBiosciences 1/200 
Anti mouse CD95 (Fas) eBiosciences 1/170 
Anti mouse IgM clone R331.12 (Alexa 488) Home made 1/400 
Anti Kappa clone R331.18 (Alexa 488) Home made 1/800 
Monoclonal Rat-anti mouse CD138 (PE) BD Biosciences 1/200 
Monoclonal Rat-anti mouse CD19 (Cy7 PE) eBiosciences 1/400 
Monoclonal Rat-anti mouse CD21/CD35 (PE) eBiosciences 1/1000 
Monoclonal Rat-anti mouse CD23 (FITC) eBiosciences 1/100 
Monoclonal Rat-anti mouse CD25 (APC) eBiosciences 1/200 
Monoclonal Rat-anti mouse CD38 (APC) eBiosciences 1/600 
Monoclonal Rat-anti mouse CD43 (PE) eBiosciences 1/100 
Monoclonal Rat-anti mouse IgD (PE) eBiosciences 1/3000 
Monoclonal Rat-anti mouse IgG1 (biotin) BD Biosciences 35064 
Monoclonal Rat-anti mouse/human CD45R (B220) (Cy7 PE) eBiosciences 1/400 
Monoclonal Rat-anti mouse/ Human CD45R (B220) (FITC) eBiosciences 1/200 
NIP (PE) Home made 1/4000 
Antigen Fluorescent Peanut Aglutinin (PNA) Vector 
Laboratories 
1/800 
	   69	  
Streptavidin (APC) eBiosciences 1/800 
Streltavidin (FITC) eBiosciences 1/400 
Streptavidin (Cy7 PE) eBiosciences 1/400 
Streptavidin (PE) eBiosciences 1/600 
 
    
2.6.2. Intracellular immunoastaining for flow cytometry  
 
Cells were collected and stained in 10µl/ 1 ×106  of FACS buffer with antibodies of 
choice (Table 4) for 20 minutes at 4˚C in dark and washed twice with 200 µl of FACS 
buffer. Surface stained cells were fixed in BD Cytofix/Cytoperm™ buffer for 20 
minutes on ice in U-bottom 96-well plate, washed by Perm/Wash™ buffer (P/W) and 
refixed in BD Cytofix/Cytoperm™ buffer for 20 minutes on ice. Cells were then 
incubated in blocking buffer (10% normal goat serum in P/W buffer) for 30 minutes at 
room temperature shaking and stained with Alexa 488-labeled Rat-anti mouse IRF4 
(IRF 3E4, BioLegend, working dilution 1/400) in staining solution for 60 minutes at 
room temperature, shaking. Cells were washed twice with P/W buffer and fixed with 
1% formaldehyde in PBS. Samples were acquired and analyzed using FACSCalibur 
(Becton Dickinson) system and FlowJo software. All centrifugation were performed at 
1800 rpm for 10 seconds at 4˚C.  
 
2.6.3. Immunostaining for detection of apoptosis  
 
To measure apoptosis in B cells, two methods were used: CaspaGLOW™ Fluorescein 
Active Caspase and TdT-mediated dUTP-biotin nick end labling (TUNEL). The CaspGLOW 
assay utilizes a permanent pan caspase inhibitor VAD-FMK (carbobenzoxy-valyl-alanyl-
aspartyl-[O-methyl]- fluoromethylketone] that irreversibly binds to the catalytic site of 
caspase protease. TUNEL staining is another method to detect apoptosis in situ, it relies on 
the ability of the enzyme terminal deoxynucleotidyl transferase to identify DNA nicks and 
incorporate labeled dUTP into free 3’-hydroxyl termini generated by the fragmentation of 
genomic DNA through apoptotic signaling cascades.  
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2.6.3.1. CaspaGLOW™ Fluorescein Active Caspase staining 
CaspGLOW staining was carried out using CaspaGLOW™ Fluorescein Active 
Caspase staining Kit with some modifications in supplier’s protocol. Cells were 
incubated in B cell medium containing FITC-VAD-FMK (working dilution 1/100) for 1 
hour at 37˚C and 5% CO2. After centrifugation at 1200 rpm for 5 minutes, cells were 
washed with wash buffer. If surface staining was required, cells were stained after 
CaspGLOW as described in the protocol of chapter 2.6.2 (immunostainig for 
flowcytometry), acquired by FACSCalibur (Becton Dickinson) and analyzed by FlowJo 
software. 
2.6.3.2. TUNEL staining 
TUNEL staining was performed using In situ cell death detection kit, Fluorscein 
(Roche Applied Science). Cells were harvested and washed twice with PBS, if 
required they were surface stained as described above (immunostaining for flow 
cytometry). Cells were resuspended in PBS at a concentration of 1-2 ×107 cells/ml 
and 100 of suspension were transferred to a U-buttom 96-well plate.  Cells were fixed 
by addition of 100 µl of 1% paraformaldehyde (PFA) and incubated for 30 minutes at 
room temperature, shaking. After centrifugation at 1200 rpm for 5 minutes, cells were 
washed twice with 200 µl PBS (staining can be stopped at this step and cells should 
be kept at 4˚C). Cells were collected by 5 minutes centrifuge at 1200 rpm and 
resuspended in 100 µl of permeabilization buffer (prepared freshly) containing 0.1% 
Triton X-100 and 0.1 M sodium citrate in PBS and incubated on ice for 2 minutes. 
Cells were then washed twice with PBS and resuspended in 50 µl of TdT-reaction 
buffer: 10µl of Enzyme solution and 40 µl of Lable solution. Cells were then incubated 
in TdT reaction buffer for 1 hour at 37˚C, 5% CO2. After two washes with PBS, cells 
were resuspended in 400 µl of PBS and acquired by FACSCalibur (Becton Dickinson) 
and analyzed by FlowJo software. 
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2.6.4. Cell cycle analysis 
 
2.6.4.1. Proliferation assay In vitro 
To analyze the cell cycle distribution of cells Ex vivo or in vitro, 5-bromo-2’-
deoxyuridine (BrdU) staining was performed. BrdU is a thymidine analog that is 
incorporated into DNA at the S phase of cell cycle (Givan et al., 1992), the 
incorporated BrdU (but not the thymidine) is then recognized by a fluorescent-
conjugated anti-BrdU which lables the new DNA, while denarured DNA is stained 
using propidium iodid (PI). To perform the cell cycle analysis, 1×106 cells were 
incubated in 3.3µM BrdU (Sigma, stock 3.3 mM (100X)) in B cell medium for 45 
minutes at 37˚C, 5% CO2; 3×105 cells were kept aside as an unpulsed control. After 
stopping the reaction by addition of PBS, cells were centrifuged at 1300 rpm for 3 
minutes at 4˚C. Surface staining was then performed if it was required. Cells were 
washed in PBS and fixed in 100 µl of BD Cytofix/Cytoperm™ buffer for 20 minutes at 
room temperature. After wash with Perm/Wash™ buffer (P/W), cells were 
permeabilized with 70 µl of BD Cytoperm™ Plus buffer (BD Biosciences) for 10 
minutes at room temperature (freezing buffer (90% FCS with 10% DMSO) is an 
alternative for BD Cytoperm™ Plus buffer), cells were then washed with P/W buffer 
and refixed with 100 µl BD Cytofix/Cytoperm™ buffer for 5 minutes at room 
temperature. After wash with P/W buffer,cells were treated with 70 µl of 
deoxyribonuclease I (DNase I; Sigma, 1mg/ml) for 1 hour at 37˚, 5% CO2 to  expose 
the BrdU-labeled DNA in cell suspension. Cells were then washe with P/W buffer and 
stained with FITC-conjugated anti-BrdU antibody (BD Biosciences) at working 
solution 1/5 for 20 minutes at room temperature in dark. After wash with P/W buffer, 
cells were resuspended in 1ml of 2.5 µg/ml PI (Sigma) and 250 µg/ml of 
Ribonuclease A solution (RNase A, Sigma) in PBS and incubated overnight at 4˚C. 
The next day, cells were acquired with FACSCalibur (Becton Dickinson) and analyzed 
using FlowJo software. 
2.6.4.2. Proliferation assay In vivo 
To assess the proliferation and survival of B cells in vivo, mice were fed with 0.8 
mg/ml of BrdU (Sigma) with 2% sucrose (light protected) for 7 days in their drinking 
	   72	  
water (mice were provided with fresh water containing BrDU every second day). At 
day 7 mice were sacrificed and B cells were collected from different lymphoid organs. 
BrdU staining and acquisition were performed as described in 2.6.4.1. 
 
2.7. Biochemical methods 
 
2.7.1. Enzyme-Linked Immunosorbent Assay (ELISA) 
 
ELISA methods are immunoassay techniques that combine the specificity of 
immunological reactions with the sensitivity of enzyme assays and allow 
quantification of immunoglobulins or antigens. One of the most common ELISA 
applications is to measure the amount of immunoglobulins in blood serum. Coating 
was performed with 50µl of capture antibodies (Table 7) or antigens (Table 6) diluted 
to the working concentration in coating buffer (0.5 M carbonate-bicarbonate buffer pH 
9.6) overnight at 4˚C in NUNC Maxisorp white 96-well plate. Coating solution was 
removed the next day and plate washed three times with 450 µl of washing buffer 
(0.05% Tween-20 in PBS). Plate was blocked in blocking uffer (3% BSA in PBS) for 1 
hour at 37˚C. then 50 µl of serum or standard (Table 7, Table 8) in Reagent Diluent 
(1% BSA in PBS) was added to the plate and incubated 1 hour at room temperature. 
Plate was washed four times with 450 µl of washing buffer and 50 µl of the Detection 
Antibody (Table 7, Table 8) was added to each well and plate was incubated for 1 
hour at room temperature. After five times washing with 450 µl of washing buffer, 50 
µl of the Streptavidin-Eu3+ (Perkin Elmer, 1/15000 dilution in reagent diluent) were 
added and plate was incubated for 30 minutes at room temperature in dark. Plate was 
then washed with 450 µl of washing buffer and incubated with 50 µl of room 
temperature DELFIA Enhancement Solution (4001-0010 Perkin Elmer) for 15 minutes 
at room temperature, gently shaking. Absorbance measurement was performed using 
Victor3™ 1420 Multilabeled Counter and Wallac 1420 Workstation Software (Perkin 
Elmer™). ELISA based quantification of antibody titers in blood serum of 
resting/immunized mice was performed according to the Bethyl ELISA protocol 
supplied with Mouse ELISA Quantification Set. 
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Table 7. ELISA reagents for total antibody titers detection of resting mice 
Capture Antibodies Clone Company Working Conc. 
Monoclonal rat anti-mouse IgM L-OMM-3 AbD Serotec 1 µg/ml 
Monoclonal rat anti-mouse IgG1 LO-MG-13 AbD Serotec 1 µg/ml 
Monoclonal goat anti-mouse IgG3 LO-MG3-13 AbD Serotec 1 µg/ml 
Monoclonal goat anti-mouse IgG2a LO-MG2a-9 AbD Serotec 0.5 µg/ml 
Monoclonal goat anti-mouse IgG2b LO-MG2b-1 AbD Serotec 1 µg/ml 
Monoclonal goat anti-mouse IgA A90-130-A Bethyl 1 µg/ml 
    
Standards    
Mouse IgM 11E10 Southern Biotech 10 ng/ml 
Mouse IgG1 15H6 Southern Biotech 10 ng/ml 
Mouse IgG3 B10 Southern biotech 100 ng/ml 
Mouse IgG2a HOPC-1 Southern Biotech 100 ng/ml 
Mouse IgG2b A-1 Southern Biotech 100 ng/ml 
Mouse IgA S-107 Southern Biotech 400 ng/ml 
    
Detection antibodies    
Anti-mouse IgM (biotin) R33.24.12 Home made 125 ng/ml 
Anti-mouse IgG1 (biotin) A85-1 BD Pharmingen 125 ng/ml 
Anti-mouse IgG3 (biotin) R40.81 BD Pharmingen 500 ng/ml 
Anti-mouse IgG2a (biotin) LO-MG2a-7 AbD Serotec 500 ng/ml 
Anti-mouse kappa chain (biotin) R331.18 Home made 500 ng/ml 
Anti-mouse IgA (biotin) 11-44-2 Southern Biotech 500 ng/ml 
 
 
 
 
 
 
	   74	  
Table 8. ELISA reagent for antigen specific antibody titer detection of immunized mice 
Antigens Clone Compny Working Conc. 
NP (4)-BSA N505010 Biosearch 
technologies 
2 µg/ml 
NP(23)-BSA N505010 Biosearch 
technologies 
2 µg/ml 
BSA   2 µg/ml 
Capture antibodies    
Monoclonal rat anti-mouse IgM L-OMM-3 AbD Serotec 1 µg/ml 
Monoclonal rat anti-mouse IgG1 LO-MG-13 AbD Serotec 1 µg/ml 
Standards    
Mouse IgM 11E10 Southern Biotech 10 ng/ml 
Mouse IgG1 15H6 Southern Biotech 10 ng/ml 
Detection antibody    
Anti-mouse IgM (biotin) R33.24.12 Home made 125 ng/ml 
Anti-mouse IgG1 (biotin) A85-1 BD Pharmingen 125 ng/ml 
 
 
2.8. Statistical analysis 
 
2.8.1. Student’s t-test 
 
Statistical analysis of normally distributed values (Gausian) was performed by two-
tailed unpaired Student’s t-test. Differences were considered significant at p<0.05. 
 
2.8.2. Wilcoxon signed-rank test 
 
The Wilcoxon signed-rank test is a non-parametric statistical test that compares two 
paired groups by calculating the difference between each set of pairs. Wilcoxon test 
can be used as an alternative to the t-test when the population data does not follow a 
normal distribution.   
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3. Results 
 
3.1. Establishment of conditional JMJD3 knock-out mice  
	  
To investigate the function of Jmjd3 in a cell-type and stage-specific manner, a 
conditional Jmjd3 knockout (KO) mouse strain based on Cre/loxP recombination 
technology was generated. To this end, a Jmjd3 conditional targeting vector was 
designed and generated in Dr. Giuseppe Testa’s lab (European Institute of Oncology, 
Milan). Although I was not directly involved in the cloning of the targeting vector, I will 
briefly describe the strategy we employed to inactivate the Jmjd3 gene. 
 
3.1.1. Generation of a conditional Jmjd3 targeting vector 	  
3.1.1.1. Design to generate mice carrying a multipurpose allele 
 
The Jmjd3 mutant allele was created using the ”Knockout-first” targeting strategy 
(Testa et al., 2004). This approach is based on the insertion of a gene-trap STOP 
cassette into the 5’ end of the target gene. The STOP cassette consists of a splice 
acceptor (sA) sequence, the LacZ reporter gene and a polyadenylation signal 
sequence. Premature transcriptional termination by the STOP cassette leads to 
functional inactivation of the target gene. The trap cassette provides also the 
possibility to monitor transcriptional activity of the target gene at the single cell level 
through measurement of LacZ enzymatic activity. The “knock-out first allele” carries 
two frt recombination sequences flanking the STOP cassette to allow its removal by 
FLP-mediated recombination. Finally, downstream of the STOP cassette, two loxP 
sites flank critical exons allowing Cre-mediated inactivation of the target gene in a cell-
type and stage-specific fashion. Mice inheriting “knock-out first allele” allow the 
investigation of the effects of a generalized inactivation of the gene of interest. 
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Crossing of the latter animals to the FLP recombinase general deleter strain generates 
offspring that looses the STOP cassette while carrying at the same time a conditional 
(floxed) allele for the gene of interest (Figure 7).  
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Figure 7. Schematic view of the knockout-first gene targeting strategy. The Knock-out-
first allele consists of an frt-flanked gene trap cassette carrying respectively a splice acceptor 
(sA), an internal ribosome entry site (IRES) sequence, the LacZ reporter gene, a promoter-
driven neomycin resistance gene and a poly adenylation (pA) site inserted into one of the first 
introns of the gene of interest. Downstream of the gene trap two loxP sites flank critical 
exons. Generation of a conditional KO allele is obtained after removal of the gene trap 
cassette via FLP-mediated recombination.   
 
 
3.1.1.1. Strategy to generate mice with a Jmjd3 multipurpose 
mutrant allele 
 
The mouse Jmjd3 (Kdm6b) gene is located on chromosome 11 and consists of 23 
exons with the fourth exon containing the ATG starting codon. Transcriptional 
analyses and chromatin immunoprecipitation assay indicated two main transcriptional 
start sites (TSS) mapping upstream respectively of exon 1 and 2 of the Jmjd3 gene 
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(De Santa et al., 2007; Lin et al., 2012). Successful inactivation of Jmjd3 in a recently 
published mouse knockout line (XB814) carrying a gene trap cassette within intron-1, 
led to the decision to target the frt-flanked STOP cassette in a similar genomic 
location.  
We employed a targeting vector developed in Dr. G. Testa group (European institute 
of Oncology) to insert an frt-flanked STOP cassette (including a neomycin (Neo) 
resistance gene) into intron 1 of Jmjd3. Moreover, two loxP sites were placed 
respectively upstream of exon 2 and downstream of exon 4 to allow conditional Jmjd3 
inactivation. In order to allow homologous recombination in mouse ES cells, the 
targeting vector was completed by two homology arms consisting respectively of 4.1 
and 5.1 Kb (Figure 8). 
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Figure 8. Scheme of the Jmjd3 multipurpose targeting vector. Schematic view of the 
targeting vector used to to generate Jmjd3 mutant ES cells. The plasmid includes respectively 
two homology arms to promote homologous recombination and the gene trap cassette 
depicted in Figure 7.  
 
3.1.2. Generation of Jmjd3 targeted ES cells 
 
The conditional Jmjd3 targeting vector depicted in Figure 2 was linearized and 
electroporated into the 129SV-derived E14Tg2a mouse ES cell line. 36 hours after 
electroporation, drug selection was started adding the neomycine analog G418 to the 
culture medium of transfected and untransfected (control) ES cells. 8 days following 
G418 treatment, the majority of untransfected ES cells succumbed to the selection 
procedure. In sharp contrast a substantial number of G418-resistant ES colonies were 
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observed in the plates that received electroporated cells. Individual G418 resistant ES 
clones (n=288) were picked and expanded for molecular analysis and freezing.   
Genomic DNA was extracted from 217 ES clones and subjected to Southern blotting 
screening to identify homologous recombinants. Specifically, a 5’ external probe 
depicted in Figure 3 was labeled and hybridized to membranes carrying genomic DNA 
from ES clones digested with EcoR1. The presence of an EcoR1 restriction site in the 
STOP cassette allowed for the discrimination between the wild-type and the targeted 
Jmjd3 allele, with the latter one giving rise to a shorter EcoR1 genomic fragment 
(Figure 9a). This analysis identified one single homologous recombinant clone (Figure 
9b) where the band corresponding to the wild-type Jmjd3 allele was coupled to the 
one representing the targeted locus (Jmjd3frtβgeo). 
 
Figure 9. Identification of Jmjd3 targeted ES cells. a) Schematic view of the Jmjd3 locus 
before and after targeting the 5’ region of the gene. b) Southern blotting analysis of the ES 
clone carrying the gene trap cassette correctly targeted into the jmjd3 locus. A Jmjd3 wild-type 
ES-clone was included in the analysis. Neomycin resistant ES clones were screened with the  
5’ external probe shown in a.  
  
To check whether the two loxP sites had both integrated into the Jmjd3 targeted locus, 
I transduced the targeted ES clone with recombinant TAT-cre. Genomic DNA was 
isolated from ES cells before and after Tat-cre transduction and subjected to PCR 
analysis. Specifically, I used a pair of oligonucleotides annealing to Jmjd3 genomic 
regions mapping respectively 5’ and 3’ to the two loxP sites (Figure 10a). This primer 
combination is predicted to amplify a 1.45 Kb PCR fragment from the Jmjd3 
wildype/floxed allele and a 129 bp PCR product from the targeted allele undergoing 
1 2 4 3 5 sA-IRES-LacZ-Neo-pA 6 7 8 9 
EcoR1 
EcoR1 
EcoR1 
1 2 4 3 5 6 7 8 9 
EcoR1 EcoR1 
10 kb 
7.6 kb 
Targeted allele 
WT allele 10 
10 
FR
T 
lox
P 
Jmjd3 WT   (10kb) 
Jmjd3 frt!geo (7.6kb) 
a b 
	   79	  
successful Cre-mediated recombination.  As shown in Figure 4b,  PCR amplification of 
genomic DNA  (Table 9) from ES cells exposed to TAT-cre gave rise to a PCR product 
of 129 bp, thus confirming successful targeting of two functional loxP sites flanking 
exons 2-4 of the Jmjd3 gene.    
Table 9. Primer combination to verify by PCR successful Cre-mediated recombination 
of the Jmjd3fl allele  
Primer         Sequence (5’-3’) 
Poly A-Fw TCTTATCATGTCTGGATCCGG 
LoxP-R1 GGAAGAGCAGATGAGACTGG 
 
 
Figure 10. TAT-Cre transduction of Jmjd3 targeted ES cells. (a) PCR strategy to confirm 
co-integration of loxP sites in Jmjd3 targeted ES cells.Red arrows indicate primers used for 
genomic PCR analysis. Numbers indicate expected length of PCR products before (Jmjd3flox) 
and after (Jmjd3Δ) Cre-mediated recombination (b) Representative gel electrophoresis of PCR 
reactions obtained using as template genomic DNA extracted respectively from Jmjd3flox ES 
cells before (-) and after (+) Tat-Cre transduction. The faint 1.5 kb band observed in Jmjd3flox 
ES cells exposed to Tat-Cre corresponds to the wild-type Jmjd3 allele. 
 
Before injection into mouse blastocyst, Jmjd3 conditional ES cells were subjected to 
karyotype analysis to exclude aneuploidy (Figure 11) that may affect pluripotency (Lui 
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et al., 1997; Longo et al., 1997).  As shown in Figure 11, analysis of 43 metaphases 
confirmed that the majority of cells carried a normal chromosome count of 40.  
 
Figure 11. Karyotype of JMJD3Frtβgeo-flox targeted ES cells. Representative metaphase 
spread of chromosomes obtained from Jmjd3Frtβgeo-flox/+ ES cells.  
 
Finally, Jmjd3 targeted ES cells were injected into C57BL/6 mouse blastocysts. Four 
male chimeras were obtained and bred to C57BL/6 females. One chimeric animal 
transmitted the targeted Jmjd3 allele through the germline. The latter chimera was 
used to establish the Jmjd3Frtβgeo-flox mouse line. 
 
3.1.3. Germline transmission of the Jmjd3 targeted allele  
	  
Transmission through the germline of the Jmjd3 KO-first allele was confirmed by 
Southern blot analysis. Genomic DNA from offspring mice was digested with EcoRI 
and hybridized to the probe used for ES cell screening. The presence of 7.6 kb 
fragment as well as a 10 kb wild-type band proved the successful transmission of 
Jmjd3Frtβgeo-flox allele through the germline (Figure 12). 
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Figure 12. Germline transmission of the Jmjd3Frtβgeo-flox allele. Southern blot analysis on 
EcoR1-digested tail genomic DNA from mice displaying germline transmission by coat color.  
The probe used for screening was described in Figure 9.  Two mice (first and third lane) 
inherited the Jmjd3Frtβgeo-flox targeted allele. 
 
 
3.1.4. JMJD3Frtβgeo-fl homozygous mice are embryonic lethal 	  
Previous work has shown that JMJD3 mutant mice die around birth (Satohh et al., 
2010; Burgold et al., 2012). Since the JMJD3Frtβgeo-flox knock-out first allele is predicted 
to interfere with JMJD3 expression, we verified this hypothesis by breeding 
JMJD3Frtβgeo-flox animals to homozygosity. Out of 37 pups born from crosses of two 
heterozygous animals, typed 21 days post-birth, none resulted homozygous for the 
JMJD3Frtβgeo-flox allele. This result indicates that the frt-flanked βgeo cassette inserted 
into intron-1 of the Jmjd3 locus prevents transcription of a full-length mRNA.  To test 
whether JMJD3Frtβgeo-flox homozygous mutants showed suffered from a late 
embryonic/early post-natal lethality we isolated embryos at day E18.5 coming from a 
cross between two JMJD3Frtβgeo-flox heterozygous mice. Genomic PCR revealed that 
two out of eight embryos were homozygous for the JMJD3Frtβgeo-flox allele, in agreement 
with the predicted Mendelian ratio of allelic inheritance (Figure 13).   
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Figure 13. JMJD3Frtβgeo-flox homozygous mice are perinathal lethal. (a) Intercross between 
heterozygous JMJD3Frtβgeo-flox mice failed to give birth to homozygous mutant mice still alive at 
21 days of postnatal life. Instead mutant animals were identified by genomic PCR genotyping 
performed on E18.5 embryos. (b) Representative genomic PCR analysis revealing the 
presence of homozygous JMJD3Frtβgeo-flox mice at day E18.5. The upper band corresponds to 
the Jmjd3 targeted locus. Arrows identify two Jmjd3 homozygous mutants. 
 
 
Jmjd3Frtβgeo-flox mice were bred to the FLPe-deleter strain (Rodriguez et al., 2000) to 
eliminate the frt-flanked βgeo trap cassette and hence generate Jmjd3fl conditional KO 
mice. Functionality of frt recombination sequences and successful removal of the trap 
cassette was confirmed by PCR using genomic DNA extracted from the tail of F1 mice 
born from the cross between Jmjd3Frtβgeo-flox and FLPe deleter mice, respectively (data 
not shown). 
Finally, to test the consequences of homozygous inactivation of the Jmjd3 allele we 
bred JMJD3fl mice to the general pgk-Cre Cre deleter strain (Lallemand et al., 1998). 
The intercross between F1 mice were analyzed. Similarly to what we had previously 
observed with JMJD3Frtβgeo-flox mice, we failed to identify mice that inherited both 
copies of mutant Jmjd3 allele that was this time inactivated through Cre-dependent 
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removal of exons 2-to-4. All together these result indicate that we successfully 
generated a Jmjd3 conditional knock-out mouse strain. 
 
 
3.2. Jmjd3 expression during B cell development  
 
3.2.1. Jmjd3 is expressed throughout B cell lymphopoiesis 
 
To investigate the expression pattern of Jmjd3 during B cell lymphopoiesis, B cell 
subsets representing different stages of maturation were purified by cell sorting from 
bone marrow and spleen (Table 10) and subjected to quantitative RT-PCR analysis 
(Figure 14). 
 
Table 10. B cell surface markers used for sorting 
B cell subset Surface markers 
pro B IgM- B220 + CD43+ CD25- 
pre B IgM- B220 + CD43- CD25+ 
Marginal zone CD19+ CD21hi CD23lo CD38hi 
Follicular/B2 CD19+ CD21+ CD23hi CD38+ 
Germinal center B FAShi CD38lo CD19+ 
B-1a CD5+ CD23- CD19+ B220+ 
B-1b CD5- CD23- CD19+ B220+ 
B-2 CD5- CD23+ CD19lo B220hi 
Plasma cells CD19lo B220lo CD138+ 
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Figure 14. Jmjd3 is expressed throughout B cell development. Transcript levels of Jmjd3 
in the indicated B cell subsets as assessed by qRT-PCR analysis. Jmjd3 mRNA levels were 
normalized to the housekeeping Rplp0 and represented as relative to those detected in pro-B 
cells. Columns represent mean transcript levels in two mice ± SD. 
 
Jmjd3 transcripts were detected starting from pro-B cells and remained fairly constant 
throughout the later stages of B cell development. 
 
3.2.2. Jmjd3 is strongly upregulated upon B cell activation  
Jmjd3 expression is induced in response to development and environmental stimuli 
(De Santa et al., 2007; Burgold et al., 2008; Agger et al., 2009). To test whether the 
expression of Jmjd3 is induced upon activation of B cells, mature B cells were purified 
from the spleen and stimulated with LPS, LPS+IL-4, anti-RP105, anti-IgM, anti-
CD40+IL-4 and CpG. Quantification of Jmjd3 transcript levels revealed that Jmjd3 is 
strongly induced in B cells in response to both T-cell dependent and -independent 
mitogens (Figure 15).  
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Figure 15. Jmjd3 expression is rapidly induced upon B cell activation. Quantification by 
PCR of Jmjd3 transcripts in primary B cells purified from the spleen of 57BL/6J mice 
stimulated for the indicated hours with different B cell mitogens. Stimulated B cells with 
different mitogens were collected at indicated time points and subjected for qPCR analysis. 
Jmjd3 mRNA levels were normalized to the housekeeping Rplp0 and represented as relative 
to those detected in resting (0 hr) B cells.  Bars represent the mean values of two mice± SD. 
 
3.2.3. B-cell specific inactivation of JMJD3 in vivo  
Given the constitutive expression of Jmjd3 throughout B cell lymphopoiesis, we 
decided to inactivate its function starting from the earliest stages of B cell 
development. To this aim, conditional JMJD3fl knock-out mice were crossed to the 
Mb1-Cre knock-in mice (Hobeika et al., 2006). In Mb1-Cre mice, Cre expression is 
under the control of the CD79a (mb1/Igα) promoter, which gets activated at the pro-B 
cell stage (Figure 16). To test the efficiency of Cre-mediated recombination, B cell 
subsets were sorted from JMJD3fl/fl; Mb1Cre experimental mice and from Mb1-cre 
controls (Table 10) and subjected to genomic qPCR using primers annealing to the 
genomic region flanked by loxP sites. Results of the qPCR analysis revealed that 
Cre-mediated recombination of the JMJd3fl allele started at the pro-B cell stage and 
reached 98% efficiency in pre-B cells. High efficiency (>90%) of Cre-mediated 
recombination was also observed in mature B cells of JMJD3fl/fl; Mb1Cre mice, 
including follicular (Fo), marginal zone (MZ) and B-1B cells (Figure 16).  
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Figure 16. Selective inactivation of Jmjd3 in B lineage cells. a) Schematic view of B cell 
development. Size of the bar below the scheme indicates expression levels of the Mb1-cre 
knock-in allele throughout B cell development. b) Genomic PCR quantification of residual 
exon 2 amplified in the indicated B cell subsets purified from Jmjd3 control (Jmjd3+/+) and 
mutant (Jmjd3-/-) mice. Residual exon 2 was determined in each sample after normalization for 
DNA input. Values are represented as relative to copies of exon 2 quantified in control proB 
cells. Mean values in three mutant and three control mice were plotted ± SD.  
 
3.2.4. Jmjd3 expression fails to be induced in KO B cells upon 
activation in vitro 
 
 
B cells express low basal levels of Jmjd3 transcripts throughout differentiation. On the 
other hand, strong induction of JMJd3 transcripts is observed upon stimulation of B 
cells with a variety of antigens/ligands (see Figure 15). To verify the effects of Cre-
mediated deletion at the Jmjd3 locus on Jmjd3 expression we isolated primary resting 
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B cells from the spleen of JMJd3fl/fl; Mb1-cre mice and Mb1-cre controls and 
stimulated them in vitro with LPS. Using primers annealing to exons present within the 
loxP-flanked Jmjd3 gene segment, we performed qRT-PCR analyses on control and 
Jmjd3 mutant B cells. Whereas Jmjd3 transcripts were strongly induced two hours 
after LPS stimulation of control B cells, we failed to detect Jmjd3 mRNA upregulation 
in cultures of Jmjd3 mutant B cells (Figure 17a). Similar results were obtained using 
primers annealing to exon16 and 17 (Figure 17b). We confirmed that B cells isolated 
from Jmjd3fl/fl;Mb1-cre mice had undergone efficient Cre-mediated recombination at 
the JMJD3 locus, as over 80% loss of Jmjd3 genomic DNA encompassing the floxed 
segment was observed (Figure 18). 
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Figure 17. Jmjd3fl/fl ;Mb1-cre B cells fail to induce Jmjd3 expression in response to LPS. 
Representative qRT-PCR analysis of Jmjd3 transcripts in Jmjd3 control (Jmjd3+/+) and 
conditional mutant (Jmjd3fl/fl ;Mb1-cre; Jmjd3-/-) B cells at the indicated hours after LPS 
stimulation. Jmjd3 mRNA levels were quantified using primer combinations annealing either to 
exons 2 and 3 encompassed within the loxP-flanked segment (a), or to exons 16 and 17 (b). 
Error bars represent the standard deviation across three technical replicates for a total of 2 
control (Jmjd3+/+) and 2 mutant (Jmjd3-/-) B cell cultures.  
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Figure 18. Efficient inactivation Jmjd3 in LPS stimulated Jmjd3 conditional mutant B 
cells. Residual Jmjd3 exon 2 assessed by qPCR on genomic DNA extracted from control and 
Jmjd3 mutant B cell. Columns represent the mean values ± SD of triplicates. 
 
 
Since the main Jmjd3 promoter sequence was included within the loxP flanked 
segment (De Santa et al., 2007; Lin et al., 2012), we anticipated the absence of 
downstream transcripts once Cre-mediated recombination had deleted the regulatory 
sequence. To confirm this scenario, control and Jmjd3 mutant B cells were stimulated 
for 2 hr with LPS and subjected to qRT-PCR using a series of primer combinations 
annealing to Jmjd3 exons downstream of exon 4 (the last exon present within the 
loxP-flanked region). In accordance with our prediction, LPS stimulation of B cells from 
Jmjd3fl/fl;Mb1-cre mice failed to up regulate transcripts containing exons mapping 
downstream of the floxed segment (Figure 19). These data suggest that Jmjd3 
expression in B cells is regulated by a promoter located within intron 1. 
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Figure 19. In B cells Jmjd3 is transcribed from a single promoter mapping of exon 2. 
qRT-PCR analysis of specific segments of the Jmjd3 transcript in Jmjd3+/+ and Jmjd3-/- B cells 
before (black bars) and 2 hours after  (grey bars) LPS activation. Arrows indicate primers used 
for the anlaysis. Combination of primers employed in individual qRT-PCR assays are indicated 
below each histogram bars. Bars indicate mean expression values ± SD of triplicates. 
 
 
3.2.5. Global H3K27me3 levels were unaltered in Jmjd3 mutant B 
cells 
 
To assess whether the strong reduction in Jmjd3 transcripts observed in primary 
Jmjd3fl/fl; Mb1-cre B cells after LPS stimulation corresponded to a comparable loss in 
Jmjd3 protein levels we performed immunoblotting analyses. Total CD19+ B cells 
isolated from the spleen of Jmjd3 mutant and control mice were purified and 
stimulated in vitro for 5 hours with LPS. Protein extracts from the stimulated cells was 
subjected to western blot analysis using a monoclonal anti-JMJD3 antibody. 
Quantification of the data revealed a reduction of over 80% of an ~200 KDa protein 
corresponding to full-length Jmjd3, in extracts of Jmjd3fl/fl;Mb1-cre B cells (Figure 20).  
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Figure 20. Western blot analysis for Jmjd3 and H3K27me3 in control andjmjd3 mutant B 
cells. Immunoblot analysis of Jmjd3 and H3k27me3 levels in lysates extracted from Jmjd3 
control (+/+) and mutant (-/-) CD19+ B cells stimulated in vitro for 5 hours with LPS. The arrow 
indicates the predicted molecular weight size of Jmjd3 protein (210 kDA). Tubulin levels were 
assessed to control for protein input.  
 
 
Given that Jmjd3 is one of two known H3K27me3-specific demethylases, we asked 
whether global levels of H3K27me3 differed between Jmjd3 mutant and control B cells 
after 3 hr of LPS stimulation. Quantification of immunoblotting data revealed that 
H3K27me3 levels did not differ substantially between control and Jmjd3 mutant B 
cells. These results are in accordance with previous studies where JMJD3 inactivation 
perturbed global H3K27me3 levels neither in macrophages nor microglia cells  (De 
Santa, 2007 and 2009; Satoh et al., 2010; Przanowski et al., 2014)   
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3.3. Jmjd3 and early B cell development 
 
3.3.1. Reduced size of the Pre-B cell compartment upon JMJD3 
inactivation 
 
To address the role of Jmjd3 in B cell lymphopoiesis, we started analyzing early B cell 
development in the bone marrow of JMJD3fl/fl;Mb1-cre compound mutants. Since 
JMJD3flox mice were established from 129-derived ES cells, most of the analyses were 
performed with mice on a mixed genetic background	   (129/SV x C57BL/6). Flow 
cytometric analysis of BM cell suspensions displayed a mild (30%), yet significant, 
reduction in the absolute number of B220+ cells in Jmjd3 fl/fl; Mb1Cre (Jmjd3 -/-) mice 
when compared to Jmjd3+/+; Mb1Cre (Jmjd3 +/+) control animals (Figure 21). 
Interestingly, a similar reduction was observed in B220+ BM cells of Jmjd3fl/+; Mb1Cre 
(Jmjd3 +/-) mice, suggesting a requirement for two functional Jmjd3 gene copies for the 
establishment of a normally sized BM B220+ B cell subset.  To determine whether 
specific B cell subsets were affected by the inactivation of Jmjd3, we performed flow 
cytometric analysis on BM single cell suspensions.  
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Figure 21. Absolute number of B220+ B cells is reduced in the BM of Jmjd3-/- mutants. 
Absolute numbers of B220+ gated cells assessed by flow cytometric analysis in Jmjd3+/+ 
(n=16), Jmjd3+/- (Jmjd3fl/+;Mb1-cre; n=15) and Jmjd3-/- (Jmjd3fl/fl;Mb1-cre; n=31) mice. Each dot 
represents a mouse. Bars represent the mean value ± SEM (t-test; *,p value < 0.05). 
 
 
Despite a substantial variability between mice of the same genotype (possibly due to 
the mixed genetic background), we found that both frequency and absolute number of 
B220+ IgM- proB/preB cells was significantly reduced in Jmjd3 -/- mutant mice in 
comparison to controls (Figure 21 and Figure 22). Using CD25 and CD43 as surface 
markers to distinguish respectively proB (CD43+CD25-) from preB (CD43-CD25+) 
cells, we observed, on average, a 40% reduction in the number and frequency of 
Jmjd3-mutant pre-B cells when compared to controls (Figure 23). This difference was 
statistically significant (p<0.05). Moreover, the frequency of Jmjd3 mutant pro-B cells 
increased around 30% in comparison to controls (12.6% vs. 18.6%), while absolute 
numbers did not significantly differ between the two experimental groups (Figure 23). 
These results indicate that Jmjd3 controls the size of the pre-B cell pool. Interestingly, 
the reduction in pre-B cells was already seen in Jmjd3+/- haploinsufficient mice 
(Jmjd3fl/+;Mb1-cre) pointing to a strict dependence of pre-B cells on two functional 
copies of Jmjd3  (Figure 22 and Figure 23).  
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Figure 22. B cell progenitors are reduced upon Jmjd3 inactivation. Frequency (left) and 
absolute number (right) of gated IgM-B220+ pro/pre B cells in Jmjd3+/+ (n=16), Jmjd3+/- (n=15) 
and Jmjd3-/- (n=31) mice. Each dot represents a mouse. Bars represent the mean value ± 
SEM (t-test; * p< 0.05, **  p< 0.01). 
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Figure 23. Increased frequency of pro-B cells upon Jmjd3 inactivation. a) Representative 
flow cytometric analysis of BM cells from respectively Jmjd3 control (Jmjd3+/+), heterozygous 
(Jmjd3+/-) and homozygous (Jmjd3-/-) mutant mice. b) Representative FACS analysis of gated 
IgM-B220+ progenitor B cells to identify respectively CD43+CD25- pro-B cells and CD43-CD25+ 
pre-B cells in Jmjd3 control and mutant mice as indicated in a. Numbers within dot plot 
indicate frequencies of boxed cells. Plots are representative of five independent experiments. 
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Figure 24. Jmjd3 ablation causes a reduction of pre B cells. Frequency (a) and absolute 
number (b) of gated B220+IgM-CD43-CD25+ pre B cells in mice with the indicated genotype. 
Bars refer to mean values ± SEM. Each dot represents a mouse. (t-test, * p< 0.05; ** p< 0.01). 
 
 
The reduced pre-B cell compartment seen in Jmjd3 conditional mutant mice was 
associated to a contraction (40%) in the number of their B220+IgMlo immature B cell 
derivatives (Figure 22 and Figure 25). Instead, both percentage and absolute number 
of B220hiIgM+ recirculating mature B cells were unaffected by Jmjd3 inactivation 
(Figure 25). 
To determine whether B cells in the BM of Jmjd3 mutant mice had undergone Cre-
mediated recombination, we sorted different B cell subsets and compared Jmjd3 gene 
copy number to that of control (Jmjd3+/+;Mb1-cre) B cells. Over 80% of Jmjd3 alleles 
had undergone Cre-mediated recombination in both progenitor and immature 
Jmjd3fl/fl;Mb1-cre B cells (Figure 26).  
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Taken together these results indicate that inactivation of Jmjd3 in proB cells leads to a 
modest yet significant impairment in the size respectively of the pre-B and immature B 
cell compartments in the BM. 
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Figure 25. Analysis of BM IgM+ B cell subsets after Jmjd3 inactivation. Frequency (a) and 
absolute number (b) of gated B220loIgM+ immature and B220+IgM+ recirculating B cells in the 
bone marrow of Jmjd3 control , heterozygous and homozygous mutant mice.  Each dot 
represents a mouse. Error bars indicate the mean values ± SEM. 
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Figure 26. Efficiency of Cre-mediated inactivation of the Jmjd3fl allele in B cell subsets. 
Genomic qPCR analysis to determine Jmjd3 exon 2 copy number in the indicated B cell 
subsets purified from Jmjd3 control (Jmjd3+/+) and mutant (Jmjd3-/-) mice. Jmjd3 exon-2 
mean values were plotted relative to those detected in control B cells belonging to the same 
subset ± SD of triplicates.  
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Moreover, phenotypic similarities between Jmjd3 -/- and Jmjd3 +/- mice indicate that 
haploinsufficiency of Jmjd3 gene may be sufficient to interfere with early B cell 
development. 	  	  
3.4. Jmjd3 and peripheral B cell development 	  
3.4.1. Total number of mature B cells is unaffected by JMJD3 
inactivation   
	  
To address the contribution of Jmjd3 in peripheral B cell development, a 
comprehensive immunophenotypic analysis was performed on single cell 
suspensions from secondary lymphoid organs of conditional Jmjd3 mutant 
(Jmjd3fl/flMb1-cre) and control (Jmjd3+/+; Mb1 Cre) mice.  
Jmjd3 inactivation had no substantial impact on the total number of B cells present in 
lymphoid organs including spleen, lymph nodes and intestinal Peyer’s patches 
(Figure 27).  
Jm
jd3
 +/
+
Jm
jd3
 -/-
0.0
5.0!1006
1.0!1007
1.5!1007
Jm
jd3
 +/
+
Jm
jd3
 -/-
0
1!1006
2!1006
3!1006
4!1006
Jm
jd3
 +/
+
Jm
jd3
 -/-
0.0
5.0!1007
1.0!1008
1.5!1008
2.0!1008
C
D
19
+ 
ce
lls
 (n
um
be
rs
) 
Spleen Mesentric Lymph Nodes Peyer’s patches 
C
D
19
+ 
ce
lls
 (n
um
be
rs
) 
C
D
19
+ 
ce
lls
 (n
um
be
rs
) 
 
Figure 27. Number of CD19+ B cells is unchanged in secondary lymphoid organs of B-
cell specific Jmjd3 KO mice. Absolute number of gated CD19+ B cells in the indicated 
secondary lymphoid organs of Jmjd3 control (Jmjd3+/+) and conditional mutant (Jmjd3-/-) mice 
were calculated based on flow cytometric analysis. Each dot corresponds to a mouse. Bars 
represent mean values ± SEM. 
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Considering the reduction in the immature B cell subset seen in the BM of Jmjd3-
deficient mice, we next asked whether the corresponding transitional B cells in the 
spleen showed a similar contraction in size. Analysis of B220+AA4.1+ transitional B 
cells in the spleen of mutant mice displayed a normal-sized pool of transitional B cells 
(Figures 28,29). These results indicate that despite reduction in the number of daily 
produced B cells in the BM of the Jmjd3-deficient mice, comparable fraction of 
immature B cells in the spleen of mutant and control mice continue their development 
towards mature B cells.  
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Jmjd3 +/+ Jmjd3 -/- 
B220+AA4.1+ 
 
Figure 28. Immature B cells in the spleen of Jmjd3-/- mice. Representative flow cytometric 
analysis of splenocytes from Jmjd3 control (Jmjd3+/+) and conditional mutant (Jmjd3-/-) mice, 
assessed for respectively transitional (B220loAA4.1+) and mature (B220+AA4.1-) B cells. 
Numbers indicate frequencies of boxed cells. Plots are representative of five independent 
experiments. 
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Figure 29. Quantification of transitional B cells in the spleen of Jmjd3 mutant mice. 
Frequency (left) and absolute number (right) of B220loAA4.1+ gated transitional B cells in 
Jmjd3 control (Jmjd3+/+) and mutant (Jmjd3-/-) mice. Each dot represents one mouse. Error 
bars represent mean values ± SEM for 15 control and 28 mutant mice. 
 
3.4.2. Jmjd3 controls the size of the MZ B cell pool 
To determine whether Jmjd3 controlled B cell maturation, the absolute number 
respectively of Follicular (FO)/B-2, marginal zone (MZ) and B-1 B cell subsets in 
secondary lymphoid organs was determined and compared between Mb1-cre 
controls and Jmjd3fl/flMb1-cre conditional mutant mice. In the spleen, FO B cells  
(CD19+ CD23+CD21+) were similar in numbers between Jmjd3 control and mutant 
animals (Figure 30). In contrast, both the number and frequency of MZ B cells 
(CD19+CD23loCD21hiCD38hi) were significantly increased in Jmjd3 mutant mice, 
being 1.5- to 1.8–fold higher than controls (Figure 30 and 31). The increase in the 
fraction of MZ B cells caused a corresponding decrease in the percentage of FO B 
cells in the spleen of Jmjd3 mutant mice (Figure 30). 
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Figure 30. Quantification of mature B cell subsets in the spleen of Jmjd3 mutant mice.   
Frequency (a) and absolute number (b) of the indicated mature B cell subsets in the spleen of 
Jmjd3 control (Jmjd3+/+) mutant (Jmjd3-/-) mice as assessed by flow cytometric analysis. 
Numbers were obtained from the analysis respectively of 14 control and 20 Jmjd3 conditional 
mutants. Bars represent the mean values ± SEM (t-test; * p <0.05, *** p < 0.001). 
 
 
 
 
 
 
Figure 31. Jmjd3 deficiency alters the proportion of  mature B cell subsets in the 
spleen.  Representative flow cytometric analysis of gated CD19+ splenic B cells in Jmjd3 
control (Jmjd3+/+; n=10 ) and conditional mutants (Jmjd3-/; n=10-). Numbers indicate 
frequencies respectively of MZ (CD21hiCD23lo) and Fo (CD21+CD23+) B cells. 
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The increased fraction of bona fide MZ B cells in Jmjd3 mutant mice was further 
assessed monitoring the expression pattern of the CD38 antigen (Vences-Catalan 
and Santos-Argumedo, 2011). As shown in Figure 27, the spleen of Jmjd3 mutant 
mice showed a higher proportion of CD19+CD23loCD38hi MZ B cells, hence 
confirming the results obtained with CD21 stainings (Figure 32). Finally, we 
performed immunofluorescence (IF) analysis of spleen sections of Jmjd3-/- and 
Jmjd3+/+ mice to determine the size of the MZ area. Specifically we used antibodies 
against respectively B220 to detect B cells, and MOMA-1 to visualize metallophilic 
macrophages lining the marginal sinus (Kraal and Janse, 1986). Quantification of the 
data revealed a modest yet significant (p<0.05) increase in the area occupied by MZ 
B cells in Jmjd3 mutant mice (Figure 33 and Figure 34). All together these results 
indicate the Jmjd3 inactivation leads to a selective expansion in the spleen of the MZ 
B cell compartment.  
 
Figure 32. Fo and MZ B cells frequencies in Jmjd3 mutants based on CD38 and CD23 
surface markers. Representative flow cytometric analysis of CD19+ gated B cells in the 
spleen of Jmjd3 control (Jmjd3+/+; n=10 ) and mutant (Jmjd3-/-; n=10) mice stained for CD38 
and CD23 expression. MZ B cells were defined as CD23loCD38hi cells, whereas Fo B cells 
are CD23+CD38+. Numbers indicate frequency of boxed cells. Plots are representative of five 
independent experiments. 
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Figure 33. Accumulation of Jmjd3-/- B cells in MZ area of the spleen. Representative 
immunofluorescence analysis of splenic sections of Jmjd3 control (Jmjd3+/+) and mutant 
(Jmjd3-/-) mmice stained for for B220 (green) and MOMA-1 (red). MZ B cells reside outside of 
the ring of MOMA-1+ macrophages delimiting the B cell follicle. 
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Figure 34. Quantification of the splenic marginal zone area in Jmjd3 control and mutant 
animals. a) Quantification of the average thickness of the marginal zone in the spleen of 
Jmjd3 control (Jmjd3+/+) and mutant (Jmjd3-/-) mice. Each dot represents the average 
thickness of an individual follicle. b) Average area of B-cell follicles in respectively three 
control and three Jmjd3 mutant mice. 16 follicles for Jmjd3-proficient and 22 follicles of 
Jmjd3-deficient mice were analyzed respectively. Bars indicate mean values ± SEM. 
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3.4.3. Jmjd3 influences B-1a/B1-b B cell ratio  
We next tested whether disruption of Jmjd3 expression influenced development of B-
1 B cells localized in body cavity serosa. On the basis of the CD5 marker, B-1 B cells 
are classified as B-1a (CD5+) and B-1b (CD5-) B cells, respectively. B-1a and B-1b B 
cells  express higher levels of CD19 and lower levels of CD23 and B220 when 
compared to Fo/B2 B cells (Montecino-Rodriguez et al., 2012).  
Flow cytometric analysis of peritoneal cavity lavages showed a comparable number 
of total CD19+ B cells between Jmjd3-/-(Jmjd3fl/fl;Mb1-cre) and control (Jmjd3+/+;Mb1-
cre) mice (Figure 35). Among B cells, Jmjd3 mutant mice showed a modest yet 
significant increase in the average number and frequency of CD19+B220+ B-2 B cells 
(Figure 31). Conversely, whereas the total number of CD19hiB220lo B-1 B cells was 
comparable between control and Jmjd3 KO mice, their distribution into B-1a and B1-b 
B cell subsets was altered in the mutant animals (figure 36 and 37). Specifically, we 
found that inactivation of Jmjd3 caused a significant reduction in the subset of CD5+ 
B-1a B cells (Figures 36 and 37). The contraction in CD5+ B1-a B cells affected both 
the frequency (42.8% vs. 62% in controls) and absolute number (1.37 vs. 0.9 × 105 in 
controls) (Figure 36). The reduction of B1-a B cells was at the expense of CD5-CD19hi 
B-1b cells that increased in numbers and frequency in Jmjd3 mutant animals (Figure 
36). These results point to a specific contribution of JMJD3 to B-1 B cell development. 
 
 
 
 
 
 
 
 
 
	   104	  
 
Jm
jd3
 +/
+
Jm
jd3
 -/-
0.0
5.0!1005
1.0!1006
1.5!1006
B
 c
el
ls
 (n
um
be
r)!
 
Figure 35. Absolute number of B cells in peritoneal cavity lavages of Jmjd3 KO and 
wild-type mice. Flow cytometric determination of CD19+ B cells in the peritoneum of Jmjd3 
control (Jmjd3+/+) and conditional mutant (Jmjd3-/-) mice.   Each dot represents a mouse. Bars 
indicate mean values ± SEM. 
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Figure 36. B cell subsets in peritoneal cavity lavages of Jmjd3 control and mutant 
animals. Frequency (a) and absolute number of the indicated B cell population as 
determined by flow cytometric analysis in respectively 17 control (black) and 36 mutant (grey) 
animals. B-1 B cells were gated as CD19hiB220+, B1-a B cells were gated as CD19hiCD5+; 
B1-b B cells were CD19hiCD5- (t-test; * p <0.05, *** p < 0.001). 
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Figure 37. B-1a B cells are reduced in frequency in Jmjd3 mutant mice. Representative 
flow cytometric analyses of respectively Jmjd3 control and mutant peritoneal cavity lavages 
stained for the indicated surface markers. Identity of B cell subsets is indicated within each 
dot plot.  Numbers indicate frequencies in boxed B cells among CD19+ gated cells. 
	  
3.4.4. JMJD3 inactivation is not counterselected upon B cell 
maturation  
	  
To confirm that B cell maturation is compatible with Jmjd3 inactivation, we determined 
the status of the Jmjd3fl allele in mature B cells purified from the spleen and 
peritoneal cavity lavages of Jmjd3fl/fl;Mb1-cre conditional mutant mice.  We performed 
quantitative PCR on genomic DNA isolated respectively from B-2 and B-1 B cells to 
determine Jmjd3 gene copy number. The analysis of qPCR data revealed that Fo, MZ 
and B-1 B cell compartments in Jmjd3fl/fl;Mb1-cre mice were mainly composed of 
Jmjd3 deficient B cells (Figure 38). All together, these results suggest that Jmjd3 has 
a selective, non-redundant, function in controlling the size of the MZ and B-1 B cell 
pools. 
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Figure 38. Efficiency of Cre-mediated recombination in Jmjd3 conditional mutant 
mature B cells. Quantification by genomic PCR of exon 2 copy number in sorted B cell 
subsets isolated from Jmjd3 control (black bars) and conditional mutant (grey bars) mice. 
Values were normalized on the basis of DNA input and represented as relative to those 
measured in control B cells belonging to the same subset. Mean values were plotted ± SEM 
of triplicates.  
 
 
3.5. Jmjd3 and B cell proliferation/turnover 
 
The inactivation of Jmjd3 in B-lineage cells has revealed specific contributions of the 
demethylase during both early and late stages of B cell development. To investigate 
the possible mechanisms responsible for the changes in numbers and frequencies of 
B cells resulting from Jmjd3 inactivation we turned to in vivo Brdu labeling assays. 
The latter approach allows the in vivo investigation of the effects of specific insults 
(e.g. the induction of a genetic mutation) on population dynamics (Allman et al., 
1993). In particular, we were interested to determine whether Jmjd3 inactivation 
influenced the proliferation and turnover respectively of progenitor and mature B cells.  
To this aim we fed Jmjd3 control and mutant mice with BrdU. Depending on the 
purpose of the experiment (proliferation vs. turnover), BrdU feeding times differed and 
hence will be described separately below.  
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3.5.1. Jmjd3 inactivation reduces BrdU incorporation in 
progenitor B cells 
	  
Data described in section 3.3 have revealed that Jmjd3 inactivation leads to a 
reduction in both the absolute number and percentage of BM preB cells. To test 
whether this effect was due to impaired/delayed proliferation of pre-B cells, we fed 
Jmjd3 conditional and mutant mice with BrdU for seven days. FACS analysis of BM 
cells from Jmjd3 control mice revealed 85% incorporation of the nucleotide analogue 
in gated IgM-B220+ pro/preB cells. Despite a certain degree of variability observed 
between mice, inactivation of Jmjd3 led to fewer BrdU+ IgM-B220+ pro/pre-B cells 
after 7 days of BrdU feeding (Figure 39). BrdU incorporation rates were instead 
comparable between mature IgM+B220hi BM B cells of Jmjd3 control and mutant 
mice. These results suggest that Jmjd3 controls the entry of preB cells into S-phase 
and hence progenitor B cell proliferation. 
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Figure 39. BrdU incorporation in Jmjd3 control and mutant B cells 7 days after in vivo 
labeling.  Quantification by flow cytometric analysis of the percentage of BrdU+ B  cells 
among respectively B cell progenitors (IgM-B220+) and mature IgM+B220+ B cells present in 
the bone marrow of Jmjd3 control (Jmjd3+/+) and mutant (Jmjd3-/-) mice. Bars represent mean 
frequencies of BrdU+ B cells ± SEM in 5 control and 4 mutant mice. 
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To find further confirmation to this hypothesis, we fed Jmjd3 control and mutant mice 
with BrdU for only 16 hours and subjected BM cells to BrdU incorporation analysis by 
flow cytometry. The fraction of BrdU-labeled progenitor B cells was substantially lower 
in Jmjd3 mutant animals in comparison to controls (Figure 39), hence supporting data 
obtained with 7 days of BrdU feeding. The delay in S-phase led to fewer BrdU labeled 
cells differentiating into B220loIgM+ immature B cells in Jmjd3 conditional mutants 
(Figure 40).  
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Figure 40. Jmjd3 mutant B cell progenitors show reduced proliferation. Percentage of 
BrdU+ B cells in  the indicated subsets of BM B cells. Mice were treated with BrdU for 16 
hours and analyzed immediately after by flow cytometry. Bars indicate mean frequencies ± 
SEM in 3 controls and 4 mutant mice. 
	  
	  
3.5.2. Jmjd3 influences peripheral B cell turnover  
 
We have shown that Jmjd3 inactivation alters the distribution of B cells into the three 
major peripheral B cell subsets. Jmjd3 may control the commitment of transitional B 
cells into specific mature B cell subsets such as the MZ or B-1B cell lineages. 
Alternatively, Jmjd3 may regulate the turnover of one or more peripheral B cell 
populations by regulating their life span. To study the turnover of B cells in peripheral 
lymphoid organs of Jmjd3 mutant animals, we administrated BrdU for 7 days in the 
drinking water and analyzed BrdU incorporation in B cell subpopulations in the spleen 
and peritoneal cavity lavages. Short-lived B220loAA4.1+CD23+ splenic transitional T2 
B cells that represent recent emigrants from the BM showed similar frequencies of 
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BrdU+ cells between Jmjd3 mutant and control mice. This result indicates that Jmjd3 
inactivation does not influence the output of B cells from the BM to peripheral 
lymphoid organs.  
Despite a considerable variability in BrdU incorporation rates, JMJD3 mutant mice 
appeared to recruit fewer BrdU+ B cells within the three major subsets of mature B 
cells (Figure 41).  These results, pending confirmation by additional experiments, 
suggest a slower turnover of mature B cells lacking functional Jmdj3.  
To test whether Jmjd3–deficient mature B cells acquired resistance to programmed 
cell death, we compared the fraction of apoptotic cells between control and mutant 
mice. For this purpose we determined the fraction of mature B cells expressing 
active/cleaved forms of caspases that were revealed through the binding to the Casp-
GLOW reagent. Flow cytometric determination of CaspGLOW+ cells revealed 
comparable fractions of apoptotic cells within the three major subsets of mature B 
cells of Jmjd3 control and mutant mice (Table 11). Collectively, these results suggest 
that Jmjd3 does not regulate BM B cell efflux while in peripheral lymphoid organs it 
increases the turnover of mature B cells independent of the regulation of apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
	   111	  
 
 
Jm
jd3
 +/
+
Jm
jd3
 -/-
0
20
40
60
Jm
jd3
 +/
+
Jm
jd3
 -/-
0
5
10
15
20
MZ 
Jm
jd3
 +/
+
Jm
jd3
 -/-
0
2
4
6
8
10
Jm
jd3
 +/
+
Jm
jd3
 -/-
0
5
10
15
20
Jm
jd3
 +/
+
Jm
jd3
 -/-
0
2
4
6
8
Jm
jd3
 +/
+
Jm
jd3
 -/-
0.0
0.5
1.0
1.5
2.0
2.5
B-1b B-2 B-1a 
Fo B220+AA4.1+CD23+ 
B
rd
U
+ 
B
 c
el
ls
 (%
) 
B
rd
U
+ 
B
 c
el
ls
 (%
) 
B
rd
U
+ 
B
 c
el
ls
 (%
) 
B
rd
U
+ 
B
 c
el
ls
 (%
) 
B
rd
U
+ 
B
 c
el
ls
 (%
) 
B
rd
U
+ 
B
 c
el
ls
 (%
) 
 
Figure 41. B-cell turnover within B cell subsets present in secondary lymphoid organs 
of Jmjd3 control and mutant mice. Frequency of BrdU+ B cells within the indicated 
populations of B cells in Jmjd3 control (Jmjd3+/+) and mutant (Jmjd3-/-) animals, as assessed 
by flow cytometric analysis. Lower panels refer to B cell subsets present in peritoneal cavity 
lavages. Bars indicate mean frequencies ± SEM in 5 controls and 4 mutant mice. 
 
Table 11.  Frequency of apoptotic B cells in the spleen of Jmjd3 control and mutant 
mice. 
	  
Average frequency ± SEM of mature B cells expressing cleaved active forms of caspases as 
assessed by flow cytometry analysis using the Casp-GLOW reagent. Five mice for each 
genotype were analyzed.  
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3.6. Is Irf4 a critical target of Jmjd3 function in mature B 
cells?   
 
A recent work has reported that inactivation of the transcription factor Irf4 in mature B 
cells leads to their accumulation in the marginal zone area as a result of the activation 
of the Notch2 pathway (Simonetti et al., 2013). Since Irf4 is a direct target of Jmjd3 in 
macrophages (Satoh et al., 2010), we asked whether Irf4 transcript levels were 
affected by Jmjd3 inactivation in MZ and Fo B cells.  Expression of Irf4 was 
determined by qRT-PCR in Fo and MZ B cells of two independent Jmjd3 mutant mice 
that showed a substantial increase in the fraction of MZ B cells. qRT-PCR analysis 
revealed 50% reduction in Irf4 transcript levels in MZ and Fo B cells of mutant 
animals when compared to the demethylase-proficient counterparts (Figure 42). 
Interestingly, expression of Irf4 was not affected in a Jmjd3 mutant animal in which 
we failed to observe a substantial increase in the MZ B cell subset. This result 
enforces the scenario whereby the increase in MZ B cells observed in Jmjd3 mutant 
animals is contributed, at least partly, by a downregulation of Irf4 expression, leading 
to a relocalization of mutant B cells to the MZ area and/or reprogramming of Fo B 
cells. 
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Figure 42. Irf4 expression is reduced in MZ and Fo B cells of Jmjd3 mutant mice. qRT-
PCR determination of Irf4 transcripts in sorted Jmjd3 control (black) and mutant (grey) MZ 
and Fo B cells. The analysis reveals also average Irf4 transcript levels in a Jmjd3 conditional 
mutant (hatched bar) in which we failed to detect major changes in the proportion of Fo and 
MZ B cells. Columns represent the mean expression levels (t-test; *, p< 0.05).  
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3.7. Role of Jmjd3 in B cell activation 	  
3.7.1. Jmjd3 controls the proliferative response of B cells to 
TLR4 agonists  
	  
The strong, transient,  upregulation of Jmjd3 measured in B cells stimulated with LPS, 
anti-RP105 and CD40 ligation pointed to a possible role for the demethylase in B cell 
activation (Figure 15). Therefore, we asked whether Jmjd3 influenced B cell 
proliferation in response to the above-indicated mitogenic stimulations. To this end we 
purified resting B cells from the spleen of Jmjd3 control (Mb1-cre) and mutant 
(Jmjd3fl/fl;Mb1-cre) animals and cultured them in vitro for 4 days in the presence of 
respectively LPS, LPS+IL-4, agonistic anti-CD180/RP-105 and anti-CD40+IL-4. The 
latter stimulations failed to induce Jmjd3 expression in mutant B cells, confirming 
efficient Cre-mediated recombination of the Jmjd3fl gene (Figure 43).   
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Figure 43. Failure to induce Jmjd3 expression by activated Jmjd3 conditional mutant B 
cells. qRT-PCR determination of Jmjd3 transcripts in Jmjd3 control (Jmjd3+/+) and mutant 
(Jmjd3-/-) splenic B cells respectively before (0 hr) and 1 hr after activation with the indicated 
mitogenic stimuli. Jmd3 transcripts were normalized to the housekeeping Rplp0 and 
represented as relative to the levels in resting B cells. Columns represent mean values of 
triplicates ± SD. 
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Growth curve analyses revealed a substantial delay and blunted response of Jmjd3 
mutant B cells to both LPS and anti-RP105 stimulation (Figure 43 a and b). Jmjd3 
mutant B cells showed two main types of responses to LPS stimulation. In most 
cases mutant B cells displayed a delayed growth that became apparent as early as 
24 hr after stimulation stimulation (Figure 44b). Notably, the growth defect was 
restricted to the first 48hr, as doubling times became more comparable between 
mutant and control B cells after 2 days of stimulation. In few cases, defective growth 
of Jmjd3 mutant B cells became apparent only at a later time point. (Figure 44b).  
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Figure 44. Jmjd3 mutant B cells show a delayed and blunted response to TLR4 
agonists. a) Growth curves of Jmjd3 control (black line) and mutant (grey line) B cells 
activated with anti-CD180/RP105, b) B cell counts in Jmjd3 control (black line) and mutant 
(grey line) cultures at different days after LPS stimulation. In most cases mutant B cells 
revealed a delayed and blunted proliferative response to LPS (right growth curve). In few 
cases Jmjd3 mutant B cells showed retarded growth detected only at a later time point (left). 
Graphs are representative of three independent experiments, each based on 2 control and 
Jmjd3 mutant B cell cultures. 
 
We hypothesized that Jmjd3 mutant B cells that succeeded to proliferate in response 
to LPS stimulation could represent Cre escape variants and thus still expressed 
JMJd3. To test this, we quantified Jmjd3 gene copy number in Jmjd3 mutant B cell 
cultures respectively 24 hr and 96 hr after LPS stimulation. Analysis of qPCR data 
revealed high efficiency Cre-mediated recombination at the Jmjd3fl locus at both time 
points, excluding therefore counter selection of mutant B cells over the culture period 
(Figure 45).  
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Figure 45. Jmjd3 is efficiently inactivated in B cells in vitro. Quantification by genomic 
qPCR of Jmjd3 exon 2 copy number in control (Jmjd3+/+) and Jmjd3 mutant  (Jmjd3-/-) B cells 
collected respectively at day-one and -four of LPS stimulation. Columns represent mean 
values of three mice ± SEM.  
 
Notably, the combined stimulation of LPS and Interleukin-4 (IL-4) rescued partially the 
growth retardation of Jmjd3-/- cells.Along the same lines, stimulation of B cells through 
the CD40 receptor, in the presence of IL-4 was largely unaffected by the inactivation 
of Jmjd3 (Figure 46). All together these results indicate that Jmjd3 is selectively 
involved in activation of B cells by LPS and other TLR4 agonists, in the absence of Il-
4 co-stimulation.  
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Figure 46. Jmjd3- mutant B cells respond fairly well to LPS+IL4 and CD40+IL4 
stimulations. In vitro growth curves of Jmjd3 control (black line) and mutant (grey) B cells 
after stimulation with the indicated mitogens. Graphs representative growth curves 
respectively of three control and three mutant mice. 
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3.7.2. Jmjd3 protects LPS-activated B cells from apoptosis  
 
To characterize the mechanisms underlying the defective growth of Jmjd3-/- B cells, 
we measured cell viability after stimulation with LPS and LPS+IL-4 stimulation. Jmjd3 
control and mutant B cells were collected at different time points after LPS +/- IL-4 
stimulation and stained with propidium iodide (PI). Flow cytometric analysis of B cells 
stimulated with LPS+IL-4 revealed a comparable fraction of PI+ dead cells between 
Jmjd3 mutant and control cultures.  In contrast, when B cells were stimulated only 
with LPS, Jmjd3 inactivation reduced by 40% the fraction PI+ B cells after three days 
of stimulation (Figure 47). This difference became less apparent at later time points, 
when majority of B cells succumbed by nutrient exhaustion. To test whether Jmjd3 
protected B cells from programmed cell death, we stained mutant and control cultures 
(stimulated with LPS) with the caspGLOW reagent that reveals expression of 
active/cleaved forms of caspases.  The results shown in Figure 42 indicate that Jmjd3 
inhibition caused a significant reduction in the proportion of apoptotic B cells three 
days after LPS stimulation. Interestingly addition of IL-4 to the culture medium 
abolished the protective effect on apoptosis caused by Jmjd3 inactivation (Figure 48). 
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Figure 47. Increased viability of Jmjd3 mutant B cells after LPS activation. Splenic B 
cells were collected at different days after LPS + IL-4 stimulation and stained with propidium 
iodide (PI). Frequencies of PI+ dead cells were measured by flow cytometric analysis 
respectively in 4 controls and 6 mutants for each time point. Columns represent mean 
frequencies ± SEM. (*, p <0.05). 
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Figure 48. Jmjd3 mutant B cells are resistant to apoptosis after LPS stimulation a) 
Representative histogram overlay of active caspase-positive B cells among Jmjd3 control 
(gray filled line) and mutant (red thin line) B cells activated with either LPS (left) or LPS+IL-4 
(right); b) Summary of data referred to the frequency of apoptotic (expressing active 
caspase(s)) B cells determined  by flow cytometry in respectively  4 controls and 10 mutant 
animals. Columns represent mean frequencies ± SEM. (*, p <0.05). 
  
The reduced susceptibility to undergo apoptosis is likely not accountable for the lower 
proliferative burst of Jmjd3 mutant B cells stimulated with LPS. Therefore, we asked 
whether loss of Jmjd3 impaired cycle progression. To address this, we performed cell 
cycle analysis on respectively LPS- and LPS+IL-4-activated B cells at different days 
of stimulation. Analysis of the data revealed comparable cell-cycle profiles between 
Jmjd3 control and mutant B cells 2 days after LPS stimulation. Instead, quite 
surprisingly, Jmjd3 deficient B cells displayed a modest increase in the proportion of 
cells in S phase three days after stimulation (Figure 49). These results indicate that 
the delayed growth of Jmjd3 mutant B cells in response to LPS stimulation is not due 
to an arrest of the cells in a specific stage of the cell-cycle.  
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Figure 49. Cell cycle distribution analysis of Jmjd3 control and mutant B cells upon 
LPS stimulation. a) Representative cell cycle analysis of Jmjd3 control and mutant mice at 
the indicated days after LPS stimulation. Numbers indicate the fraction of cells in the various 
boxed stages of the cell-cycle; b) Summary of cell cycle distribution data obtained 
respectively from 6 control (Jmjd3+/+) and 12 Jmjd3 mutant (Jmjd3-/-) B cell cultures analyzed 
at day three of LPS stimulation. Columns represent mean values  ± SD. 
 
In accordance with growth curve data, cell-cycle distribution of Jmjd3 mutant B cells 
stimulated with LPS+IL-4 was comparable to that of controls (Figure 50). This result 
confirms that Jmjd3 plays a non-redundant function in B cell activation that is limited 
to selective forms of mitogenic stimulation. 
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Figure 50. Normal cell cycle distribution in LPS+IL-4 stimulated Jmjd3 mutant B cells. 
a) Representative cell-cycle distribution analysis of Jmjd3 control (Jmjd3+/+) and mutant 
(Jmjd3-/-) B cells respectively at two and three days of LPS+IL-4 stimulation. b) Summary of 
cell cycle distribution analysis determined at day-3 of LPS stimulation respectively in 7 control 
and 12 Jmjd3 mutant mice. Columns represent mean frequencies (± SD).  	  
3.7.3. Jmjd3 controls expression of cell-cycle regulators  	  
Satoh and colleagues (Satoh et al., 2010) have shown that Jmjd3 controls cell cycle 
progression in bone marrow-derived macrophages through the regulation of the 
expression of cell-cycle genes including c-Myc, c-Myb, Cyclin D1 (CCND1) and Cyclin 
D2 (CCND2). To determine whether the reduced proliferation of Jmjd3-/- B cells upon 
LPS activation was caused by impaired regulation of cell-cycle modulators, we 
quantified transcript levels of c-Myc, Ccnd2 and Ccnd3 in control and Jmjd3 mutant B 
cell cultures activated with LPS. c-Myc expression was strongly induced 2 hours post 
LPS stimulation in control B cells. In contrast, Jmjd3 mutant B cells failed to achieve 
comparable c-Myc mRNA levels at the same time point. The differences between 
control and mutant cultures in c-Myc transcripts persisted over the entire period of 
LPS stimulation. In a similar fashion Ccnd2 and Ccnd3 expression was significantly 
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blunted in Jmjd3 mutant B cell cultures 24 hr after LPS activation. Importantly, 
whereas differences in Ccnd2 transcript levels persisted between control and mutant 
B cells at later time points, Ccnd3 mRNAs were affected by Jmjd3 selectively at the 
24hr time point of LPS stimulation (Figure 51). Given that Jmjd3 loss leads to growth 
retardation limited to the first 24-48 hr of LPS stimulation, it is possible that the major 
determinant for the delayed proliferative response is the transient failure of mutant B 
cells to activate Ccnd3 expression. 
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Figure 51. Jmjd3 regulates expression of cell-cycle genes. Quantification by qRT-PCR of 
mRNA levels for the indicated cell cycle genes in Jmjd3 control (black) and mutant (grey) B 
cell cultures at different time points (hr) after LPS stimulation.  Transcript levels were 
normalized to the housekeeping gene Rplp0 and represented as relative to mRNA levels of 
controls before LPS stimulation (0 hr). Columns represent mean transcript levels ± SEM (t-
test; *,p <0.05; **, p <0.01). 
 
In mouse embryonic fibroblasts Jmjd3  activates expression of the Cdkn2a locus 
encoding for the tumor suppressors p16INK4a and p19ARF  (Agger et al., 2009 and 
Barradas et al., 2009). To test whether a similar regulation occurred in B cells, we 
measured transcript levels for p16INK4a and p19ARF in Jmjd3 control and mutant 
cultures after endotoxin treatment. In Jmjd3 proficient B cells p16INK4a and p19ARF 
were strongly up-regulated 3 days after stimulation. In contrast, p16INK4a and, to a 
lesser extent, p19ARF were modestly induced in Jmjd3 mutant B cells (Figure 52). The 
impaired activation of Cdkn2a expression in Jmjd3 mutant cells, and in particular that 
of p19ARF could protect B cells from p53-mediated apoptosis  (Ramiro et al., 2006). 
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Figure 52. Tumor suppressors p16INK4a , p19ARF  and TP53 fail to be induced in Jmjd3 
mutant B cells after LPS stimulation. qRT-PCR analysis of Cdkn2a-encoded p16INK4a, 
p19ARF and of TP53 in control (black) and Jmjd3 mutant (grey) B cells at the indicated days of 
in vitro LPS stimulation. Transcript levels were normalized to Rplp0 and represented as 
relative to those in control B cells prior to stimulation (Day 0). Columns represent mean 
transcript levels of triplicates ± SEM (Wilcoxon test; *,p <0.05). 
 
To further investigate a possible link between Jmjd3 and p53, we measured p53 
transcript levels in control and mutant B cells activated with LPS. qRT-PCR analysis 
revealed that Jmjd3 -/- B cells fail to induce p53 expression two days after LPS 
stimulation (Figure 52). This result suggests that Jmjd3 selectively induces the p53 
expression in response to LPS stimulation. 
These results identify two (apparently) opposing roles for Jmjd3 during B cell 
activation. Upon LPS stimulation, Jmjd3 activates the entry of B cell into cell cycle 
contributing to the upregulation of c-Myc and the cyclins D2 and D3. On the other 
hand Jmjd3 sensitizes B cells to senescence and/or p53-induced apoptosis through 
the regulation of Cdkn2a and possibly Tp53 expression. The combination of these 
effects lead to a delayed proliferative response of B cells to LPS, while heightening 
their resistance to apoptotic signals. 
 
 
	   122	  
3.7.4. Jmjd3 limits plasma cell differentiation in response to 
LPS  
	  
 
Stimulation of B cells with LPS triggers plasma cell differentiation. Since Jmjd3 is 
potently induced during the early phases of LPS stimulation, we investigated whether 
inactivation of the histone demethylase could influence LPS-induced terminal 
differentiation.  Primary B cells purified from the spleen of Jmjd3 control (Mb1-cre) 
and conditional mutant (Jmjd3fl/fl;Mb1-cre) mice were stimulated in vitro for four days 
with LPS +/- Il-4 and analyzed by flow cytometry. Staining with the plasma cell marker 
CD138/Syndecan-1 in combination with CD19 revealed a significant increase in the 
fraction of CD19loCD138+ pre-plasma cells (also called plasma blasts) in Jmjd3 
mutant cultures in comparison to controls (Figure 53). Interestingly, the higher 
proportion of PCs was seen in Jmjd3 mutant LPS cultures both at day-3 and day-4 of 
the stimulation, whereas the combined action of LPS and IL-4 led to a larger 
proportion of PCs in mutant cultures only at the later time point (day-4; Figure 53 and 
54). These results are in accordance with our previous data, and suggest that 
stimulation through the IL-4 receptor rescues at least partly the alterations of Jmjd3 
mutant B cells stimulated through TLR4.  
 
	   123	  
LPS 
Jmjd3 +/+ 
CD19 
C
D
13
8 
LPS+IL-4 
Jmjd3 -/- 
 
Figure 53. In vitro plasma cell differentiation of Jmjd3 mutant B cells after LPS 
stimulation.  Representative flow cytometric analysis of day-4 Jmjd3 control and mutant B 
cell cultures activated with either LPS (upper plots) or LPS+IL-4 (lower plots). Numbers 
indicate percentage of CD19loCD138+ plasma blasts.  
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Figure 54. Frequency of plasmablasts generated in vitro after stimulation of Jmjd3 
control and mutant B cells. Summary of the data relative to the flow cytometric 
quantification of the percentage of CD19loCD138+ plasmablasts detected respectively at day-3 
and -4 of LPS +/- IL-4 stimulation in Jmjd3 control (black bars) and mutant (grey bars) 
animals. Mean frequencies were plotted ± SD. Data are representative of three independent 
experiments (t-test; *, p< 0.05). 
 
In accordance with the increased fraction of Syndecan-1+ plasma cell precursors, the 
transcript levels for the transcription factor and PC determinant Prdm1/Blimp1 (which 
is essential for PC differentiation) were substantially increased in Jmjd3 mutant 
cultures simulated with LPS in comparison to controls (Figure 55). However, not all 
the genes associated with terminal differentiation were increased upon Jmjd3 
inactivation; surprisingly, expression of Irf4 in mutant B cells was not induced at day 
two after LPS stimulation. This result was in contrast with previous studies describing 
that Irf4 is required for class switch recombination and plasma cell differentiation 
(Klein et al., 2006; Sciammas et al., 2006 ; Ochiai et al., 2013) (Figure 56). 
 
 
 
 
	   125	  
 
Da
y 0
Da
y 1
Da
y 2
Da
y 3
0
5
10
15
20
25
P
rd
m
1 
re
la
tiv
e 
m
R
N
A 
le
ve
ls
  
*! *!
*!
 
Figure 55. Higher Prdm1 transcript levels in Jmjd3 mutant B cell cultures after LPS 
stimulation. qRT-PCR determination of Prdm1 transcripts in cultures respectively of Jmjd3 
control (black bars) and mutant (grey bars) B cells collected at the indicated time points. Data 
are representative of 2 independent experiments. Bars indicate mean frequencies of three 
mice ± SD (t-test; *, p< 0.05). 
 
	  
Figure 56. Irf4 is not upregulated in Jmjd3 mutant B cells upon LPS stimulation. 
Quantification by qRT-PCR of Irf4 transcript levels in Jmjd3 control (Black bars) and mutant 
(grey bars) B cell cultures at the indicated time points after LPS stimulation. Bars represent 
mean values of three mice ± SD (t-test; **, p< 0.01) 
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3.7.5. Jmjd3 and Ig isotype switching  
	  
To analyze the ability of Jmjd3 -/- B cells to undergo Ig CSR, we activated B cells with 
either LPS or LPS+Il-4. The frequency of IgG3+ B cells was 2-fold reduced in Jmjd3 -/- 
LPS culture when compared to controls, whereas LPS+IL-4 cultured mutant B cells 
displayed comparable frequencies of IgG1+ B cells to the controls (Figure 57 and 
Figure 58). Impaired switching of mutant B cells in response to LPS was in 
accordance with downregulation of Irf4 expression that is essential in CSR. Thus we 
conclude that Jmjd3 inactivation facilitates the isotype switching in vitro.  
 
 
Figure 57. In vitro Ig class switch recombination analysis in Jmjd3 mutant B cells. 
Representative flow cytometric analysis of Jmjd3 control (Jmjd3+/+) and mutant (Jmjd3-/-) B 
cells after four days of LPS (a) or LPS+IL-4 (b) stimulation, stained respectively for surface 
IgG3 and IgG1 expression. Numbers indicate  percentage of boxed Ig class-switched B cells.  
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Figure 58.  Jmjd3 inactivation interferes with IgG3 class switch recombination after 
LPS stimulation. Percentage of IgG3+ and IgG1+ B cells generated in Jmjd3 control 
(Jmjd3+/+) and mutant (Jmjd3-/-) cultures after four days of respectively LPS (left) or LPS+IL-4 
(right) stimulation. Each dot represents one independent B cell culture. Bars indicate mean 
values ± SEM (t-test test; *, p< 0.05). 
 
3.8 Humoral immunity in B-cell specific Jmjd3 mutant mice  
 
3.8.1. Jmjd3 inactivation does not affect serum Ig titers 
The increased fraction of short-lived antibody-secreting PCs detected in Jmjd3 mutant 
B cell cultures in response to LPS stimulation, motivated us to measure serum 
immunoglobulin titers in Jmjd3 mutant mice. Enzyme Linked Immunosorbent assays 
(ELISA) showed that inactivation of Jmjd3 did not impair the ability of mutant animals 
to produce antibodies respectively of the IgG3, IgG1, IgG2c, IgA and IgM isotypes 
(Figure 59). These results point to a redundant role for Jmjd3 in the regulation of 
plasma cell homeostasis in vivo.  
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Figure 59. Ig serum titers in Jmjd3 mutant mice. Quantification by ELISA of serum Ig titers 
in unimmunized Jmjd3 control (black symbols; n=5) and mutant (grey symbols; n=5) mice. 
Each dot represents a mouse. Bars represent mean values ± SEM. 	  	  
3.8.2. Jmjd3 and the recruitment of B cells into the germinal 
center reaction 
The germinal center (GC) reaction plays a crucial role in humoral immune responses 
to T cell-dependent antigens by producing high-affinity antibody-secreting plasma 
cells and memory B cells (Klein and Dalla-Favera, 2008). To address whether B cells 
got recruited into the GC reaction in the absence of Jmjd3, we stained single cell 
suspensions from spleen, mesenteric lymph nodes (MLN) and Peyery’s patches (PP) 
of control and mutant mice with antibodies against GC B cell markers. The frequency 
of CD19+CD95/FashiCD38lo GC B cells present in spleen and gut associated lymphoid 
tissues, which display chronic GCs, was comparable between controls and Jmjd3 
mutant animals (Figure 60). Therefore we conclude that Jmjd3 does not control the 
entry and (presumably the persistence) of B cells into the GC reaction.   
	   129	  
 
Figure 60. Jmjd3 deficient B cells are able to form GCs. Flow cytometric analysis of 
CD19+CD38loCD95hi GC B cells in spleen, mesenteric lymph nodes (MLN) and Peyer’s 
Patches (PP) of Jmjd3 control (Jmjd3+/+) and mutant (Jmjd3-/-) unimmunized mice. Numbers 
indicate percentage of GC B cells among gated CD19+ cells.  
 
Frequency and absolute numbers of GC B cells were comparable between Jmjd3 -/- 
and control mice in the analyzed organs (Figure 61). We conclude that Jmjd3 is 
dispensable for the formation and/or maintenance of germinal center B cells. 
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Figure 61. Frequency and absolute numbers of GC B cells in Jmjd3 conditional mutant 
mice. Summary of data relative to frequencies (upper panel) and absolute numbers (lower 
panels) of GC B cells in the indicated lymphoid organs of Jmjd3 control (Jmjd3+/+) and mutant 
(Jmjd3-/-) mice. Bars indicate mean frequencies ± SEM. 
 
3.8.3. Jmjd3 inactivation does not affect T-cell dependent 
antibody responses 
  
We finally asked whether the recruitment of B cells into the GC in the absence of 
Jmjd3 could influence their ability to differentiate into antigen-specific antibody 
secreting cells. To this end, we immunized controls (Mb1-cre) and Jmjd3-/-  
(Jmjd3fl/fl;Mb1-cre) mice with the T-cell dependent antigen NP27 coupled to chicken 
gamma globulin (NP-CGG). Blood serum was collected at different time points after 
the immunization and antigen-specific igG1 titers were quantified in the blood of 
control and mutant animals. Control and Jmjd3 mutant mice showed a comparable 
rise in NP-specific IgG1 serum levels in response to the immunization (Figure 62). 
These results exclude a major role in the generating of antibody-secreting plasma 
cells originating from the GC reaction. 
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Figure 62. Antigen-specific IgG1 serum titers produced in Jmjd3 mutant mice after 
immunization with the T-cell dependent antigen NP-CGG. Quantification by ELISA of NP-
specific IgG1 titers in the serum of Jmjd3 control (black dots) and mutant (grey dots) mice at 
the indicated time points after NP-CGG immunization. Each dot represents a mouse. Bars 
indicate mean concentrations. 
 
 
3.9. Effects of Jmjd3 inactivation on B cell development in 
mice on a pure C57BL/6J genetic background 	  
The genetic background may influence the phenotypic outcome of a genetic mutation, 
especially if it affects an epigenetic determinant. Hence, the variable penetrance of 
phenotypes seen in Jmjd3 mutant mice could depend on the 129 x C57BL/6 mixed 
genetic background. To address this point we recently completed the backcross of 
Jmjd3fl mice to obtain conditional mutants on a pure C57BL/6J genetic background. 
Preliminary analyses on the first mutant animals bred to the Mb1-cre strain will be 
described below.   
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3.9.1. Jmjd3 is dispensable for early B cell development and MZ 
B cell differentiation in C57BL/6 mice 
Flow cytometic analysis of BM cell suspensions revealed a fairly normal distribution of 
Jmjd3 mutant B cells between the fraction of progenitors (B220loIgM-), immature 
(B220loIgM+) and mature (B220+IgM+) recirculating B cells.  Moreover, absolute 
number of the different B cell subset was comparable between control and mutant 
animals. (Figure 63). In a similar fashion, flow cytometric characterization of splenic B 
cell populations failed to show major alterations in the ratio between Fo and MZ B 
cells in response to Jmjd3 inactivation.  Although preliminary, these data point to a 
substantial contribution of the 129SV genetic background to the B cell developmental 
defects observed in Jmjd3 mutant animals analyzed on the mixed genetic 
background.  
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Figure 63. Analysis of early B cell development in Jmjd3 mutant mice on the C57BL/6J 
pure genetic background. a) Representative flow cytometric analysis of Jmjd3 control 
(Jmjd3+/+) and mutant (Jmjd3-/-) BM cells on the C57BL/6 background. Numbers indicate 
frequency of boxed populations. b) Frequency of pro-B and pre-B cells within gated IgM-
B220+ BM cells of representative cases of Jmjd3 control (Jmjd3+/+) and mutant (Jmjd3-/-) 
animals on the C57BL/6J genetic background. 
 
3.9.2. Jmjd3 regulates B-1a B cell development in C57BL/6 mice 
We next turned out attention to the analysis of B-1 B cell development in the absence 
of Jmjd3. For this purpose single cell suspensions from peritoneal cavity lavages 
were subjected to flow cytometric analysis. In analogy with what had been observed 
in mutant animals on the mixed genetic background, Jmjd3 mutant C57BL/6J mice 
showed a lower frequency and absolute number of CD5+ B-1a B cells in comparison 
to controls (Figure 64, Figure 65).  
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Figure 64. Peripheral B-cell development in Jmjd3 deficient mice on the C57BL/6 
genetic background. a) Representative flow cytometric analysis of gated CD19+ splenic B 
cells in Jmjd3 control (Jmjd3+/+) and mutant (Jmjd3-/-) animals. b) Summary of data related to 
frequencies of respectively Fo, MZ and GC B cells in Jmjd3 control (black dots) and mutant 
(grey dots) animals. 
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Figure 65. B-1 B cell development in Jmjd3 mutant mice on the C57BL/6J genetic 
background. a) Representative flow cytometric analysis of gated CD19+ B cells in peritoneal 
cavity lavages from Jmjd3 control (Jmjd3+/+) and mutant (Jmjd3-/-) mice on the C57BL/6 
genetic background; (b) Summary of the data on absolute numbers of the indicated B cell 
subsets in peritoneal cavity lavages of respectively four controls (black dots) and three 
mutant (grey dots) animals.  
 
3.9.3. Jmjd3 is required for LPS-driven C57BL/6J B cell 
activation  
To determine whether Jmjd3 was critical for the response of C57BL/6 B cells to 
bacterial endotoxin, we stimulated control (Mb1-cre) and Jmjd3 mutant (Jmjd3fl/fl; 
Mb1-cre on pure C57BL/6J background) primary splenic B cells with LPS. Growth 
curve analysis confirmed the non-redundant role of Jmjd3 in B cell responses to LPS 
in vitro. Indeed mutant B cell cultures showed a defective proliferative response that 
became evident as early as 24 hr after the initial stimulation  (Figure 66).  
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Figure 66. Growth defects of C57BL/6J Jmjd3 mutant B cells after LPS stimulation. 
Representative growth curves of Jmjd3 control (Jmjd3+/+) and mutant (Jmjd3-/-) B cells 
activated in vitro with LPS for the indicated days.  Graph is representative of two control and 
two mutant mice. Bars indicate mean values of triplicates ± SEM. 
To confirm that the Jmjd3 floxed segment had undergone Cre-mediated 
recombination. We performed quantitative genomic PCR on B cells three days after in 
vitro stimulation. As shown in Figure 67, B cells in mutant cultures were almost 
completely devoid of a functional jmjd3 allele. We conclude that Jmjd3 is required for 
optimal proliferation of B cells in response to the LPS.  
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Figure 67. Efficiency of Cre-mediated recombination of the Jmjd3fl allele in LPS-
activated mutant B cells on the C57BL/6J genetic background. Quantification by genomic 
qPCR of Jmjd3 exon2 copy number in Jmjd3 control (Jmjd3+/+) and mutant (Jmjd3-/-) B cells 
collected 3 days after LPS stimulation. Values were normalized for DNA input and 
represented as relative to control B cells. Columns represent mean values of triplicates ± 
SEM. 
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4. Discussion 
The work presented in this thesis has focused on the understanding of the in vivo role 
of the Histone H3 lysine demethylase Jmjd3 in B cell lymphopoiesis and activation. 
For this purpose, I generated mice carrying a conditional knock-out (KO) allele for the 
Jmjd3 gene. Using Cre/loxP recombination technology, inactivation of JMJD3 function 
was achieved throughout B cell development by means of the Mb1-cre knock-in 
strain. A comprehensive in vivo analysis of B cell-specific Jmjd3 KO mice has 
unraveled functional contributions of the histone demethylase at specific stages of B 
cell differentiation and for optimal response of B cells to innate immune stimuli.  
Gene expression analysis on purified murine B cell subsets revealed that Jmjd3 is 
expressed moderately throughout B cell development at relatively constant levels. A 
transient potent up-regulation of JMJD3 gene expression is seen in B cells few hours 
after the exposure to different mitogens including LPS stimulation, CD40 ligation and 
B cell receptor cross-linking.  These results led us to hypothesize a possible 
contribution of Jmjd3 to both B cell differentiation and activation to innate and 
adaptive stimuli. Indeed, the analysis of B-cell specific Jmjd3 mutant animals has 
revealed several abnormalities resulting from functional inactivation of the histone 
demethylase.   
In early stages of B cell development, Jmjd3 controlled the size of the pre-B cell pool. 
This regulation was exerted, at least in part, by facilitating the entry into S-phase and 
hence acting mainly on the fraction of rapidly proliferating large pre-B cells. The loss 
of JMJD3 did not however fully prevent further differentiation of progenitor B cells, 
which progressed to the immature stage after successfully rearranging their 
immunoglobulin light chain genes. The recruitment of naïve/transitional B cells to the 
main three mature B cell subsets was affected by Jmjd3 inactivation. Specifically, I 
found a significant reduction in the number and percentage of B-1 B cells residing in 
the peritoneal cavity. Moreover, the subset of marginal zone B cells that resides in the 
spleen was enlarged in response to functional loss of JMJD3 activity. Instead, the 
major population of Follicular/B2 resting mature B cells was by and large comparable 
in numbers and frequencies between Jmjd3 control and mutant mice. Whereas, 
JMJD3 did not influence the efflux of immature/naive B cells from the bone marrow, in 
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vivo BrdU incorporation studies have suggested a slower turnover of mature B cells 
lacking Jmjd3.  
In vitro activation studies have revealed an unexpected selectivity in the contribution 
of Jmjd3 to B cell proliferative responses. Indeed, whereas, Jmjd3 mRNA levels 
increased after stimulation of B cells through both innate (e.g. TLR4/RP105) and 
adaptive receptors (e.g. BCR and CD40), only LPS stimulation caused a major defect 
in the proliferation of Jmjd3 mutant B cells. Interestingly, the impaired proliferative 
response to endotoxin following Jmjd3 loss, affected primarily the first one/two cell 
divisions pointing to a possible role for the histone demethylase in the reprogramming 
of resting B cells into their proliferative counterpart.  
The analysis of the data obtained through the analysis of Jmjd3 conditional mutant 
mice has provided me with the opportunity to interpret the results in the frame of the 
existing literature. I will discuss in the following paragraphs the major findings of this 
study in an attempt to reconcile the data within a scenario where Jmjd3 exerts a 
critical regulatory function in B cell differentiation and proliferation. 
 
4.1. Jmjd3 and early B cell development 
The inactivation of Jmjd3 in pro-B cells was achieved crossing Jmjd3fl  mice to the 
Mb1-cre strain. The inactivation of Jmjd3 in pro B cells did not affect their number. 
Moreover, we could show that the vast majority of B220+CD43+IgM- proB cells had 
undergone Cre-mediated recombination, thus excluding a major counter selection of 
mutant cells. This result indicates that Jmjd3 is dispensable for the differentiation from 
pro-B to preB cells. The latter transition is dependent on the expression of a 
functional immunoglobulin heavy chain receptor that results from a productive VDJ 
recombination event. Previous work by Su et al has shown that the H3K27 
thrimethylation activity of Ezh2 regulates in a critical fashion IgH VDJ recombination 
(Su et al., 2003). Specifically, it was hypothesized that H3K27me3 deposition at 
promoters of DH-proximal VH genes (leading to their silencing) is required to allow 
RAG proteins to employ distal VH elements in V-to DJ recombination reactions. The 
failure to observe major defects in the proB to preB cell transition in Jmjd3 mutant 
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mice excludes that removal of H3K27me3 from germline VH gene promoters is 
necessary to activate the VDJ recombination process.  At the same time, we cannot 
exclude a possible functional redundancy between Jmjd3 and other histone H3K27 
demthylases such as UTX in the regulation of VDJ recombination. Finally, it remains 
to be determined whether JMJD3 mutant mature B cells suffer from major skewing in 
the antibody heavy chain gene repertoire.  
The loss of JMJD3 caused a contraction in the size of the pre-B cell compartment. 
This defect was mainly caused by a reduction in the number of proliferating pre-B 
cells, as confirmed by short in vivo BrdU pulse experiments.  The failure of mutant 
pre-B cells to proliferate may result from the role of Jmjd3 in regulating pre-BCR 
effector functions. In particular, Jmjd3 may be required to induce the expression of 
G1-S-specific cyclins such as Cyclin D3 following pre-BCR signaling. Indeed, data 
from mature B cells show a failure of Jmjd3 mutants to induce Ccnd3 expression in 
response to LPS stimulation. Notably, Ccnd3 deficient mice show a selective defect in 
pre-B cell proliferation (Cooper et al., 2006). Pre-BCR signaling is enhanced by 
concomitant engagement of the Interleukin-7 (IL-7) receptor through its binding to IL-7 
(Lu et al, 2003). Preliminary data obtained from bone marrow pro/pre B cell cultures 
indicated that Jmjd3 inactivation does not interfere with IL-7 driven pre-B cell 
proliferation (M. Rahmat and S. Casola, personal communication). It remains to be 
determined whether the positive regulation exerted by Jmjd3 on the expression of 
Interferon Regulatory Factor 4 (IRF4) transcription factor may also contribute to 
define the ultimate proliferative potential of progenitor B cells (Lu, 2008). Finally, 
previous reports indicated the property of Jmjd3 to induce the expression of the 
Cdkn2a tumor suppressor locus encoding respectively for the CDK inhibitor 
p16INK4a and the tumor suppressor p19ARF (Agger et al., 2009; Barradas et al., 
2009; Sola et al., 2011; Zhao et al., 2013). Whether Jmjd3 controls Cdkn2a 
expression in pre B cells and whether this regulation sensitizes cells to apoptosis 
and/or counterbalances pro-proliferative signals represent the next questions to be 
addressed. 
A better understanding of the contribution of Jmjd3 to pre-B cell proliferation will come 
from the comparison between the transcriptome profiles of Jmjd3-proficient and 
deficient large pre-B cells. These results will be intersected with genome wide 
distribution maps of H3K27me3 and H3K4me3 to be obtained from purified wild-type 
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pre-B cells, to ultimately define direct targets of JMJD3 function in proliferating pre-B 
cells.  
In summary, by inducing concomitantly genes (e.g, Ccnd3, IRF4, Cdkn2a) with 
opposite roles in cell-cycle progression, Jmjd3 may exert a fine balance between pro-
proliferative and pro-differentiation signals to ultimately control the size of the pre-B 
cell compartment.  
 
4.2. Jmjd3 and peripheral B cell subset differentiation 
Immature B cells expressing a functional, non-autoreactive, BCR exit the bone 
marrow and migrate to peripheral lymphoid organs. Here only a small fraction of 
these cells (less than 10%) will complete their differentiation to become ultimately  
either Follicular B2, marginal zone or B-1 B cells.  Immunophenotypic analysis of 
single-cell suspensions from secondary lymphoid organs has unraveled selective 
contributions of Jmjd3 to peripheral B cell subset differentiation. 
Upon Jmjd3 inactivation, the total number of CD19+ B cells in the spleen remained 
unperturbed. Distribution of B cells among Fo and MZ B cell subsets revealed a 
preferential enrichment for Jmjd3 mutant B cells in the MZ B cell compartment.  A 
recent study by Simonetti and co-workers (Simonetti et al., 2013) has assigned to Irf4 
an important role in the regulation of the Fo versus MZ B cell lineage choice. 
Specifically, inducible loss of IRF4 in mature B cells caused a rapid repositioning of 
mutant Fo B cells to the MZ. This migration was driven by increased responsiveness 
of IRF-4-defective mature B cells to Notch-2. Importantly, Notch2 is essential for the 
development and persistence of MZ B cells (Saito et al., 2003). Since IRF4 was 
shown by us (present thesis) and others (Satoh et al., 2010) to be regulated by 
JMJD3, we hypothesize that the increased number of MZ B cells measured in Jmjd3 
mutant mice may result from impaired IRF4 expression. We will attempt to address 
this question in the future by increasing IRF4 expression levels in Jmjd3 conditional 
mutant B cells via lentiviral complementation, using bone marrow transplantation 
approach. 
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B-cell receptor (BCR) signaling is required for the differentiation and survival of 
mature B cells (Kraus et al., 2004). Over the past years it has become increasingly 
evident that the strength of the BCR signal(s) contributes critically to peripheral B cell 
lineage commitment (Casola, 2007; Pillai and Cariappa, 2009) “Strong” BCR signals, 
possibly resulting from antigen recognition, facilitate B-1 B cell development whereas 
“weaker” signals facilitate MZ and/or Fo B cell development. We could show that 
upon Jmjd3 inactivation, B-1 B cell development was distorted. Specifically, in JMjd3 
conditional mutants we observed a major and selective loss of CD19hiCD5+ B-1a B 
cells whereas, B-1b B cells (CD19hiCD5-) increased proportionally, leaving ultimately 
the total number of B-1 B cells largely unaffected.  
Targeted disruption of genes encoding for effectors of BCR signaling often result in a 
substantial decrease or, in some cases, to complete absence of B-1a B cells (Berland 
and Wortis, 2002). BCR effectors important for B1-a B cell differentiation often 
regulate intracellular Ca2+ flux, which in turn activates the NFAT (Nuclear Factor of 
Activated T cells) family of transcription factors. Studies with gene-targeted mice have 
shown that NFATc1 is critical for development and/or survival of B-1a B cells (Berland 
and Wortis, 2003). MZ and B-1 cells are both recruited into T-cell independent 
antibody responses, (Cinamon et al., 2008; Martin and Kearney, 2002; Baumgarth, 
2010). However, only B-1a B cells depend strictly on the function of NFATc1 for their 
development (Berland and Wortis, 2003). Interestingly, a study by Yasui and 
colleagues has recently described that NFATc1 expression is epigenetically regulated 
by Jmjd3 during murine osteoclast differentiation (Yasui et al., 2011). Hence, we 
suggest that Jmjd3 may control B-1a B cell development and/or maintenance through 
the regulation of NFATc1 expression. This prediction will be validated measuring 
Nfatc1 transcript levels in the remaining population of Jmjd3 mutant B-1a B cells. 
Should this experiment result uninformative (the remaining B-1a B cells in Jmjd3 
mutants may have gone through a stringent selection process based on the 
expression of normal NFATc1 levels), we will consider the possibility to reconstitute 
lethally irradiated mice with B-cell specific Jmjd3 conditional mutant hematopoietic 
stem cells complemented with Nfatc1-expressing lentiviral vectors.  
In vivo BrdU labeling experiments have also revealed a possible role for Jmjd3 in 
mature B cell homeostasis. Indeed, recruitment of immature B cells into the three 
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major mature B cell subsets was reduced in response to B-cell specific Jmd3 
inactivation. Since, the frequency of immature B cells that gets recruited into the 
mature B cell compartments is strictly dependent on the turnover of the latter 
population, we conclude from this that Jmjd3 plays a role in the regulation of mature B 
cell lifespan. This control is not exerted through a control of B cell survival as we 
failed to observe major changes in the fraction of apoptotic cells in the various mature 
B cell subsets following Jmjd3 inactivation. 
The stepwise transition of B cells through subsequent stages of development is 
driven by the continuous rewiring of the transcriptional program sustaining B cell 
function and identity. Factors such as Jmjd3 acting on the H3K27me3/H3K4me3 
epigenetic axis may exert essential functions at very defined stages of differentiation 
where the fine balance in expression levels of a limited set of transcription factors 
defines the fate of the developing B cells.  Hence identifying Jmjd3 target genes in 
mature B cells will provide precious insights into the molecular mechanisms through 
which Jmjd3 may support peripheral B cell development. 
4.3. Jmjd3 and B cell activation and terminal differentiation 
 
4.3.1. Jmjd3 gets rapidly induced upon B cell activation  
Stimulation of B cells through both adaptive (BCR and CD40) and innate immune 
receptors (TLRs) triggers important molecular responses that range from a transient 
phase of clonal expansion to differentiation into terminally differentiated antibody-
secreting plasma cells. B cell activation through these receptors is also accompanied 
to genetic rearrangements occurring at the IgH locus whereby the Cµ constant region 
is replaced by that of other isotypes including  Cγ3, Cγ1, Cε and Cα.  
We have shown that Jmjd3 expression is substantially increased in response to in 
vitro stimulation of resting primary B cells through respectively BCR, CD40 and TLR4 
receptors. The induction of Jmjd3 was transient and reached its peak on average 2-
to-3 hr after the initial stimulation. After reaching its highest levels, Jmjd3 was rapidly 
down-regulated reaching basal low levels comparable to those of resting mature B 
cells. Previous work has shown that members of the NF-κB transcription factor family 
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are responsible for Jmjd3 induction in macrophages in response to LPS stimulation 
(De Santa et al., 2007 and 2009).  Given that BCR, CD40 and TLRs activate the NF-
κB pathway in response to cognate ligand interaction, we propose that B cells, as 
macrophage, employ the NF-κB signaling pathway to rapidly induce Jmjd3 
expression.  
In vitro activation of Jmjd3 mutant B cells revealed a surprising behavior of the cells. 
Specifically, stimulation of mutant B cells through BCR or CD40 receptors triggered a 
robust proliferative burst that was comparable to that observed in control cultures. In 
sharp contrast, stimulation with LPS induced a selective impairment in the 
proliferative response of Jmjd3 mutant cells. Similar results were observed when we 
mimicked LPS stimulation using an agonistic antibody against RP-105 (Miyake et al., 
1995). The analysis of growth curves of B cells stimulated with LPS showed a 
peculiar behavior of Jmjd3 mutant cultures. Upon LPS stimulation, the lack of Jmjd3 
delayed substantially the first cell division. Instead growth of mutant cells proceeded 
in a fairly comparable fashion to that of control B cells starting from the third day of 
stimulation. Hence the lack of Jmjd3 seems to impair/delay/interfere with the 
activation of a transcriptional program that ensures robust continuous proliferation of 
B cells for 3 to 4 days following the initial stimulation with endotoxin. Interestingly, the 
defect seen in LPS cultures of Jmjd3 mutant B cells was alleviated when interleukin-4 
(IL-4) was added to the culture medium. Given that IL-4 stimulation leads to the 
activation of the JAK/STAT pathway, we infer that the latter may compensate for 
JMJD3 loss to promote cell proliferation in response to LPS stimulation. Recent work 
in microglia cells has revealed that the JAK/STAT pathway can potentiate NF-κB 
dependent induction of Jmjd3 expression in response to LPS stimulation (Przanowski 
et al., 2014).   These data point to a convergence of the JAK/STAT and NF-κB 
pathways on Jmjd3 to execute downstream transcriptional programs including the 
induction of pro-inflammatory genes. Notably, constitutive activation alone of the 
JAK/STAT pathway was sufficient to induce a subset such pro-inflammatory genes 
whereas this was not achieved after Jmjd3 overexpression. Hence, we can envision a 
scenario whereby activation of the JAK/STAT pathway may overcome the 
requirement for Jmjd3 to induce one or more genes necessary to trigger B cell 
proliferation in response to LPS stimulation. The identification of such genes will 
represent a major focus of our future studies.  
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To understand the mechanisms responsible for the delayed proliferative response of 
Jmjd3 mutant B cells after LPS stimulation, we performed cell-cycle distribution 
analysis. However, these studies failed to reveal specific defects (e.g. blocks at 
defined stages of the cell-cycle) in mutant B cells. Hence, from this we hypothesize 
that transient induction of Jmjd3 is necessary in resting B cells for optimal activation 
of different set of genes that permit respectively the entry and the progression through 
the various stages of the first cell cycle following LPS stimulation. In accordance with 
previous reports (Satoh et al., 2010), we could show that Jmjd3 regulated optimal 
expression in B cells of the G1/S cyclins Ccnd2 and Cnnd3. In particular, loss of 
Jmjd3 blunted Ccnd2 induction and delayed Ccnd3 upregulation. The latter result 
may help explain the delayed progression through the first cell-cycle displayed by 
Jmjd3 mutant B cells following LPS activation.  
While this thesis was finalized, we obtained the first analyses of RNA sequencing 
data from Jmjd3 control and mutant B cells, isolated respectively before and 24 hr 
after LPS stimulation. Among the differentially expressed genes that were down 
regulated in Jmjd3 mutant B cells we found a strong enrichment for gene ontology 
categories associated to multiple cell cycle checkpoints and to mitosis (M. Rahmat, F. 
Zanardi and S. Casola, data not shown). Notably, such transcriptomic changes were 
already observed in Jmjd3 mutant B cells prior to stimulation. These results are 
consistent with a scenario whereby B cells require Jmjd3 to express optimal, basal, 
levels of mRNAs encoding for cell-cycle genes that become crucial to initiate the first 
cell division once they get stimulated with LPS. Why Jmjd3 requirement is restricted 
to LPS stimulated B cells represents a major focus of our future studies.  
Previous work has proposed a role for Jmjd3 in the induction of the Cdkn2a tumor 
suppressor locus (Agger et al., 2009; Barradas et al., 2009; Sola et al., 2011). This 
regulation was recently shown to provide a barrier to somatic cell reprogramming 
(Zhao et al., 2013). In accordance with these data, we found lower transcript levels for 
both p16INK4a and p19ARF tumor suppressors in Jmjd3 mutant B cells activated via 
TLR4. The failure to up regulate p19ARF may confer resistance to p53–dependent 
apoptosis following LPS stimulation. Indeed, we could show that by day-3 of LPS 
activation, there was a lower fraction of apoptotic cells within Jmjd3 mutant cultures 
when compared to controls. The property of Jmjd3 to induce Cdkn2a expression in 
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activated B cells may represent a fail-safe mechanism to limit the chance of acquiring 
chromosomal translocations as bystander effects of Ig isotype switching catalyzed by 
Activation Induced Cytidine deaminase (AID). Taken together these results position 
Jmjd3 within a regulatory network that guarantees on one hand optimal B cell 
proliferation in response to LPS stimulation, and, on the other, sensitizes cells to p53-
dependent apoptosis through a direct regulation of Cdkn2a expression.  
From the first bioinformatics analyses of RNA sequencing data, 2628 genes resulted 
differentially expressed in a significant manner between resting wild-type and Jmjd3 
mutant B cells. These genes were almost equally distributed among  down- (56%) 
and up- (44%) regulated genes in Jmjd3 mutants. Gene ontology analysis revealed 
that genes downregulated in Jmjd3 mutant B cells were significantly enriched for 
categories related to the cell-cycle and DNA replication. Up-regulated genes were 
instead enriched for gene categories involved in immune response to stimuli. 
Interestingly (and quite unexpectedly) the comparison of transcriptomes between 
Jmjd3 mutant and control B cells analyzed at 24 hr after LPS stimulation revealed a 
smaller number (595) of differentially expressed genes.  The majority (82%) of the 
latter genes resulted up-regulated in mutant B cells.  
We next assessed whether genes differentially expressed in Jmjd3 mutant B cells 
were marked respectively by H3K27me3 and/or H3K4me3 in their wild type 
counterparts. For this analysis we took advantage of H3K4me3 and H3K27me3 
genome-wide distribution maps that our lab has recently generated for different B cell 
subsets including follicular and marginal zone B cells (C. Carrisi and S. Casola, 
unpublished data). We intersected lists of differentially expressed genes with targets 
respectively of H3K27me3-only, H3K4me3-only and both histone marks in Fo and MZ 
B cells. Preliminary results indicate that over 70% of differentially expressed genes in 
resting Jmjd3 mutant B cells (1873 out of 2628) were marked by H3K4me3-only in 
their corresponding wild-type cells. These results are in accordance with previous 
data obtained in macrophages showing the preferential recruitment of Jmjd3 to target 
genes marked by high levels of H3K4me3 (De Santa et al., 2009). These preliminary 
data will be validated determining the H3K4me3 status of differentially expressed 
genes in Jmjd3 mutant B cells.  
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4.3.2. Jmjd3 and terminal B cell differentiation 
Stimulation of B cells with LPS triggers terminal differentiation of B cells. This process 
is strictly dependent on the up regulation of Irf4, Prdm1, Xbp-1 transcription factors 
(Klein et al., 2006, Sciammas et al., 2006). Given that Blimp1 and Irf4 genes are 
marked by H3K27me3 and are tightly regulated by Ezh2 to prevent premature plasma 
cell differentiation, we hypothesized that inactivation of Jmdj3 demethylase activity 
could prevent terminal differentiation. Moreover, we scored lower Irf4 transcript levels 
in Jmjd3 mutant B cell cultures after LPS activation. However, flow cytometric 
analysis indicated that the frequency of CD19loCd138hi plasma blasts (PBs) was not 
reduced in Jmjd3 mutant B cell cultures. Actually, we found a higher proportion of 
PBs in day-4 cultures of LPS-activated mutant B cells. We interpret the latter result 
with a delayed activation and improved survival of mutant B cells, which hence may 
lead to the detection of a higher fraction of PBs at day-4 of LPS stimulation.  In 
summary, inactivation of Jmjd3 does not prevent onset of terminal differentiation. 
Measurement of Ig serum titers in unimmunized mice revealed comparable levels of 
all isotypes in controls and Jmjd3 mutant animals. Although we have yet to determine 
Jmjd3 gene status in ex vivo isolated PCs, these results suggest a minor contribution 
of Jmjd3 to plasma cell homeostasis. 
 
4.3.3. Jmjd3 and Immunoglobulin class-switch recombination   
Stimulation of B cells with LPS leads to a potent induction of AID expression and 
consequently to IgG3 isotype switching. Hence, we asked whether Jmjd3 inactivation 
had an influence on the generation of IgG3 class-switched B cells. Indeed, flow 
cytometric analyses revealed a lower proportion of IgG3+ B cells in Jmjd3 mutant 
cultures. The reduction in Ig-switched Jmjd3 mutant B cells is likely not due to 
impaired AID expression as we observed comparable frequencies of IgG1+ B cells in 
mutant and control cultures after stimulation with LPS+IL-4. Since Ig class switch 
recombination correlates with number of cell divisions (Deenick et al., 1999) and 
given that Jmjd3 mutant B cells showed a defective proliferative response to LPS (but 
not LPS + IL-4), we conclude that the reduced fraction of IgG3+ B cells in Jmjd3 
mutant cultures is primarily caused by impaired proliferation.  
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4.4. Jmjd3 and the germinal center reaction 
Our laboratory has recently assigned a critical role to Ezh2 methyltransferase activity 
in the regulation of the germinal center reaction (Caganova et al., 2013). Hence we 
asked whether inactivation of the H3k27me3 demethylase activity of Jmjd3 could 
impact on the formation and maintenance of germinal center responses. To this end, 
we performed flow cytometric analyses in gut associated lymphoid tissues 
(mesentheric lymph nodes and Peyer’s patches) that show chronic germinal centers 
as a result of continuous microbial stimulation. Analyses revealed a comparable 
fraction of GC B cells between control and Jmjd3 mutant animals.  We extended 
these analyses performing immunizations with the T-cell dependent antigen NP-CGG. 
The measurement of antigen-specific IgG1 titers at different time points after 
immunization excluded a major contribution of Jmjd3 to GC responses. This result will 
be ultimately confirmed analyzing the fraction of GC B cells in the spleen of mutant 
and control animals at different time points after immunization. Moreover, since serum 
high-affinity antigen-specific IgG1 antibody levels were comparable between control 
and Jmjd3 mutant animals in recall responses, we conclude that Jmjd3 is not 
essential for memory B cell generation.   
In conclusion, analysis of Jmjd3 conditional knockout mice has revealed essential 
contributions of the histone demethylase to B cell subset differentiation and to B cell 
activation in response to innate immune stimuli such as microbial LPS.  
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